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Summary 
 
 
 
More than one in three people in the western world will be diagnosed with 
cancer at some point during their lifetime (1, 2). Breast cancer and prostate 
cancer represent the most common types of cancer with high survival rates. An 
important treatment modality in cancer management is radiotherapy (RT) with 
approximately half of all cancer patients receiving this treatment. Despite 
advances in technologies, radiation-induced side effects still occur and vary 
widely among patients which can broadly be related to radiation dosimetric 
variables, adjuvant cancer treatments and factors inherent to the patient, 
including genetics. As these side effects can impair the quality of life of cancer 
survivors, therapy-induced toxicity has become very important. The subject of 
this PhD dissertation is the identification of factors predicting or influencing the 
development of normal tissue toxicity and the development of integrated models 
that are able to predict which cancer patients are most likely to develop adverse 
events after RT. 
  
RT treatment for prostate cancer can result in toxicity to the gastrointestinal 
(GI), genitourinary (GU) and reproductive organs. In this PhD research, only GU 
symptoms were evaluated in prostate cancer patients treated with high-dose 
primary or post-operative intensity-modulated RT (IMRT), as GI toxicity was 
very rare. Acute RT-induced nocturia is in our study population the predominant 
acute toxicity endpoint; it is a frequently occurring but under-reported GU 
symptom. Nocturia was recently found to be associated with a decreased 
quality of life and with an increased prevalence of depression because of more 
frequent nightly voids. A number of clinical, dosimetric parameters and SNPs in 
TGFB1, capturing all common variants in the 5’ region of the gene, were tested 
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for association with the endpoint. The presence of mild pre-treatment 
complaints, treatment with primary IMRT and two polymorphisms in TGFB1 
were identified as risk factors. These results were published in a first paper, 
presented in Paper I (chapter 6). 
 
Recent refinements of radiotherapy techniques allow for a better sparing of 
the rectum resulting in a minimization of GI toxicity. In contrast to the incidence 
of late GU symptoms that remains unchanged due to the full inclusion of the 
bladder neck and, in case of postoperative RT, the vesicourethral anastomosis 
in the high-dose region. Late radiation-induced haematuria and nocturia are the 
most frequently observed late GU symptoms. Models for prediction of these 
endpoints were build using an in-house developed statistical algorithm 
considering clinical, dosimetric and genetic data. The genetic data were 
obtained by a custom-designed Illumina GoldenGate platform containing 384 
genetic variations. The variations were selected based on an extended 
candidate gene approach. Both integrated prediction models have acceptable 
predictive performance. The model predicting late haematuria and late nocturia 
has an AUC of 0.82 and 0.76, respectively. The paper resulting from this study 
is presented in Paper II (chapter 7).  
 
Acute skin toxicity is assessed in breast cancer patients treated with 
adjuvant RT after breast-conserving surgery. The endpoints of interest are the 
development of moderate to severe acute dermatitis and moist desquamation. 
Normofractionated (25x2 Gy) or hypofractionated (15x2.67 Gy) IMRT in prone 
or supine position is prescribed. Systemic therapies like chemotherapy, 
hormone therapy and trastuzumab are administered when indicated. Eight 
SNPs were selected based on literature data regarding a possible involvement 
in toxicity after cancer therapy. BMI, large bra cup size, fractionation schedule 
and concurrent hormone therapy were significantly associated with the 
development of dermatitis and moist desquamation. Additional factors modifying 
the risk of dermatitis were supine IMRT, the administration of trastuzumab and 
the genetic variation MLH1 rs1800734. The paper resulting from this study is 
presented in Paper III (chapter 8). 
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Some issues to improve research in the field of normal tissue injury can be 
addresses. First, a distinction should be made between individual approach 
(prediction) and population approach (association) which are both different in 
their objectives, measurements and their applicability in the clinical context. 
Secondly, due to a diversity in symptoms recorded by multiple scoring systems 
the comparison between studies and the pooling of data is hampered. In 
addition, predicting a dichotomised endpoint is accompanied with a loss of 
information but a new level of complexity is added when an ordinal endpoint is 
predicted. This is illustrated by the prediction of acute dermatitis. Thirdly, the 
added value of genetic polymorphisms, each conferring small effect sizes, in 
predicting a complex trait should be discussed. Together with alternative 
approaches for the prediction of radiation-induced toxicity, like cellular, 
apoptosis and gene-expression assays are overviewed. 
In conclusion, the success of predicting normal tissue toxicity will depend on 
our efforts to collaborate in joining expertise of different research areas and in 
creating a standardized manner of collecting dosimetric, clinical and biological 
data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
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Samenvatting 
 
 
 
Meer dan een derde van de mannen en vrouwen in de westerse wereld zal ooit 
de diagnose van kanker krijgen (1, 2) met borst- en prostaatkanker als de twee 
meest voorkomende types; beiden hebben een hoge kans op overleving. 
Radiotherapie (RT) is een belangrijke behandeling die wordt toegepast bij 
ongeveer de helft van de kankerpatiënten. Ondanks de technologische 
vooruitgang treden nog steeds neveneffecten op ten gevolge van de bestraling. 
Deze variëren sterk tussen patiënten onderling en kunnen verband hebben met 
de ontvangen dosis door de gezonde weefsels, met ondersteunende 
kankerbehandelingen en met factoren inherent aan de patiënt, zoals de 
genetica onder de vorm van single nucleotide polymorfismen (SNPs). Daar 
deze neveneffecten de levenskwaliteit van de overlevenden sterk kan 
beïnvloeden, is het belangrijk dit verder te onderzoeken. Het onderwerp van dit 
proefschrift is het identificeren van factoren die geassocieerd of voorspellend 
zijn voor het optreden van straling-geïnduceerde normale weefsel toxiciteit en 
het genereren van geïntegreerde modellen die kunnen voorspellen welke 
kankerpatiënten de grootste kans hebben om deze toxiciteit te ontwikkelen. 
 
RT behandeling voor prostaatkanker kan leiden tot schade aan de gastro-
intestinale (GI), genito-urinaire (GU) en de voortplantingsorganen. Aangezien 
het optreden van GI symptomen eerder ongewoon is, werden in dit onderzoek 
enkel GU symptomen onderzocht bij prostaatkanker patiënten die behandeld 
zijn met hoge-dosis primaire of postoperatieve intensiteit-gemoduleerde RT 
(IMRT). Acuut RT-geïnduceerde nycturie is in onze studiepopulatie de 
voornaamste vorm van acute toxiciteit; het is een veel voorkomend maar weinig 
gemeld GU symptoom. Nycturie werd onlangs in verband gebracht met een 
verminderde levenskwaliteit en met een verhoogd voorkomen van depressie 
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vanwege het frequenter nachtelijk opstaan. Een aantal klinische, dosimetrische 
parameters en SNPs in TGFB1, die alle varianten in de 5'-regio van het gen 
omvat, werden onderzocht op hun relatie met het eindpunt. De aanwezigheid 
van milde klachten voor de start van RT, behandeling met primaire IMRT en 
twee polymorfismen in TGFB1 kwamen naar voor als als risicofactoren. Deze 
resultaten werden gepubliceerd in Paper I (hoofdstuk 6) . 
 
Recente technologische ontwikkelingen in RT kunnen het rectum beter 
vrijwaren van bestraling met een minimaal voorkomen van GI toxiciteit tot 
gevolg. Daarentegen, het voorkomen van late GU symptomen blijft onveranderd 
door de volledige inclusie van de blaashals en – in geval van postoperatieve RT 
– de vesicourethrale anastomose, in de hoge dosis regio. Chronische straling-
geïnduceerde hematurie en nycturie zijn de meest voorkomende chronische GU 
symptomen. Modellen die het optreden van deze eindpunten voorspellen, 
werden gebouwd met behulp van een intern ontwikkeld statistisch algoritme 
waarin klinische, dosimetrische en genetische data werden opgenomen. De 
genetische data werden verkregen door een op maat ontworpen Illumina 
GoldenGate platform met 384 genetische variaties. De polymorfismen werden 
geselecteerd op basis van een uitgebreide kandidaatgen benadering. Beide 
geïntegreerde modellen hebben een aanvaardbare voorspellende waarde. Het 
model dat chronische hematurie en nycturie voorspelt, heeft een AUC van, 
respectievelijk, 0.82 en 0.76. Paper II geeft deze resultaten weer (hoofdstuk 7). 
 
Acute huidreacties werden geregistreerd bij borstkanker patiënten 
behandeld met adjuvante RT na borstsparende chirurgie. De eindpunten zijn 
het ontwikkelen van matige tot ernstige acute dermatitis en vochtige 
desquamatie. Normofractionering (25x2 Gy) of hypofractionering (15x2.67 Gy) 
IMRT in buik- of ruglig wordt voorgeschreven. Systemische therapieën zoals 
chemotherapie, hormoontherapie en trastuzumab worden toegediend wanneer 
nodig. Acht SNPs werden geselecteerd die volgens literatuurdata mogelijks 
betrokken zijn bij het ontwikkelen van toxiciteit na kankertherapie. BMI, grote 
bh-maat, fractioneringsschema en hormoontherapie gelijktijdig met RT, waren 
significant geassocieerd met de ontwikkeling van dermatitis en vochtige 
schilfering. Bijkomende factoren die het risico op dermatitis wijzigen bleken 
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IMRT in buiklig, de toediening van trastuzumab en de genetische variatie MLH1 
rs1800734. De paper als gevolg van deze studie wordt weergegeven in Paper 
III (hoofdstuk 8). 
 
Het onderzoek naar normale weefsel schade ten gevolge van RT staat nog 
voor een aantal grote uitdagingen. Ten eerste moet een duidelijk onderscheid 
gemaakt worden tussen de individuele (predictie) en de algemene (associatie) 
benadering die beiden verschillen in hun doelstellingen, meetmethodes en hun 
toepasbaarheid in klinische context. Ten tweede wordt de vergelijking tussen 
studies en het uitwisselen van data bemoeilijkt. Dit is het gevolg van meerdere 
scoringssystemen die een verscheidenheid aan symptomen beoordeeld. 
Bovendien gaat het voorspellen van een binair eindpunt gepaard met verlies 
aan informatie maar meer complexiteit wordt geïntroduceerd wanneer een 
ordinaal eindpunt voorspeld wordt. Dit wordt aangetoond bij de predictieanalyse 
van acute dermatitis. Ten derde zou de toegevoegde waarde van genetische 
polymorfismen, die elk slechts een klein effect bijdragen, in het voorspellen van 
een complex kenmerk moet worden besproken. Alternatieve methodes voor de 
voorspelling van straling-geïnduceerde toxiciteit, zoals cellulaire, apoptose en 
genexpressie assays worden ook besproken. 
Tot slot, het succes om normale weefsel toxiciteit te voorspellen zal 
afhangen van onze inspanningen tot samenwerken in het verzamelen van 
expertise in verschillende onderzoeksdomeinen en in het creëren van een 
gestandaardiseerde manier om dosimetrische, klinische en biologische 
gegevens te verzamelen. 
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Résumé 
 
 
 
Plus d'un tiers des hommes et des femmes du monde occidental sera 
diagnostiqué avec le cancer à un moment donné de leur vie (1, 2). Le cancer du 
sein et le cancer de la prostate sont les deux types de cancers les plus 
fréquents; les deux ont un taux de survie élevé. La radiothérapie (RT) est un 
traitement important qui est utilisé pour environ la moitié des patients atteints de 
cancer. Malgré les progrès technologiques, les effets secondaires induits par 
les radiations ionisantes se manifestent encore. Ceux-ci varient 
considérablement entre les patients et peuvent être associés à la dose reçue 
par les tissus sains, aux thérapies de soutiens et à des facteurs inhérents au 
patient, comme la génétique sous forme de polymorphisme d'un nucléotide 
(SNP). Étant donné que ces effets secondaires peuvent fortement affecter la 
qualité de vie des survivants au cancer, il est important d'étudier davantage 
cette question. Le sujet de cette thèse de doctorat est d’identifier des facteurs 
prédictifs ou des facteurs qui influencent le développement de la toxicité du 
tissu normal et le développement de modèles intégrés qui peuvent prédire 
quels patients atteints de cancer sont les plus susceptibles de développer des 
effets indésirables après la RT. 
 
Le traitement RT du le cancer de la prostate peut entraîner une toxicité à 
l'appareil gastro–intestinal (GI), génito-urinaire (GU) et aux organes 
reproducteurs. Dans cette thèse, seuls les symptômes GI sont évalués dans les 
patients atteints du cancer de la prostate traités par une dose élevée primaire 
ou post-opératoire avec radiothérapie conformationelle avec modulation 
d'intensité (IMRT), étant donné que la toxicité gastro-intestinale était très rare. 
La nycturie aiguë induite par la RT, critère prédominant de toxicité aiguë dans 
xiv 
 
notre population d’étude, est un des symptômes GU commun mais sous-
déclaré. La nycturie a récemment été associée à une diminution de la qualité de 
vie et une incidence accrue de dépression à cause des mictions nocturnes 
fréquentes. Un certain nombre de paramètres cliniques et dosimétriques, et les 
SNP de TGFB1, contant tous les variants communs dans la région 5' du gène, 
ont été testés pour la relation avec le point de terminaison. La présence de 
plaintes légères avant le début de la radiothérapie, le traitement primaire avec 
IMRT et deux polymorphismes dans TGFB1 ont été identifiés comme des 
facteurs de risque. Ces résultats ont été publiés dans un premier document, 
présenté dans Paper I (chapitre 6). 
 
Les améliorations récentes des techniques de radiothérapie permettent une 
meilleure épargne du rectum, résultant dans une incidence minimale de toxicité 
GI. Contrairement à l'incidence des symptômes tardifs GU qui reste inchangé 
en raison de l’inclusion du col de la vessie et, en cas de radiothérapie 
postopératoire, de l'anastomose vésico-urétrale dans la région à forte dose. 
L’hématurie et la nycturie radio-induite sont les symptômes GU chroniques les 
plus courants. Les modèles qui prédisent la présence de ces paramètres ont 
été élaborées en utilisant un algorithme statistique tenant compte des données 
cliniques, génétiques et dosimétriques. Les données génétiques ont été 
obtenues grâce à une plateforme Illumina GoldenGate conçue sur mesure avec 
384 variations génétiques. Les variations ont été sélectionnées basée sur une 
approche de gène candidat étendue. Les deux modèles de prévision intégrés 
ont des performances prédictives acceptables. Le modèle qui prédit que 
l'hématurie chronique et la nycturie, ont une AUC de, respectivement, 0.82 et 
0.76. Paper II montre les résultats (chapitre 7). 
 
Des réactions aiguës de la peau ont été évaluées chez les patients de 
cancer du sein traitées avec la radiothérapie adjuvante après chirurgie 
mammaire conservatrice. Les paramètres d'intérêt sont le développement de la 
dermatite aiguë modérée à sévère et de desquamation. L’IMRT normo 
fractionnée (25x2 Gy) ou hypofractionnée (15x2.67 Gy) en position décubitus 
ventral ou dorsal est prescrit. Les traitements systémiques comme la 
chimiothérapie, l'hormonothérapie et le trastuzumab sont administrées lorsque 
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indiqué. Huit SNP ont été sélectionnés, sur la base de données de la littérature, 
qui pourrait être impliqués dans le développement de la toxicité après la 
thérapie du cancer. L’IMC, une grande taille de poitrine, le fractionnement et 
l'hormonothérapie simultanément avec la RT, étaient significativement associés 
avec le développement de la dermatite et de desquamation. D'autres facteurs 
modifiant le risque de dermatite ont été IMRT en position couchée, 
l'administration de trastuzumab et la variation génétique MLH1 rs1800734. Le 
document qui résulte de cette étude est présenté dans Paper III (chapitre 8). 
 
La recherche de toxicité tissulaire normale causée par RT est encore 
confrontée à plusieurs défis. Tout d’abord, il convient de faire une distinction 
claire entre l’approche de l’'individu (prédiction) et approche globale 
(association) car les deux diffèrent dans leurs objectifs, méthodes de mesure et 
de leur applicabilité dans le contexte clinique. Deuxièmement, la comparaison 
entre les études et l'échange de données plus difficile. Ceci est le résultat de 
plusieurs systèmes de notation revue une variété de symptômes. En outre, les 
prévisions d'un critère binaire associée à la perte d’information, mais plus la 
complexité est introduite lorsqu'un point d'extrémité ordinal est prévu. En outre, 
la prévision d'un critère dichotomique est accompagnée d’une perte 
d’information, mais un nouveau niveau de complexité est ajouté quand un 
critère ordinal est prévu. Ceci est démontré dans la prédiction de la dermatite 
aiguë. Troisièmement, la valeur ajoutée des polymorphismes génétiques, 
chacun contribuant que peu d'effet dans la prévision d'un trait complexe, devrait 
être discuté. Des méthodes alternatives pour la prédiction de la toxicité induite 
par les rayonnements, tel que de essaies cellulaires, d'apoptose et l'expression 
des gènes, sont également examinés. 
En conclusion, la réussite de la prédiction de la toxicité tissulaire normale 
dépendra de nos efforts pour coopérer à la collecte d'expertise dans différents 
domaines de recherche et à la création d’une méthode rationalisée pour la 
collecte de données dosimétriques, cliniques et biologiques. 
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Part I 
Patients vary in their normal tissue response to 
radiation
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1 Radiotherapy is an important treatment modality in 
cancer management 
Yearly, almost 700.000 women in the western world are diagnosed with breast 
cancer and the same number of men with prostate cancer. They represent the 
most common types of cancer (1). For all stages together, the 5-year survival 
rate for breast cancer patients is 89% and more than 90% for prostate cancer 
patients (2). Mammographic screening for breast cancer patients and PSA-
screening for prostate cancer patients result in early diagnosis, which improves 
the chances of successful treatment.  
This chapter outlines the use of radiotherapy as a cornerstone in cancer 
management, the impact of the treatment at the DNA level and the cascade of 
effects associated with DNA damage. The application of radiotherapy in the 
treatment of breast and prostate cancer is then explained in more detail. 
 
1.1 Radiotherapy in cancer management 
Just a few years after Wilhelm Roentgen discovered x-rays in 1895 and Antoine 
Becquerel discovered radioactivity in 1898, various forms of radiation were used 
to treat cancer. Immediately, it was apparent that radiation therapy (RT) held 
great promise as an effective therapeutic modality (3). Approximately 50% of all 
cancer patients receive RT at some point during the course of their treatment 
(4). At present, RT is the most important non-surgical modality for curative 
treatment of cancer. Since it accounts for only 5% of the total cost of cancer 
care, it is also cost effective (5). 
Radiation is mainly delivered by external beam RT. An external radiation 
source generates ionizing radiation (IR) that is directed towards the tumour. The 
most frequently used form of external beam RT is high-energy x-rays generated 
by linear accelerators (6). Other forms are particle therapy which uses high-
energy charged particles, like electrons, protons and carbon ions. In 
brachytherapy, a radiation source is brought into the tumour site either by 
implantation or an afterloader (6).  
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RT is based on the balance between cure and toxicity. The success of RT in 
cancer treatment principally depends on the total radiation dose given, which is 
limited by the tolerance of the normal tissues surrounding the tumour (7) This 
can be quantitatively described by dose-response curves for tumour control and 
normal tissue damage, see Figure 1.1.  
 
Figure 1.1: Dose-response curves for 
radiotherapy. Sigmoidal shaped 
response curves for tumour control and 
normal tissue damage. The probability of 
tumour cure increases with radiation dose 
with accompanying probability of severe 
late normal tissue damage. The dotted 
line shows a theoretical dose associated 
with ~60% tumour control and ~5% 
severe late toxicity. Adapted from Barnett 
et al. (7).  
 
External beam RT is usually given over a course of multiple fractions as it 
maximises tumour kill and minimizes normal tissue damage. Based on empirical 
studies with respect to these normal tissue reactions, conventional fractionation 
regimens of 1.8-2 Gy per fraction at a rate of five fractions per week have been 
the backbone over the last decades in most institutions (8, 9).  
Altered fractionation regimens and new technologies like computerized 
treatment planning systems, image-guided RT and intensity-modulated 
radiotherapy (IMRT) can substantially improve the therapeutic ratio by better 
tumour control and reduction of normal tissue toxicity (10, 11). Cure rates can 
be further improved by combining molecular targeting agents, hormone and 
chemotherapy with radiotherapy (5).  
In this PhD dissertation, all patients were treated with IMRT, an advanced 
form of three-dimensional conformal RT. IMRT includes modulation of the beam 
intensity; this is achieved by beam modifiers, such as multileaf collimators. As a 
result, concave-shaped dose distributions and tight dose gradients are created 
to closely sculpt the 3D shape of the target. In addition, IMRT allows the 
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delivery of high radiation doses to the tumour while limiting the radiation dose to 
the normal tissues, as shown in Figure 1.2 (6, 12). 
 
Figure 1.2: Concept of IMRT for 
example in prostate cancer 
(transversal slice of the male 
abdomen). In each direction, the 
beam is modulated by varying the 
intensity of its smaller units. This 
precise radiation dose conforms to the 
shape of the tumour and the amount of 
radiation to normal tissues surrounding 
the treated area is minimized. Adapted 
from (13).  
 
 
1.2 Radiotherapy – mode of action 
RT is the treatment of cancer using IR. Interaction of IR with the cellular 
environment results in energy depositions causing ionizations (8, 14). 
Ionizations produce highly reactive free radicals, that have the potential to break 
chemical bonds. Damage to DNA is the most harmful effect to cells, for 
example, single-strand breaks (SSBs), double-strand breaks (DSBs), DNA 
crosslinks and various base modifications leading to SSBs and/or DSBs (8, 15). 
Of them, DSBs are biologically the most important lesions as they are more 
difficult to repair than other DNA lesions because the two DNA ends can 
separate, and accompanying base damage hampers DSB ligation (14, 16). 
DNA damage can be induced by direct interaction of IR with DNA or indirectly 
by the generation of reactive species (oxygen (ROS) and nitrogen (RNS)) in 
close proximity to the DNA (15).  
Upon DNA damage, a complex coordinated system is triggered that 
determines the fate of the cell. This DNA damage response (DDR) 
encompasses processes of DNA repair and signal transduction mechanisms 
that alert the cell to the presence of DNA damage. Firstly, sensor proteins 
detect the sites of damage within the DNA. This signal is then amplified by a set 
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of proteins known as transducers. They function to relay the signal to 
downstream effector pathways determining cell fate, either arrest the cell cycle 
to allow repair of damaged DNA or, if the damage is beyond repair, initiate the 
cell to undergo programmed cell death or apoptosis (8, 16, 17). Figure 1.3 lists 
many of the key genes involved. The DDR is explained in more detail. 
 
Figure 1.3: 
Summary of the 
pathways and 
mechanisms 
involved in cell 
response to RT. 
Adapted from West 
et al. (14).  
 
 
 
 
 
 
ATM lies at the heart of the signalling response induced by DNA damage 
and is activated through the MRN (MRE11-RAD50-NBN) complex which is the 
primary sensor of DSBs (15). Cells rely on two major pathways to repair DSBs: 
non-homologous end joining (NHEJ) and homologous recombination (HR) (16). 
They are complementary and are used under different circumstances (17). HR 
requires a homologous template, usually a sister chromatid, occurs in S and G2 
phases of the cell cycle and is error free. NHEJ repairs DSBs without requiring 
sequence homology throughout the cell cycle (16, 17). Although it was 
commonly believed that HR plays a major role in G2 phase, recent studies have 
shown that NHEJ represents the major DSB repair pathway in G2, with HR only 
being essential for the repair of a minor subset ( 15%) of IR-induced DSBs 
(18). When the classical route is impeded due to missing or mutated NHEJ 
components, alternative NHEJ pathways can operate which rely on factors 
involved in HR and SSB repair like the MRN complex, PARP1, XRCC1 and 
LIG1 or LIG3 (17). SSBs are initially detected by PARP1 and are through ATR 
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activation, repaired by the mechanisms base excision repair (BER) or 
nucleotide excision repair (NER). The latter corrects bulky helix-distorting 
lesions, the BER system targets nonbulky lesions (base modifications) and 
abasic sites (15). It is, however, estimated that 1% of these single-strand 
lesions are converted into DSBs which are repaired by NHEJ or HR through 
ATR and ATM activation (15). In addition, mismatch repair (MMR) removes 
nucleotides arising from replication errors and accumulating data suggest that 
MMR proteins are involved in DDR upon exposure of IR (19). ATM activation 
leads to phosphorylation of CHK2, TP53 and CDC25 which triggers checkpoint 
activation and cell cycle arrest, in G1/S and/or G2/M phase. These checkpoints 
induce transient cell cycle arrest, allowing sufficient time for DNA repair (8). 
ATR, on the other hand, signals via CHK1 to promote cell cycle arrest. If DSB 
repair fails, apoptosis or cellular senescence is induced via ATM/ATR signalling 
(14). Another function of ATM is shown to be the protection of cells from ROS 
accumulation by stimulating NADPH production and promoting the synthesis of 
nucleotides required for DSB (20). 
Besides DNA damage, ROS and RNS may also damage proteins, lipids and 
mitochondrial DNA (21). They may spread from targeted cells to non-targeted 
bystander cells through intercellular communication mechanisms, where the 
oxidative metabolism is further disrupted (21).  
 
1.2.1 Efficacy of radiation treatment 
Splitting up radiation dose in multiple dose fractions, maximizes tumour control 
and minimizes normal tissue damage. The rationale behind it is explained by 
radiobiological factors summarized as the five Rs of RT: DNA repair, 
reoxygenation, repopulation, redistribution and intrinsic radiosensitivity (22). In 
this context, it is believed that radiation-induced lethality is primarily caused by 
DNA damage in targeted cells. 
Fractionation spares normal tissue because it allows the cell to repopulate 
and to recover from the DNA damage. Tumour cells, on the other hand, 
proliferate faster than normal tissue leaving them less time to repair the damage 
and together with the many genetic changes, they are more susceptible for 
radiation-induced cell death. Redistribution brings with each successive 
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radiation dose more cells into radiosensitive phases of the cell cycle. Decreased 
tumour burden leads to better vascularity and oxygenation, which increases the 
radiosensitivity in the tumour (8). Intrinsic radiosensitivity represents the 
radiosensitivity of different cell types and tumour cells (9). 
 
1.3 Radiotherapy for breast cancer and prostate cancer 
Breast-conserving surgery followed by breast irradiation, is recommended as 
the primary treatment for early-stage breast cancer (23). RT reduces the risk of 
local recurrence substantially and prevents the need for mastectomy (24-26). 
Moderate whole breast hypofractionated regimens (42.5 Gy in 16 fractions or 40 
Gy in 15 fractions) were shown to be equally effective as to the standard RT 
schedule of 50 Gy in 25 fractions (27, 28). This was expected based on the 
radiobiological model that a larger dose per fraction given over a shorter period 
of time is just as effective as the more traditional longer regimen (29). The use 
of sequential tumour bed boost improves local control but with higher rates of 
fibrosis (30). Introduction of modern technologies has facilitated the planning 
and delivery of for example simultaneous integrated boost, to further shorten 
course of RT (31), or, optimization of prone positioning to reduce toxicity rates 
(32). In addition, modalities like accelerated partial breast irradiation and 
extreme breast hypofractionation are currently under investigation (31).  
RT is also combined with systemic treatment. Hormonal therapy under the 
form of tamoxifen or aromatase inhibitors can be administered to oestrogen 
positive-receptor breast cancer patients. Chemotherapy, preferably not given 
concomitantly with RT to avoid toxicity, is mostly a combination of antracyclines 
and taxanes (33). The targeted agent trastuzumab has been shown to improve 
survival in patients with HER-2 positive tumours (34). 
 
Management options for prostate cancer are more diverse. They include radical 
prostatectomy, RT (external beam or brachy), and watchful waiting or closely 
monitoring the cancer in slowly growing or low graded prostate cancer (35). 
Radical prostatectomy and RT show a similar level of effectiveness (36).  
Currently, most men who receive external beam RT are treated with 
conventionally fractionated treatment regimens to a total dose of 74-80 Gy. 
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Such dose escalation has shown to improve biochemical control over standard-
dose RT of 64-70 Gy (37). Moreover, hypofractionated regimens (2.1-3.5 Gy) 
are tested in clinical trials but there is no clear evidence that those schedules 
improve outcomes or result in lower toxicity when compared with conventionally 
fractionated regimens (38). Extreme hypofractionation and high-dose rate 
brachytherapy are alternative approaches and are currently under investigation 
(37, 39, 40). Hormone therapy like LHRH-analogues or anti-androgens are 
often used concomitantly with RT in prostate cancer patients. 
 
In this PhD research, breast cancer patients are treated with the standard 
fractionation schedule (50 Gy in 25 fractions) or with moderate 
hypofractionation of 40 Gy in 15 fractions. Prostate cancer patients are treated 
either with radical RT with three different dose levels (74 Gy in 36 fractions, 76 
Gy in 37 fractions or 80 Gy in 38 fractions), or with postoperative RT after 
radical prostatectomy. The prostatic bed received 74 Gy in 36 fractions in the 
adjuvant setting and 76 Gy in 37 fractions in the salvage setting. 
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2 Radiation-induced side effects are inevitable 
Many patients receiving curative radiotherapy will experience toxicity due to the 
unavoidable irradiation of surrounding healthy tissue.  
The first section of this chapter describes radiation-induced toxicity in 
general and the specific effects in breast and prostate cancer patients. It also 
gives an overview of the available scoring systems to assess toxicity. The 
pathogenesis is explained in more detail in the second section of this chapter 
and the third section deals with the factors influencing the development of 
normal tissue toxicity. These factors can be implemented in models that predict 
an individual’s probability for developing radiation-induced side effects. 
 
2.1 Radiation-induced normal tissue toxicity 
Normal tissue is inevitably included in the irradiated target volume to ensure 
coverage of the microscopic tumour burden or to anticipate upon tumour and 
organ movement between fractions (8, 41). The tolerance of these normal 
tissues to radiation dictates the dose that is prescribed which is limited by late 
toxicity. Typically, RT schedules are designed to ensure that the risk of severe 
adverse effects does not exceed 5-10%. This basically means that the dose is 
submaximal in the majority of the patients (7).  
Dose-response relationships for normal tissues are suggested to have a 
threshold at low doses and saturate at high doses (Figure 2.1). There is 
evidence that normal tissue dose-response relationships are steep, which 
means that small changes in dose results in relatively large differences in 
toxicity (42). Normal tissue complication probability (NTCP) models have been 
introduced to predict the probability of a defined undesirable effect on the 
patient as a function of dose or biologically equivalent dose and volume. Curves 
for normal tissue complications are less well-defined than tumour control 
probability curves (TCP). They are steeper, reflecting less heterogeneity in the 
biology of normal tissues (8).  
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Figure 2.1: Cumulative frequency dose-
response curves for skin telangiectasia 
and for spinal cord necrosis. Adapted from 
Barnett et al. (7). 
 
 
 
 
 
Some tissues are thought to be functionally organised in series. The failure 
of a critical part of the tissue leads to a complication and largely depends on the 
maximum dose delivered to the organ. This is the case in nerves, 
gastrointestinal (GI) tract and bronchi (43). Recently, breast tissue is also 
shown to behave as a serial organ (44). In parallel organs, regions of an organ 
can be damaged without impairing global organ function; there is a ‘functional 
reserve’ which allows a certain volume fraction to lose function before a clinical 
unacceptable endpoint is reached. The response of such organs is dependent 
on the volume of the organ affected, for example lung, liver or kidney (43). 
 
Depending on the time of symptom appearance, radiation toxicity is 
commonly classified as acute, consequential or late effects (Figure 2.2). Acute 
toxicity is observed during or within weeks after completion of RT and is usually 
reversible. It occurs in rapidly proliferating tissues as a result of cell death, such 
as in epithelial surfaces of the skin or the mucosa of the alimentary tract. Acute 
effects are generally manageable and transient due to proliferation and 
repopulation of surviving stem cells (41). Late side effects are progressive and 
manifest six months to many years after treatment in tissues with a slow 
turnover of cells. They include radiation-induced fibrosis, atrophy, vascular 
damage, neural damage and a range of endocrine and growth-related effects 
(Figure 2.2) (45). Severe late toxicity impacts negatively on the quality of life 
and can, in extreme cases, be life-threatening. The long-time course for their 
development prevents titration of dose against toxicity in individual patients. 
Acute reactions that fail to heal completely and persist into the late period are 
12 
consequential late effects. They are related to the severity of acute reactions 
(14, 41). 
 
 
Figure 2.2: The toxicity of RT. From Barnett et al. (7). 
 
In breast cancer patients, RT has a direct effect on the skin; other organs 
like lung, heart and coronary arteries are at risk as well. When the node region 
is irradiated, the shoulder, brachial plexus and axillary lymphatic are also at risk 
for potential injury. Acute skin reactions such as erythema, dry desquamation, 
hyperpigmentation and moist desquamation and the symptom of fatigue 
dominate the early toxicity profile. Late toxicity can be divided into two groups: 
the more common effects on the cosmetic appearance of the breast such as 
persistent breast oedema, hyperpigmentation, atrophy, telangiectasia and 
fibrosis, and the uncommon permanent injury to other organs such as brachial 
plexopathy, radiation pneumonitis, cardiac morbidity or secondary malignancy 
(46). 
Male pelvic irradiation injury can occur in GI, genitourinary (GU) and 
reproductive organs. Radiation can cause functional effects in organs including 
the small bowel, rectum, anus, bone and bone marrow, bladder, urethra, ureter, 
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testicles and sexual organs. The most commonly recorded symptoms are: 
abdominal cramps, diarrhoea, mucus loss, rectal bleeding, faecal incontinence 
and urgency at the GI system and, dysuria, nocturia, pollakiuria, haematuria, 
urgency and incontinence at the GU system. Long-term symptoms can be seen 
at variable intervals following radiation (46). 
 
2.1.1 Assessment of normal-tissue effects 
Several classification systems are used to record normal-tissue reactions. The 
most widely used scoring systems in radiation oncology are RTOG/EORTC 
(Radiation Therapy Oncology Group/ European Organization for Research and 
Treatment of Cancer) (47), LENT/SOMA (Late Effects Normal Tissues: 
Subjective, Objective, Management and Analytic) (48) and the comprehensive 
dictionary for recording and grading side effects, the CTCAE (Common 
Terminology Criteria for Adverse Effects) (49). The most recent developed 
system is CTCAEv.4.0 (50). At the Ghent University Hospital, an in-house 
developed toxicity score is used which is based on RTOG, CTCAEv3.0 and 
LENT/SOMA toxicity scoring systems (51, 52). Toxicity is graded according to 
severity on a scale of none, mild, moderate or severe, with some as either none 
or yes. This assortment of diverse scoring systems leads however to the 
assessment of multiple and different endpoints which hampers comparisons 
across studies and pooling of data. 
 
2.2 Pathogenesis of normal tissue side effects 
The development of radiation-induced tissue injury begins with an ionizing event 
that results in direct damage to DNA but also initiates a cascade of events on 
the cellular and molecular level that is similar to the wound healing process as 
shown by Figure 2.3. 
Until the 1990s, the pathogenesis of normal tissue effects was described 
through the ‘target-cell theory’, which states that radiation-induced toxicity is a 
direct consequence of killing parenchymal and vascular cells (53). Possible 
mechanisms for radiation-induced cellular lethality are apoptosis, which can be 
directly activated by the DDR, and, mitotic death in which cells fail to complete 
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mitosis correctly (8). The timing of developing the symptomatic injury depends 
on the proliferation kinetics of the irradiated tissue; chronic injury is caused by a 
delayed reduction in the number of target cells. Subsequent healing is based on 
the proliferation of the surviving stem cells within irradiated volume or by 
migration of them from non-irradiated tissue (8). This hypothesis is, however, 
inadequate to explain the pathogenesis of late effects but remains useful to 
explain the effects of the early responding tissue (45). 
 
Figure 2.3: Radiation-induced fibrosis (below) has features in common with the 
normal wound healing response (above). From Bentzen et al (45).The final tissue 
remodeling phase in normal wound healing, which becomes less active with time, is 
deregulated in radiation fibrosis. Instead of resolving, a progressive increase in fibrosis 
occurs over many months or even years (54). 
 
Since the mid-1990s, it became clear that radiation-induced injury is an 
orchestrated, active biological response which is initiated at the time of 
irradiation and persists until the late effects manifest clinically (55). Radiation 
injury includes damage to the stromal (fibrosis), the parenchymal (atrophy) and 
vascular compartments where cytokines play an important role, as shown in 
Figure 2.4. An immediate early gene response is induced by radiation with a 
rapid increase of the expression of pro-inflammatory cytokines such as TNFα, 
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IL-1, IL-6, IFN, VEGF and EGFR. They drive the formation of inflammatory 
lesions with changes in the local vasculature allowing infiltration of neutrophils, 
macrophages and lymphocytes (56). Anti-inflammatory cytokines like TGFβ, IL-
10 and IL-4, restore the integrity and homeostasis through promoting 
angiogenesis and tissue regeneration or replacement by fibrosis with deposition 
of extracellular material. The involvement and impact of any cytokine will vary 
with cell type or tissue and with time (57). 
 
 
Figure 2.4: Cytokine network underlying the development of normal tissue response 
following radiation exposure. From Schaue et al. (56). DAMPs: damage-associated 
molecular patterns; PMN: polymorphonuclear leukocytes; Mɸ: macrophage; M1: killer 
macrophages; M2: repair macrophages. 
 
ROS formation, directly after irradiation, is followed by downstream activation of 
metabolic sources of pro-oxidant production. This includes mitochondria, nitric 
oxide synthases and oxidoreductase enzymes, such as the NADPH oxidases 
and may be secondarily linked to DNA damage response pathways (56, 58). 
Changes in the balance between free radicals and antioxidants (59-61) may 
participate in radiation injury by the activation of redox-sensitive signaling 
pathways. Some radiation-inducible redox-sensitive transcription factors are 
NFκB, Egf1 and AP-1, involved in the cytokine production, ATM, the core 
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protein of the DDR and HIF-1, a major contributor to angiogenic cytokine 
production (62-64). 
Pro-inflammatory cytokines generate cellular ROS and require ROS for 
signal pathway activation (65, 66). In contrast, anti-inflammatory cytokines tend 
to inhibit ROS/RNS mediated effects and display anti-oxidant properties (67, 
68). This balance of pro- and anti-inflammatory cytokines is critical in 
determining the outcome; it may shift back and forth for a long time after 
radiation exposure and it appears that the redox status of the cell is the turning 
point (56). 
 
2.3 Factors influencing the development of radiation-
induced toxicity 
A substantial degree of variability among patients in the response to a standard 
course of RT has been observed for a long time. A variety of factors influence 
the likelihood of a patient developing toxicity; these can broadly be related to 
dosimetry, adjuvant cancer treatments and factors inherent to the patient.  
Dosimetry-related factors include total dose, dose per fraction, irradiated 
volume and dose inhomogeneity (7). Late effects tend to be more sensitive to 
changes in fraction size, and are less sensitive to changes in overall treatment 
time than early responses. In this respect, an increase of fraction size must be 
accompanied with a reduction of the total dose (29). The volume of normal 
tissues exposed to high radiation doses will also affect development of toxicity 
and depends on the organizational structure (parallel vs. serial) and the 
radiosensitivity of the critical components (functional subunits) (69, 70).  
Interaction with other treatment modalities, typically surgery and/or systemic 
therapy such as chemotherapy or hormone therapy, may influence the pattern 
of toxicity after RT (71, 72). 
Age, body weight, pre-existing symptoms, use of cigarettes are all factors 
that can possibly affect the development of normal tissue toxicity (72-75). In 
addition, patients with certain underlying conditions or diseases may be more 
susceptible for the development of adverse events. Case reports suggest that 
patients with co-morbid conditions like collagen vascular diseases, diabetes or 
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hypertension and inflammatory bowel disease are at greater risk for developing 
normal tissue toxicities. However, retrospective studies have generally not 
found substantial increases in the risk for toxicity (76-79). 
  
2.3.1 Factors associated with toxicity in breast and prostate cancer 
patients 
Large breasts and dose inhomogeneity are established risk factors for acute 
and late skin toxicity after whole-breast RT (80, 81). Additionally, post-operative 
infection and boost to the tumour bed have previously been shown to be 
associated with the development of late skin toxicity (80, 82). A recent study 
suggests, however, that the development of breast fibrosis depends more on 
the maximum RT dose instead of the effect of treated breast volume (44). 
Cardiac disease after breast cancer RT, especially present in patients with left-
treated breasts, is found to be associated with the mean dose to the heart, with 
a 7.4% increase rate in major coronary event per Gy (83). Women with pre-
existing cardiac risk factors are at higher absolute risk than other women (83).  
 
Established risk factors for acute and late rectal radiation-induced toxicities 
for prostate cancer include prior abdominal surgery, concomitant androgen 
deprivation and previous co-morbid conditions as diabetes mellitus, 
haemorrhoids, or inflammatory bowel disease (78, 84-86). Development of 
acute rectal toxicity is also associated with an increased risk of developing late 
rectal complications (87-90). The volume of rectal tissue exposed to high doses 
of RT has been shown to be associated with the development of rectal toxicity 
which is consistent with the serial behaviour of the GI tract (8, 89, 91). 
Factors associated with GU toxicity are pre-treatment GU complaints, prior 
transurethral resection of the prostate (TURP) and the presence of acute GU 
toxicity (84, 86, 92-94). Evaluation of the dosimetry and the relationship with GU 
complications is difficult due to highly variable bladder filling (95) and 
differences in bladder contouring: for some studies the bladder is a solid organ, 
containing the bladder wall and its entire contents (51, 93), whereas others 
contour the bladder wall alone (96-98). Prostate cancer patients treated at GUH 
undergo daily medical imaging to verify bladder filling and the bladder is 
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contoured as a solid organ. Acute symptoms are suggested to be related to 
swelling and inflammation of the prostatic urethra (99); late toxicity is possibly 
related to damage to the bladder neck and dose to the trigone region (100). 
Recently, image-guided RT using implanted prostatic fiducial markers showed 
to reduce the dose to this region together with the levels of urinary toxicity (94). 
Late bladder toxicity typically manifests many years after rectal toxicity with 
increasing rates over time (89). 
Erectile dysfunction (ED) is a relatively common complication in prostate 
cancer treatment and the occurrence of spontaneous erections before treatment 
is the best indicator for the preservation of erections sufficient for intercourse 
(101). Other factors associated with decline in erectile function are higher age, 
worsening co-morbid conditions and androgen deprivation therapy (102, 103). 
Moreover, the use of magnetic resonance imaging permits, by vessel-sparing 
RT, a reduction in the dose delivered to vascular structures critical for erectile 
function (104). At the start of this PhD research, erectile function prior to RT 
was not standard recorded and was therefore not analysed. 
 
2.3.2 Different approaches for prediction modelling 
The parameters mentioned above can be used to develop predictive models 
which would enable us to calculate the individual’s probability to develop 
radiation-induced side effects in order to personalize RT treatment. Their 
predictive value can be evaluated applying several approaches. The most 
commonly used methods for predictor selection are logistic regression for binary 
outcome and Cox regression for time-to-event outcome. A brief overview of the 
clinically usable models with applied methodology is given. 
 
Predictive models are created in prostate cancer patients with the focus on 
rectal toxicity symptoms such as rectal bleeding and faecal incontinence. Within 
the AIROPROS 0102 trial, a number of prediction models, displayed as 
nomograms, were constructed that deal with clinical and dosimetric factors 
(105-107). The nomograms were developed based on forward and backward 
multivariate logistic regression analysis, incorporating covariates associated 
with univariate analysis (p≤0.20), to yield an individualised estimation of the 
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toxicity risk. The performance of the models was quantified by AUC and the 
sensitivity and specificity. For some models, calibration was assessed and 
bootstrapping was applied to correct for overfit (106). The authors were able to 
develop nomograms for the different rectal symptoms (105-107). The most 
recent model that predicts mean faecal incontinence is given as example (107), 
see Figure 2.5.  
 
 
Figure 2.5: Nomogram for late mean faecal incontinence (longitudinal definition) 
according to Fiorino et al (2012) (107). V40 Gy (%): the percentage of the rectum receiving 
40 Gy or more. This model has an AUC of 0.73 with sensitivity = 66.7% and specificity = 
74.0%. Use of the nomogram: each predictor represents a number of points, achieved by 
drawing a straight upwards line to the ‘Pre-points’ axis. Subsequently, the points for each 
predictor are summed and this sum is located on the ‘Total points’ axis. Then, draw a line 
straight downwards to find the patients probability of developing late faecal incontinence. 
 
 
The EORTC trial could demonstrate that an additional RT-boost in breast 
cancer patients reduces the risk of local recurrence but increases the rate of 
development of fibrosis at 10 years of follow-up (30). For guiding clinicians in 
their decision of delivering a boost, the authors proposed nomograms to predict 
the risk of moderate or severe fibrosis at 10 years. Therefore, the dataset was 
split in a model development dataset and in a validation dataset. Models were 
developed applying multivariate Cox analysis including only the factors 
univariately significant at the 0.20 level, via backward elimination at the 0.10 
statistical significance level. Furthermore, bootstrap resampling for model 
calibration and for internal validation, provided a bias-corrected estimate of the 
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c-index. Sensitivity and specificity of the models were not calculated but 
according to the total points derived from the nomogram, patients were 
classified in subgroups, as shown in Figure 6.2. 
 
 
Figure 2.6: Prediction of the 10-year risk of moderate or severe fibrosis when treated 
with a boost according to Collette et al (2008) (30). (A) Nomogram; the c-index of the 
model is 0.66 in the development set and 0.62 in the validation set. (B) The cumulative 
incidence according to the total prognostic score derived from the nomograms. The 
horizontal line indicates 20% cumulative incidence of moderate to severe fibrosis. The 
model is able to discriminate the patients with >125 points on the nomogram (high-risk 
subgroup), the patients that show a low risk of fibrosis (<125 points) are not well 
discriminated (30). 
 
Another methodology was applied for the prediction of esophagitis after RT 
in non-small cell lung cancer patients (108). Again, patients were divided into a 
training set and a validation set. Multivariate logistic regression models were 
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generated on the training set by the use of forward-stepwise selection 
procedures. Factors included in the model needed to meet three criteria: they 
should be statistically significant, they should increase the discriminating ability 
of the model and the model should be well-calibrated. Then, three risk groups 
(low, intermediate, high) were created by recursive partitioning analysis (RPA) 
including the significant predictors from multivariate analysis. The performance 
of the model, under the form of c-statistic, and the RPA were evaluated using 
the validation set, see Figure 2.7. 
 
 
Figure 2.7: Recursive partitioning analysis (RPA) for radiation esophagitis (RE) grade 
≥2 and grade ≥3 according to Palma et al. (2013). T: Training set; V: Validation set. The 
percentage of the volume of the oesophagus receiving 60 Gy (V60) is the only factor with 
good discrimination score (c > 0.60). The c-statistic of the predictive model for grade ≥2 
was 0.58 and for grade ≥3 was 0.66 (108). 
 
 
In this PhD, associations between different types of parameters (clinical, 
treatment and dosimetric) and the endpoint of interest were investigated by 
applying logistic regression. Prediction models were developed applying the 
least absolute shrinkage and selection operator or Lasso method. Additionally, 
we add genetic data under the form of genetic polymorphisms, as it is 
suggested that they play an important role in influencing the susceptibility for 
development of radiation injury and, thus, may enrich the predictive 
performance of models (109, 110). This genetic part is discussed in more detail 
in the following chapter.  
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3 Radiosensitivity is influenced by genetic factors 
The study of genetic variation on radiation response is called radiogenomics; it 
focuses on uncovering the underlying genetic causes of individual variation in 
sensitivity to radiation. The most common source of variation between humans 
are single nucleotide polymorphisms or SNPs.  
In this chapter, we start by describing the suggested allelic architecture of 
radiosensitivity and explain the unique features of SNPs. Furthermore, different 
approaches to select polymorphisms and genotyping assays are discussed. 
 
3.1 Radiosensitivity heritability and allelic architecture 
Radiosensitivity can result in different observations. This can be (i) in cellular 
context (measured in the laboratory using a clonogenic, chromosome damage, 
DNA damage or apoptosis assay) or (ii) in clinical setting, described by 
differences in toxicity after RT with some tissues more radiosensitive than 
others, or (iii) susceptibility to radiation-induced cancer (111, 112). The high 
heritability of enhanced chromosomal and cellular radiosensitivity has been 
shown by many studies with values ranging from 58% to 78% (113-117). In 
contrast, data to assess the heritability of clinical radiosensitivity based upon 
family history are not available, but, is perhaps somewhat lower than for 
chromosomal and cellular radiosensitivity (117). One study comparing intra- and 
interpatient variability, estimated that about 80% of the total variation in the 
development of skin telangiectasia was attributed to patient-related factors, 
such as genetics and physiology (118). Cellular and clinical radiosensitivity 
follow an approximately Gaussian distribution as is the case for height, which 
has a strong heritability component (111, 119, 120).  
Radiosensitivity is considered to be a complex polygenic trait (7, 110). It is 
previously proposed that the allelic architecture of this trait includes a spectrum 
of sequence alterations ranging from rare highly penetrant alterations to 
common alterations with small relative risks (1.1 – 1.5), as shown in Figure 3.1 
(111, 120, 121). Earlier studies identified rare homozygous mutations resulting 
in large effects on clinical radiosensitivity with a high relative risk (>10) (121), for 
example in patients with severe syndromes such as ataxia telangiectasia, 
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Blooms syndrome and Nijmegen breakage syndrome (122). However, it is 
unknown whether high-risk radiosensitivity alleles exist outside patients with 
genetic Mendelian syndromes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Allelic architecture of radiosensitivity. From West et al. (111). Allelic 
architecture refers to the number, type, effect size and frequency of susceptibility variants 
in relation to a specific trait. Rare high-risk alleles are typically discovered by family studies 
and linkage analysis, rare intermediate-risk alleles by re-sequencing in case–control 
studies and common low risk alleles by candidate gene SNP studies and GWAS (123).  
 
3.2 Single Nucleotide Polymorphisms 
A SNP is a single base substitution and may occur every 100 to 300 bases 
among the 3 billion base-pair genome; they are generally described as allelic 
variants that occur in the population with a frequency of >1% and are typically 
characterized as low-penetrance variants. This is in contrast to mutations, which 
are usually rare, but associated with high penetrance. The allele frequencies 
may differ between ethnic groups or in different geographical regions, usually as 
a result of genetic drift or natural selection (111, 124). The human genome is 
organised into haplotype blocks separated by recombination hot spots. Within 
each block, alleles of multiple SNPs are inherited together as a single unit; they 
are in linkage disequilibrium (LD).  
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In genetic studies, SNPs can serve as genomic markers for their association 
with complex diseases and traits and for predicting disease susceptibility and 
drug response, contributing to personalised medicine. They are also used in 
studies of human migration and evolution (124). Depending on their position, 
genetic variants can have an impact on function; SNPs in coding regions can 
have an effect at the protein level, with altered protein stability or catalytic 
activity. SNPs in regulatory regions of the genome can affect gene expression, 
and those in non-coding sequences can influence splicing, RNA cleavage, 
stability or export (125). Identification of the variants causing the disease or trait 
may bring more insights into disease aetiology. However, most SNPs do not 
cause disease, they rather represent a physical location to pinpoint the disease 
on the human genome map. Hence, most SNPs that are statistically associated 
with the disease from genetic association studies, are likely in LD with the true 
causative alleles. The next step to investigate the causal role are additional 
functional and mechanistic studies (126). Additionally, SNPs can be used to 
determine the likelihood that an individual will develop a disease which can 
serve as the basis for a prediction assay. These assays might enable us to 
permit an earlier intervention to prevent development of the disease of interest. 
For example, in pharmacogenomics, the FDA recommendation of the dosage of 
warfarin, given to prevent systemic embolism, is based on a SNP profile in the 
CYP2C9 gene and the VKORC1 gene (127).  
 
3.2.1 Different genetic inheritance models 
Bi-allelic polymorphisms can occur under the form of three genotypes; wild type 
and homozygous variant genotype when two copies of the, respectively, major 
or minor alleles are present and the heterozygous genotype when one of each 
allele is present. To assess the genetic effect of each genotype, different 
genetic inheritance models can be defined. The most commonly used genetic 
models are the recessive, dominant, additive and codominant models. In the 
recessive model, patients carrying the homozygous variant genotype are 
considered to be different from the group of patients with the wild type and 
heterozygous genotype. In the dominant model, patients containing at least one 
minor allele are grouped and compared with patients carrying the wild type. In 
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the additive model, it is assumed that the effect of the heterozygous genotype is 
in between the effects of both homozygous genotypes in a dose-dependent 
manner. A comparison of the three genotypes is performed in the codominant 
model, with usually the wild type as a reference compared with the 
heterozygous and homozygous variant genotype separately. A special case is 
the over-dominant model where the risk conferred by the heterozygous 
genotype falls outside both homozygous risks (128). This can be tested by 
comparing the heterozygous genotypes to all homozygous genotypes. 
In the present PhD research, the dominant, recessive and codominant 
models are tested for association of SNPs with the phenotype. Testing multiple 
hypotheses at the conventional significance level of 0.05 may lead to inflated 
false-positive results and requires multiple-testing correction. In this work, 
multiple testing is performed by the Benjamini-Hochberg procedure. 
 
3.3 How are SNPs selected? 
Genetic studies can be performed using different approaches, the candidate 
gene approach and the genome-wide approach. 
In candidate gene association studies, there is a prior knowledge of the 
genes based on the pathogenesis of the phenotype. The idea is that maximising 
the biological plausibility would increase the chance of success. This approach, 
however, is limited by its reliance on the existing knowledge to identify 
candidate genes (126) but can be broadened by selecting genes that participate 
in the entire pathway of interest. In this way, the variability in that pathway is 
explored without restricting the analysis to a single gene (129). Subsequently, 
different criteria can be applied to perform the SNP selection. Some criteria are 
listed: the validation status of the SNP, to increase the certainty of selecting 
genuine polymorphic variants, the position of the variant in the different gene 
regions (3’ or 5’ near gene or untranslated region (UTR), introns or exons), the 
functionality of the polymorphism, which can already be extensively studied or 
examined in silico by different web-based tools, like SNPs3D (130). SNPs can 
also be selected within evolutionary conserved sequences within different 
species which are likely of functional importance (129). 
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Genome-wide association studies (GWASs) are primarily designed to 
provide an unbiased survey of the effects of common genetic variants (131). LD 
is exploited to tag the most common haplotypes which are extracted from the 
International HapMap Project data set. However, despite the density of the 
SNPs on the arrays, it covers only a fraction of the total variation in the genome 
(131). The drawback of this method is the large dataset necessary to identify 
SNPs related to the phenotype at a certain confidence level taking into account 
the multiple testing correction. 
 
3.4 SNP genotyping methods 
There is a diversity of high-fidelity SNP genotyping techniques, with different 
strategies; some of them are preceded by a polymerase chain reaction (PCR). 
The restriction fragment length polymorphism (RFLP) technique involves 
restriction endonucleases and their affinity to bind and cleave unique and 
specific restriction sites. The single base extension reaction (SnapShot®) is 
based on primer extension incorporating a single fluorescently labelled 
dideoxynucleotide by DNA polymerase and TaqMan Assays rely on the 5’-3’ 
nuclease activity of the Taq polymerase and fluorophore-based detection (132). 
The High Resolution Melting Analysis (HRMA) technique measures the 
differential fluorescence of double-strand specific DNA intercalating dyes while 
the DNA amplicon is melted. SNP platforms are based on direct hybridisation to 
allele-specific oligonucleotides or on the combination of primer extension and 
ligation or by aggregating both techniques for example in the Affymetrix 
GeneChip, Illumina GoldenGate and Infinium Beadchips arrays. Other arrays 
using mass spectrometry (iPlex), denaturing high performance liquid 
chromatography or quantitative-PCR are also available but are not further 
discussed. 
 
The predominantly used genotyping techniques in this PhD research are 
PCR-RFLP and HRMA. Additionally, a custom Illumina GoldenGate platform 
containing 384 SNPs was designed by applying the extended candidate gene 
approach. After a comprehensive literature search, genes within an entire 
pathway were selected. The pathways are involved in the early response to IR, 
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DNA checkpoint control and repair of DNA damage upon exposure to IR, ROS 
metabolism and hormonal metabolism. SNPs in those genes were selected 
either based on evolutionary conservation or on evidence for functionality. They 
were supplemented by SNPs previously shown to be associated with cancer 
predisposition in GWA case-control studies. 
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4 Aim of the research 
A substantial degree of variability exists among patients in their response to RT 
(118). Although long-term severe, sometimes life-threatening, side effects are 
present in only a minority of the patients, more patients experience moderate 
toxicity which can seriously impair patients’ quality of life. Examples are poor 
cosmetic outcome following breast irradiation or rectal and urinary complaints 
after prostate irradiation. Acute toxicity can cause pain and discomfort (81). In 
addition, there is growing clinical evidence that acute reactions are associated 
with the development of late toxicity; in breast cancer patients, telangiectasia 
seem to be late sequelae of moist desquamation and acute erythema seems to 
be a risk factor for poor cosmetic outcome (133, 134).  
The first aim of this thesis was to investigate the influence of patient-, 
treatment-, dosimetric parameters and genetic variation on the risk of 
developing acute radiation-induced toxicity in breast and prostate cancer 
patients.  
The second aim was to develop integrated predictive risk models for late 
toxicity in prostate cancer patients that allows a patient individualized estimation 
of its pre-treatment risk. Such models are clinical applicably to guide the 
allocation of patients to treatment groups based on their probability of severe 
RT-induced toxicity and simultaneously improve the therapeutic ratio.  
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5 Outline of the research 
External beam RT is a standard treatment modality for localized and locally 
advanced prostate cancer. More recent technologies such as IMRT allow for the 
delivery of high doses to the prostate, together with a better sparing of the 
rectum which results in a low rate of severe GI complications. Due to the full 
inclusion of the bladder neck and the vesicourethral anastomosis in the high-
dose region, the risk of developing severe GU toxicity remains, however, 
unchanged (88). In this PhD research, we have chosen to break down the 
overall toxicity to specific symptoms that are likely to reflect a specific radiation 
pathophysiology. As GI toxicity is very rare in our study cohort of prostate 
cancer patients, the analysis was performed for GU symptoms only: dysuria, 
incontinence, haematuria, urgency, nocturia and increased daily frequency.  
Acute RT-induced nocturia is in our study population the predominant acute 
toxicity endpoint in prostate cancer patients treated with primary or 
postoperative high-dose IMRT. A number of clinical and dosimetric parameters, 
together with five SNPs in the TGFB1 gene, capturing all common variants in 
the 5’ region of the gene (135), were tested for association with the endpoint. 
The polymorphic sites were examined by PCR-RFLP and HRMA. The results of 
this study are presented in a first paper (chapter 6) entitled ACUTE RADIATION-
INDUCED NOCTURIA IN PROSTATE CANCER PATIENTS IS ASSOCIATED WITH 
PRETREATMENT SYMPTOMS, RADICAL PROSTATECTOMY, AND GENETIC MARKERS IN THE 
TGFB1 GENE. 
Late radiation-induced haematuria and nocturia are the most frequently 
observed late GU symptoms. Models for prediction of these endpoints are 
developed containing clinical, dosimetric and genetic data. The genetic data 
were obtained by a custom-designed Illumina GoldenGate platform containing 
384 genetic variations. To deal with missing data and the high number of 
predictors, the EMLasso, an in-house developed and validated method, was 
applied. The results of this study are presented in a second paper (chapter 7) 
entitled INTEGRATED MODELS FOR THE PREDICTION OF LATE GENITOURINARY 
COMPLAINTS AFTER HIGH-DOSE INTENSITY-MODULATED RADIOTHERAPY FOR PROSTATE 
CANCER: MAKING INFORMED DECISIONS. 
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The current breast cancer cohort is treated with adjuvant RT after breast-
conserving surgery. Normofractionated (25x2 Gy) or hypofractionated (15x2.67 
Gy) IMRT in prone or supine position is prescribed. Systemic therapies like 
chemotherapy, hormone therapy and trastuzumab are administered when 
indicated. The endpoints of interest are the development of acute dermatitis and 
moist desquamation. In this PhD research, treatment- and patient-related 
factors such as bra size cup, body mass index (BMI) and smoking status, 
supplemented with eight SNPs are investigated for the association with the 
endpoints. Five of the eight SNPs were selected based on their putative effect 
on the expression levels of radiation-responsive genes (136). The other SNPs 
were chosen based on their previous association with toxicity induced by RT or 
methylating agents (137-140). The polymorphic sites were examined by PCR-
RFLP, HRMA and single base extension technique. The results of this study are 
represented in the third paper (chapter 8) entitled FACTORS MODIFYING THE RISK 
FOR DEVELOPING ACUTE SKIN TOXICITY AFTER WHOLE-BREAST INTENSITY MODULATED 
RADIOTHERAPY.  
31 
 
 
 
References 
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide 
burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 
2010;127(12):2893-917. 
2. http://surveillance.cancer.gov/statistics/. 
3. Kelsey CR, Rosenstein BS, Marks LB. Predicting toxicity from radiation therapy--it's 
genetic, right? Cancer. 2012;118(14):3450-4. 
4. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer 
treatment - Estimating optimal utilization from a review of evidence-based clinical guidelines. 
Cancer. 2005;104(6):1129-37. 
5. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and Radiation Therapy: Current Advances 
and Future Directions. International Journal of Medical Sciences. 2012;9(3):193-9. 
6. Moding EJ, Kastan MB, Kirsch DG. Strategies for optimizing the response of cancer and 
normal tissues to radiation. Nature Reviews Drug Discovery. 2013;12(7):526-42. 
7. Barnett GC, West CML, Dunning AM, Elliott RM, Coles CE, Pharoah PDP, et al. Normal 
tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nature Reviews 
Cancer. 2009;9(2):134-42. 
8. Joiner M, van der Kogel A. Basic clinical radiobiology. 4th Edition ed. London (UK): 
Hodder Arnold; 2009. 
9. Beyzadeoglu M, Ozyigit G, Ebruli C. Basic Radiation Oncology: Springer Berlin 
Heidelberg; 2010. 
10. Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK 
Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for 
treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098-107. 
11. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional 
versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 
preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology. 
2012;13(1):43-54. 
12. Gerber DE, Chan TA. Recent Advances in Radiation Therapy. American Family 
Physician. 2008;78(11):1254-62. 
13. http://www.redorbit.com/images/pic/29857/intensity-modulated-radiotherapy-image-2/. 
14. West CM, Barnett GC. Genetics and genomics of radiotherapy toxicity: towards 
prediction. Genome Medicine. 2011;3. 
15. Kavanagh JN, Redmond KM, Schettino G, Prise KM. DNA Double Strand Break Repair: 
A Radiation Perspective. Antioxidants & Redox Signaling. 2013;18(18):2458-72. 
16. O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human 
genetics. Nature Reviews Genetics. 2006;7(1):45-54. 
17. Polo SE, Jackson SP. Dynamics of DNA damage response proteins at DNA breaks: a 
focus on protein modifications. Genes & Development. 2011;25(5):409-33. 
18. Beucher A, Birraux J, Tchouandong L, Barton O, Shibata A, Conrad S, et al. ATM and 
Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in 
G2. Embo Journal. 2009;28(21):3413-27. 
19. Martin LM, Marples B, Coffey M, Lawler M, Lynch TH, Hollywood D, et al. DNA mismatch 
repair and the DNA damage response to ionizing radiation: Making sense of apparently 
conflicting data. Cancer Treatment Reviews. 2010;36(7):518-27. 
20. Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway 
promoting anti-oxidant defence and DNA repair. Embo Journal. 2011;30(3):546-55. 
32 
21. Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress 
and prolonged cell injury. Cancer Letters. 2012;327(1-2):48-60. 
22. Hirst DG, Robson T. Molecular biology: the key to personalised treatment in radiation 
oncology? British Journal of Radiology. 2010;83(993):723-8. 
23. Hall WH. Treatment of early-stage breast-cancer. Jama-Journal of the American Medical 
Association. 1991;265(3):391-5. 
24. Early Breast Canc Trialists C. Effect of radiotherapy after breast-conserving surgery on 
10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 
10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-16. 
25. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis 
and results after 12 years of follow-up in a randomized clinical-trial comparing total mastectomy 
with lumpectomy with or without irradiation in the treatment of breast-cancer. New England 
Journal of Medicine. 1995;333(22):1456-61. 
26. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year 
follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus 
irradiation for the treatment of invasive breast cancer. New England Journal of Medicine. 
2002;347(16):1233-41. 
27. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK 
Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for 
treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. 
Lancet Oncology. 2013;14(11):1086-94. 
28. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-Term 
Results of Hypofractionated Radiation Therapy for Breast Cancer. New England Journal of 
Medicine. 2010;362(6):513-20. 
29. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. British 
Journal of Radiology. 1989;62(740):679-94. 
30. Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, et al. 
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast 
cancer - A study based on the EORTC trial 22881-10882 'boost versus no boost'. European 
Journal of Cancer. 2008;44(17):2587-99. 
31. Coles CE, Brunt AM, Wheatley D, Mukesh MB, Yarnold JR. Breast Radiotherapy: Less is 
More? Clinical Oncology. 2013;25(2):127-34. 
32. Mulliez T, Veldeman L, van Greveling A, Speleers B, Sadeghi S, Berwouts D, et al. 
Hypofractionated whole breast irradiation for patients with large breasts: A randomized trial 
comparing prone and supine positions. Radiother Oncol. 2013. 
33. Adamowicz K, Marczewska M, Jassem J. Combining systemic therapies with radiation in 
breast cancer. Cancer Treatment Reviews. 2009;35(5):409-16. 
34. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant 
Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine. 
2011;365(14):1273-83. 
35. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. 
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results 
from the MRC RT01 randomised controlled trial. Lancet Oncology. 2007;8(6):475-87. 
36. Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE. Radical 
prostatectomy vs. intensity-modulated radiation therapy in the management of localized 
prostate adenocarcinoma. Radiotherapy and Oncology. 2009;93(2):185-91. 
37. Tree AC, Alexander EJ, Van As NJ, Dearnaley DP, Khoo V. Biological Dose Escalation 
and Hypofractionation: What is There to be Gained and How Will it Best be Done? Clinical 
Oncology. 2013;25(8):483-98. 
38. Zaorsky NG, Ohri N, Showalter TN, Dicker AP, Den RB. Systematic review of 
hypofractionated radiation therapy for prostate cancer. Cancer Treatment Reviews. 
2013;39(7):728-36. 
33 
 
 
 
39. http://www.controlled-trials.com/ISRCTN45905321. 
40. Zamboglou N, Tselis N, Baltas D, Buhleier T, Martin T, Milickovic N, et al. High-Dose-
Rate Interstitial Brachytherapy as Monotherapy for Clinically Localized Prostate Cancer: 
Treatment Evolution and Mature Results. International Journal of Radiation Oncology Biology 
Physics. 2013;85(3):672-8. 
41. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: 
consequences and mechanisms. Lancet Oncology. 2003;4(9):529-36. 
42. Turesson I. Individual variation and dose dependency in the progression rate of skin 
telangiectasia. International Journal of Radiation Oncology Biology Physics. 1990;19(6):1569-
74. 
43. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of 
normal tissue complication probability models in the clinic. International Journal of Radiation 
Oncology Biology Physics. 2010;76(3):S10-S9. 
44. Mukesh B, Harris E, Collette S, Coles CE, Bartelink H, Wilkinson J, et al. Normal tissue 
complication probability (NTCP) parameters for breast fibrosis: Pooled results from two 
randomised trials. Radiotherapy and Oncology. 2013;108(2):293-8. 
45. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology 
meets molecular pathology. Nature reviews Cancer. 2006;6(9):702-13. 
46. Small W, Woloschak GE. Radiation Toxicity: A Practical Guide: Springer US; 2006. 
47. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group 
(RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). 
International Journal of Radiation Oncology Biology Physics. 1995;31(5):1341-6. 
48. Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, et al. Late effects 
toxicity scoring - The SOMA scale. Radiotherapy and Oncology. 1995;35(1):11-5. 
49. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: 
Development of a comprehensive grading system for the adverse effects of cancer treatment. 
Seminars in Radiation Oncology. 2003;13(3):176-81. 
50. http://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm. 
51. De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, et al. 
Intensity-modulated radiotherapy as primary treatment for prostate cancer: Acute toxicity in 114 
patients. International Journal of Radiation Oncology Biology Physics. 2004;60(3):777-87. 
52. Ost P, Fonteyne V, Villeirs G, Lumen N, Oosterlinck W, De Meerleer G. Adjuvant High-
Dose Intensity-Modulated Radiotherapy after Radical Prostatectomy for Prostate Cancer: 
Clinical Results in 104 Patients. European urology. 2009;56(4):669-75. 
53. Stewart FA, Dorr W. Milestones in normal tissue radiation biology over the past 50 years: 
From clonogenic cell survival to cytokine networks and back to stem cell recovery. International 
Journal of Radiation Biology. 2009;85(7):574-86. 
54. Westbury CB, Yarnold JR. Radiation Fibrosis - Current Clinical and Therapeutic 
Perspectives. Clinical Oncology. 2012;24(10):657-72. 
55. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN. A perpetual cascade of 
cytokines postirradiation leads to pulmonary fibrosis. International Journal of Radiation 
Oncology Biology Physics. 1995;33(1):99-109. 
56. Schaue D, Kachikwu EL, McBride WH. Cytokines in Radiobiological Responses: A 
Review. Radiation Research. 2012;178(6):505-23. 
57. McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, et al. Failla Memorial 
Lecture - A sense of danger from radiation. Radiation Research. 2004;162(1):1-19. 
58. Collins-Underwood JR, Zhao WL, Sharpe JG, Robbins ME. NADPH oxidase mediates 
radiation-induced oxidative stress in rat brain microvascular endothelial cells. Free Radical 
Biology and Medicine. 2008;45(6):929-38. 
34 
59. Mikkelsen RB, Wardman P. Biological chemistry of reactive oxygen and nitrogen and 
radiation-induced signal transduction mechanisms. Oncogene. 2003;22(37):5734-54. 
60. Robbins MEC, Zhao W. Chronic oxidative stress and radiation-induced late normal tissue 
injury: a review. International Journal of Radiation Biology. 2004;80(4):251-9. 
61. Zhao W, Diz DI, Robbins ME. Oxidative damage pathways in relation to normal tissue 
injury. British Journal of Radiology. 2007;80:S23-S31. 
62. Granet C, Miossec P. Combination of the pro-inflammatory cytokines IL-1, TNF-alpha and 
IL-17 leads to enhanced expression and additional recruitment of AP-1 family members, Egr-1 
and NF-kappa B in osteoblast-like cells. Cytokine. 2004;26(4):169-77. 
63. Lavin MF. Radiosensitivity and oxidative signalling in ataxia telangiectasia: an update. 
Radiotherapy and Oncology. 1998;47(2):113-23. 
64. Salceda S, Caro J. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) protein is rapidly 
degraded by the ubiquitin-proteasome system under normoxic conditions - Its stabilization by 
hypoxia depends on redox-induced changes. Journal of Biological Chemistry. 
1997;272(36):22642-7. 
65. Han D, Ybanez MD, Ahmadi S, Yeh K, Kaplowitz N. Redox Regulation of Tumor Necrosis 
Factor Signaling. Antioxidants & Redox Signaling. 2009;11(9):2245-63. 
66. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, et al. Stress and 
radiation-induced activation of multiple intracellular signaling pathways. Radiation Research. 
2003;159(3):283-300. 
67. Liu RM, Pravia KAG. Oxidative stress and glutathione in TGF-beta-mediated 
fibrogenesis. Free Radical Biology and Medicine. 2010;48(1):1-15. 
68. Zhao WH, Xie WJ, Xiao Q, Beers DR, Appel SH. Protective effects of an anti-
inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. 
Journal of Neurochemistry. 2006;99(4):1176-87. 
69. Hopewell JW, Trott KR. Volume effects in radiobiology as applied to radiotherapy. 
Radiotherapy and Oncology. 2000;56(3):283-8. 
70. Withers HR, Taylor JMG, Maciejewski B. Treatment volume and tissue tolerance. 
International Journal of Radiation Oncology Biology Physics. 1988;14(4):751-9. 
71. Azria D, Gourgou S, Sozzi WJ, Zouhair A, Mirimanoff RO, Kramar A, et al. Concomitant 
use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive 
patients. British Journal of Cancer. 2004;91(7):1251-60. 
72. De Langhe S, De Ruyck K, Ost P, Fonteyne V, Werbrouck J, De Meerleer G, et al. Acute 
Radiation-Induced Nocturia in Prostate Cancer Patients Is Associated With Pretreatment 
Symptoms, Radical Prostatectomy, and Genetic Markers in the TGF beta 1 Gene. International 
Journal of Radiation Oncology Biology Physics. 2013;85(2):393-9. 
73. Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP. The 
Impact of Clinical Factors on the Development of Late Radiation Toxicity: Results from the 
Medical Research Council RT01 Trial (ISRCTN47772397). Clinical Oncology. 2011. 
74. Freedman GM, Anderson PR, Li JS, Eisenberg DF, Hanlon AL, Wang L, et al. Intensity 
modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation 
for breast cancer. American Journal of Clinical Oncology-Cancer Clinical Trials. 2006;29(1):66-
70. 
75. Sharp L, Johansson H, Hatschek T, Bergenmar M. Smoking as an independent risk 
factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast. 
2013;22(5):634-8. 
76. Holscher T, Bentzen SM, Baumann M. Influence of connective tissue diseases on the 
expression of radiation side effects: A systematic review. Radiotherapy and Oncology. 
2006;78(2):123-30. 
77. Chon BH, Loeffler JS. The effect of nonmalignant systemic disease on tolerance to 
radiation therapy. Oncologist. 2002;7(2):136-43. 
35 
 
 
 
78. Herold DM, Hanlon AL, Hanks GE. Diabetes mellitus: A predictor for late radiation 
morbidity. International Journal of Radiation Oncology Biology Physics. 1999;43(3):475-9. 
79. Peters CA, Cesaretti JA, Stone NN, Stock RG. Low-dose rate prostate brachytherapy is 
well tolerated in patients with a history of inflammatory bowel disease. International Journal of 
Radiation Oncology Biology Physics. 2006;66(2):424-9. 
80. Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, et al. The 
Cambridge Breast Intensity-modulated Radiotherapy Trial: Patient- and Treatment-related 
Factors that Influence Late Toxicity. Clinical Oncology. 2011;23(10):662-73. 
81. Feight D, Baney T, Bruce S, McQuestion M. Putting Evidence Into Practice: Evidence-
Based Interventions for Radiation Dermatitis. Clinical Journal of Oncology Nursing. 
2011;15(5):481-92. 
82. Poortmans PM, Collette L, Bartelink H, Struikmans H, Van den Bogaert WF, Fourquet A, 
et al. The addition of a boost dose on the primary tumour bed after lumpectomy in breast 
conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 
"boost versus no boost" trial. Cancer Radiotherapie. 2008;12(6-7):565-70. 
83. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of 
Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer. New England Journal 
of Medicine. 2013;368(11):987-98. 
84. Peeters STK, Heemsbergen WD, Van Putten WLJ, Slot A, Tabak H, Mens JW, et al. 
Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter 
randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology 
Physics. 2005;61(4):1019-34. 
85. Peeters STH, Lebesque JV, Heemsbergen WD, van Putten WLJ, Slot A, Dielwart MFH, 
et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate 
cancer. International Journal of Radiation Oncology Biology Physics. 2006;64(4):1151-61. 
86. Budaus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, et al. Functional Outcomes 
and Complications Following Radiation Therapy for Prostate Cancer: A Critical Analysis of the 
Literature. European Urology. 2012;61(1):112-27. 
87. Alicikus ZA, Yamada Y, Zhang ZG, Pei X, Hunt M, Kollmeier M, et al. Ten-Year 
Outcomes of High-Dose, Intensity-Modulated Radiotherapy for Localized Prostate Cancer. 
Cancer. 2011;117(7):1429-37. 
88. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late 
rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-
modulated radiotherapy for localized prostate cancer. International Journal of Radiation 
Oncology Biology Physics. 2008;70(4):1124-9. 
89. Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al. 
Preliminary Toxicity Analysis of 3-Dimensional Conformal Radiation Therapy Versus Intensity 
Modulated Radiation Therapy on the High-Dose Arm of the Radiation Therapy Oncology Group 
0126 Prostate Cancer Trial. International Journal of Radiation Oncology Biology Physics. 
2013;87(5):932-8. 
90. Heemsbergen WD, Peeters STH, Koper PCM, Hoogeman MS, Lebesque JV. Acute and 
late gastrointestinal toxicity after radiotherapy in prostate cancer patients: Consequential late 
damage. International Journal of Radiation Oncology Biology Physics. 2006;66(1):3-10. 
91. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in 
radiation-induced rectal injury. International Journal of Radiation Oncology Biology Physics. 
2010;76(3):S123-S9. 
92. Fiorino C, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in 
external radiotherapy: Pelvis. Radiotherapy and Oncology. 2009;93(2):153-67. 
93. Jereczek-Fossa BA, Zerini D, Fodor C, Santoro L, Serafini F, Cambria R, et al. 
Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-
dimensional conformal external beam radiotherapy. International Journal of Radiation Oncology 
Biology Physics. 2010;78(1):26-34. 
36 
94. Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved Clinical 
Outcomes With High-Dose Image Guided Radiotherapy Compared With Non-IGRT for the 
Treatment of Clinically Localized Prostate Cancer. International Journal of Radiation Oncology 
Biology Physics. 2012;84(1):125-9. 
95. Rosewall T, Catton C, Currie G, Bayley A, Chung P, Wheat J, et al. The relationship 
between external beam radiotherapy dose and chronic urinary dysfunction - A methodological 
critique. Radiotherapy and Oncology. 2010;97(1):40-7. 
96. Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, et al. Predictors for 
chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional 
conformal radiotherapy: Dose-volume analysis of a phase II dose-escalation study. International 
Journal of Radiation Oncology Biology Physics. 2007;69(4):1100-9. 
97. Boersma LJ, van den Brink M, Bruce AM, Shouman T, Gras L, te Velde A, et al. 
Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) 
conformal radiotherapy for prostate cancer, using dose-volume histograms. International 
Journal of Radiation Oncology Biology Physics. 1998;41(1):83-92. 
98. Ahmed AA, Egleston B, Alcantara P, Li LN, Pollack A, Horwitz EM, et al. A Novel Method 
for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for 
Age-Based Risk-Adapted Dose Constraints. International Journal of Radiation Oncology Biology 
Physics. 2013;86(4):709-15. 
99. Zelefsky MJ, Ginor RX, Fuks Z, Leibel SA. Efficacy of selective alpha-1 blocker therapy in 
the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. 
International Journal of Radiation Oncology Biology Physics. 1999;45(3):567-70. 
100. Ghadjar P, Zelefsky MJ, Spratt DE, af Rosenschold PM, Oh JH, Hunt M, et al. Impact of 
Dose to the Bladder Trigone on Long-Term Urinary Function After High-Dose Intensity 
Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation 
Oncology Biology Physics. 2014;88(2):339-44. 
101. Pinkawa M, Gagel B, Piroth MD, Fischedick K, Asadpour B, Kehl M, et al. Erectile 
Dysfunction After External Beam Radiotherapy for Prostate Cancer. European Urology. 
2009;55(1):227-36. 
102. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence 
of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts 
male aging study. Journal of Urology. 2000;163(2):460-3. 
103. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for 
prostate cancer and radiation dose to the penile structures: A critical review. Radiotherapy and 
Oncology. 2007;84(2):107-13. 
104. McLaughlin PW, Narayana V, Meriowitz A, Troyer S, Roberson PL, Gonda R, et al. 
Vessel-sparing prostate radiotherapy: Dose limitation to critical erectile vascular structures 
(internal pudendal artery and corpus cavernosum) defined by MRI. International Journal of 
Radiation Oncology Biology Physics. 2005;61(1):20-31. 
105. Valdagni R, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M, et al. Development of a 
set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. 
International Journal of Radiation Oncology Biology Physics. 2008;71(4):1065-73. 
106. Valdagni R, Kattan MW, Rancati T, Yu CH, Vavassori V, Fellin G, et al. Is it time to tailor 
the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of 
nomograms for late rectal syndrome. International Journal of Radiation Oncology Biology 
Physics. 2012;82(5):1957-66. 
107. Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Borca VC, et al. Late Fecal 
Incontinence After High-Dose Radiotherapy for Prostate Cancer: Better Prediction Using 
Longitudinal Definitions. International Journal of Radiation Oncology Biology Physics. 
2012;83(1):38-45. 
108. Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, et al. Predicting 
Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual 
37 
 
 
 
Patient Data Meta-Analysis. International Journal of Radiation Oncology Biology Physics. 
2013;87(4):690-6. 
109. Andreassen CN, Alsner J, Overgaard J. Does variability in normal tissue reactions after 
radiotherapy have a genetic basis - where and how to look for it? Radiotherapy and Oncology. 
2002;64(2):131-40. 
110. Andreassen CN. Can risk of radiotherapy-induced normal tissue complications be 
predicted from genetic profiles? Acta Oncologica. 2005;44(8):801-15. 
111. West CML, Dunning AM, Rosenstein BS. Genome-Wide Association Studies and 
Prediction of Normal Tissue Toxicity. Seminars in Radiation Oncology. 2012;22(2):91-9. 
112. Foray N, Colin C, Bourguignon M. 100 Years of Individual Radiosensitivity: How We Have 
Forgotten the Evidence. Radiology. 2012;264(3):627-31. 
113. Finnon P, Robertson N, Dziwura S, Raffy C, Zhang W, Ainsbury L, et al. Evidence for 
significant heritability of apoptotic and cell cycle responses to ionising radiation. Human 
Genetics. 2008;123(5):485-93. 
114. Curwen GB, Cadwell KK, Winther JF, Tawn EJ, Rees GS, Olsen JH, et al. The heritability 
of G(2) chromosomal radiosensitivity and its association with cancer in Danish cancer survivors 
and their offspring. International Journal of Radiation Biology. 2010;86(11):986-95. 
115. Roberts SA, Spreadborough AR, Bulman B, Barber JBP, Evans DGR, Scott D. Heritability 
of cellular radiosensitivity: A marker of low-penetrance predisposition genes in breast cancer. 
American Journal of Human Genetics. 1999;65(3):784-94. 
116. Surowy H, Rinckleb A, Luedeke M, Stuber M, Wecker A, Varga D, et al. Heritability of 
baseline and induced micronucleus frequencies. Mutagenesis. 2011;26(1):111-7. 
117. Talbot CJ, Tanteles GA, Barnett GC, Burnet NG, Chang-Claude J, Coles CE, et al. A 
replicated association between polymorphisms near TNF alpha and risk for adverse reactions to 
radiotherapy. British Journal of Cancer. 2012;107(4):748-53. 
118. Safwat A, Bentzen SM, Turesson I, Hendry JH. Deterministic rather than stochastic 
factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. 
International Journal of Radiation Oncology Biology Physics. 2002;52(1):198-204. 
119. Barnett GC, West CML, Coles CE, Pharoah PDP, Talbot CJ, Elliott RM, et al. 
Standardized total average toxicity score: a scale- and grade-independent measure of late 
radiotherapy toxicity to facilitate pooling of data from different studies. International Journal of 
Radiation Oncology Biology Physics. 2012;82(3):1065-74. 
120. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the 
missing heritability of complex diseases. Nature. 2009;461(7265):747-53. 
121. Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: 
A systematic review. Radiotherapy and Oncology. 2009;92(3):299-309. 
122. Pollard JM, Gatti RA. Clinical radiation sensitivity with DNA repair disorders: an overview. 
International Journal of Radiation Oncology Biology Physics. 2009;74(5):1323-31. 
123. Andreassen CN. Searching for genetic determinants of normal tissue radiosensitivity - 
Are we on the right track? Radiotherapy and Oncology. 2010;97(1):1-8. 
124. Shastry BS. SNP alleles in human disease and evolution. Journal of Human Genetics. 
2002;47(11):561-6. 
125. Savas S, Geraci J, Jurisica I, Liu G. A comprehensive catalogue of functional genetic 
variations in the EGFR pathway: Protein-protein interaction analysis reveals novel genes and 
polymorphisms important for cancer research. International Journal of Cancer. 
2009;125(6):1257-65. 
126. Pharoah PDP, Dunning AM, Ponder BAJ, Easton DF. Association studies for finding 
cancer-susceptibility genetic variants. Nature Reviews Cancer. 2004;4(11):850-60. 
38 
127. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MTM, et al. Estimation of 
the Warfarin Dose with Clinical and Pharmacogenetic Data. New England Journal of Medicine. 
2009;360(8):753-64. 
128. Savas S, Liu G, Xu W. Special considerations in prognostic research in cancer involving 
genetic polymorphisms. Bmc Medicine. 2013;11:11. 
129. Kooloos WM, Wessels JAM, van der Straaten T, Huizinga TWJ, Guchelaar HJ. Criteria 
for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF 
inhibitors as a case study. Drug Discovery Today. 2009;14(17-18):837-44. 
130. www.snps3d.org. 
131. Marian AJ, Belmont J. Strategic Approaches to Unraveling Genetic Causes of 
Cardiovascular Diseases. Circulation Research. 2011;108(10):1252-69. 
132. https://www.lifetechnologies.com/be/en/home/life-science/gene-expression-analysis-
genotyping/genotyping-genomic-profiling.html. 
133. Lilla C, Ambrosone CB, Kropp S, Helmbold I, Schmezer P, von Fournier D, et al. 
Predictive factors for late normal tissue complications following radiotherapy for breast cancer. 
Breast Cancer Research and Treatment. 2007;106(1):143-50. 
134. Tanteles GA, Whitworth J, Mills J, Peat I, Osman A, McCann GP, et al. Can cutaneous 
telangiectasiae as late normal-tissue injury predict cardiovascular disease in women receiving 
radiotherapy for breast cancer? British Journal of Cancer. 2009;101(3):403-9. 
135. Schirmer MA, Brockmoller J, Rave-Frank M, Virsik P, Wilken B, Kuhnle E, et al. A 
putatively functional haplotype in the gene encoding transforming growth factor beta-1 as a 
potential biomarker for radiosensitivity. International journal of radiation oncology, biology, 
physics. 2011;79(3):866-74. 
136. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG. Genetic analysis of radiation-
induced changes in human gene expression. Nature. 2009;459(7246):587-U120. 
137. Murray RJS, Tanteles GA, Mills J, Perry A, Peat I, Osman A, et al. Association between 
single nucleotide polymorphisms in the DNA repair gene LIG3 and acute adverse skin reactions 
following radiotherapy. Radiotherapy and Oncology. 2011;99(2):231-4. 
138. Suga T, Ishikawa A, Kohda M, Otsuka Y, Yamada S, Yamamoto N, et al. Haplotype-
based analysis of genes associated with risk of adverse skin reactions after radiotherapy in 
breast cancer patients. International Journal of Radiation Oncology Biology Physics. 
2007;69(3):685-93. 
139. Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, et al. 
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. 
Journal of Medical Genetics. 2008;45(3):142-6. 
140. Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, et al. Acute 
Normal Tissue Reactions in Head-and-Neck Cancer Patients Treated with Imrt: Influence of 
Dose and Association with Genetic Polymorphisms in DNA Dsb Repair Genes. International 
Journal of Radiation Oncology Biology Physics. 2009;73(4):1187-95. 
  
 
  
 
  
 
 
 
 
 
 
 
Part II 
Identification of factors modifying or predicting  
the risk to develop radiation-induced toxicity 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
 
 
6 Paper I 
 
Acute Radiation-Induced Nocturia in Prostate Cancer Patients Is Associated With 
Pretreatment Symptoms, Radical Prostatectomy, and Genetic Markers in the 
TGFB1 Gene 
 
De Langhe Sofiea M.Sc., De Ruyck Kima PhD, Ost Pietb MD PhD, Fonteyne 
Valérieb MD PhD, Werbrouck Jokea PhD, De Meerleer Gertb MD PhD, De Neve 
Wilfriedb MD PhD, Thierens Huberta PhD. 
 
aDepartment of Basic Medical Sciences, Ghent University, Proeftuinstraat 86, 
9000 Gent, Belgium. 
bDepartment of Radiation Oncology, Ghent University Hospital, De Pintelaan 
185, 9000 Gent, Belgium. 
 
 
Reprint from International Journal of Radiation Oncology Biology Physics: 2013; 
85:393-399 
 
 
 
SUMMARY 
Severe nocturia occurs in approximately 25% of the prostate cancer patients as 
a side effect of radiation therapy, and thus sleep disturbance diminishes 
patients’ quality of life. This study of 322 patients demonstrates that clinical 
factors such as prior radical prostatectomy and the presence of mild 
pretreatment symptoms, as well as genetic markers in the TGFB1 gene, 
contribute to the development of severe radiation-induced nocturia. 
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ABSTRACT 
Purpose: After radiation therapy for prostate cancer, approximately 50% of the 
patients experience acute genitourinary symptoms, mostly nocturia. This may 
be highly bothersome with a major impact on the patient’s quality of life. In the 
past, nocturia is seldom reported as a single, physiologically distinct endpoint, 
and little is known about its aetiology. It is assumed that in addition to dose-
volume parameters and patient- and therapy-related factors, a genetic 
component contributes to the development of radiation-induced damage. In this 
study, we investigated the association among dosimetric, clinical, and TGFB1 
polymorphisms and the development of acute radiation-induced nocturia in 
prostate cancer patients. 
Methods and Materials: Data were available for 322 prostate cancer patients 
treated with primary or postoperative intensity modulated radiation therapy 
(IMRT). Five genetic markers in the TGFB1 gene (-800 G>A, -509 C>T, codon 
10 T>C, codon 25 G>C, g.10780 T>G), and a high number of clinical and 
dosimetric parameters were considered. Toxicity was scored using an symptom 
scale developed in-house. 
Results: Radical prostatectomy (P<.001) and the presence of pretreatment 
nocturia (P<.001) are significantly associated with the occurrence of radiation-
induced acute toxicity. The -509 CT/TT (P=.010) and codon 10 TC/CC (P=.005) 
genotypes are significantly associated with an increased risk for radiation-
induced acute nocturia. 
Conclusions: Radical prostatectomy, the presence of pretreatment nocturia 
symptoms, and the variant alleles of TGFB1 -509 C>T and codon 10 T>C are 
identified as factors involved in the development of acute radiation-induced 
nocturia. These findings may contribute to the research on prediction of late 
nocturia after IMRT for prostate cancer. © 2013 Elsevier Inc. 
INTRODUCTION 
External beam radiation therapy (RT) is a standard treatment modality for 
localized and locally advanced prostate cancer (1). Modern technologies such 
as intensity modulated radiation therapy (IMRT) allow for the delivery of high 
doses to the prostate while lowering the dose to the neighboring organs at risk 
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(2, 3). This combination is of importance because a higher dose to the prostate 
improves local tumor and biochemical control (3). The use of modern radiation 
technology is needed to avoid excessive late toxicity with higher doses, as has 
been shown in randomized trials (4).  
However, even with IMRT, up to 50% of the patients treated with doses >70 
Gy experience bladder or bowel symptoms during treatment – so-called acute 
toxicity (5). Clinical variables such as any pretreatment genitourinary (GU) 
symptoms, androgen suppression, and prior transurethral resection of the 
prostate (TURP) appeared to be important prognostic factors for radiation-
induced acute GU toxicity (2, 6). Although late toxicity is reported more 
frequently, acute toxicity has been found to be an independent predictor for late 
toxicity (7). Radiation-induced GU toxicity is frequently scored using the 
Radiation Therapy Oncology Group (RTOG) scoring scale (8). This grading 
method includes criteria such as increased urinary frequency, nocturia, dysuria, 
urgency, and haematuria. 
A frequently occurring and under-reported GU symptom, occurring during or 
shortly after radiation therapy is nocturia (2, 3). Nocturia was recently found to 
be associated with a decreased quality of life and with an increased prevalence 
of depression because of more frequent nightly voids. Quality of life and well-
being are already affected in patients with a nocturnal voiding frequency of ≥2 
times (9). Nocturia is a storage problem of the bladder with a dynamic and 
irritative character (10) and is suggested to result from radiation-induced 
inflammation of the prostatic urethra (11). The majority of clinical studies do not 
evaluate nocturia as a specific endpoint or use grading systems other than 
RTOG to score nocturia (6, 12). In addition, many studies combine multiple 
symptoms, which are all suggested to differ in aetiology (10), into a single 
toxicity score (1, 6, 7).  
Because extrinsic factors, such as RT planning and delivery, are better 
controlled today, factors intrinsic to the patient arise as potentially more 
important in the development of radiation-induced toxicity. Identification of 
genes that possess genetic markers associated with clinical radiosensitivity may 
lead to a better understanding of the molecular pathogeneses underlying 
normal tissue injury and may allow a more rational approach to prevent 
radiation toxicity (13). 
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The multifunctional cytokine transforming growth factor-β1 (TGFB1) triggers 
a wide diversity of radiation responses depending on the genetic makeup and 
environment of the target cell. It is considered a biomarker of inflammatory and 
fibrotic responses to RT and has also been shown to play a key role in the 
cellular response to radiation-induced DNA damage (14). The 5’ region of the 
TGFB1 gene is highly polymorphic and likely to have an impact on the 
pathogenesis of numerous diseases through altered TGFB1 expression (15). 
Several studies have claimed associations between polymorphisms in the 
TGFB1 gene and acute or late adverse effects of RT in lung, prostate, breast, 
and gynecological cancer patients (13, 16, 17). Up to now, no studies have 
considered the relationship between TGFB1 polymorphisms and radiation-
induced nocturia in prostate cancer. 
Because dosimetric and patient-related risk factors add variability in 
radiation toxicity outcome, it is necessary to take these factors into account 
when trying to link genotype with a clinical phenotype (13). Therefore, we 
examined the effects of dose parameters, clinical, and individual genetic 
variations in TGFB1 to the development of radiation-induced nocturia during RT 
or within 3 months after RT in prostate cancer patients treated with high-dose 
IMRT. 
MATERIALS AND METHODS 
Patients 
The study population consisted of 322 Caucasian men treated with IMRT as 
primary or postoperative treatment for prostate cancer at the Ghent University 
Hospital between 1999 and 2010. All patients had a follow-up of at least 3 
months to be considered eligible for this study. 
The dose was prescribed as the median dose to the planning target volume, 
and the maximal rectal dose (R) was used as hard constraint. Prescription 
doses of 74, 76, or 80 Gy were delivered in, respectively, 36 (74R72), 37 
(76R74), or 38 (80R76) fractions with 18-MV photons of an Elekta linear 
accelerator (Crawley, United Kingdom) as described previously (2, 3, 18). Two 
hundred twenty-two patients were treated with primary IMRT, and 100 patients 
were treated with postoperative IMRT after radical prostatectomy (Table 1). 
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Table 1: Overview of prescription doses and RT-induced nocturia in primary and post-
operative IMRT setting. 
Treatment 
Prescription group 
All 
(n=322) 
No 
RT-induced  
nocturia 
(n=240) 
RT-induced  
nocturia 
(n=82) 
Primary IMRT (n = 222) 
    
 
P74R72 13 (5.9) 7 (53.8) 6 (46.2) 
 
P76R74 24 (10.8) 21 (87.5) 3 (12.5) 
 
P80R76 185 (83.3) 122 (65.9) 63 (34.1) 
Post-operative IMRT (n = 100) 
    
Adjuvant A76R74 51 (51.0) 47 (92.2) 4 (7.8) 
Salvage S74R72 49 (49.0) 43 (87.8) 6 (12.2) 
Abbreviations: RT = radiotherapy; IMRT = intensity-modulated radiation therapy; P = 
prescription; A = adjuvant; S = salvage; R = maximal rectal dose. 
Data in parentheses are percentages. 
 
To check the relationship between dosimetric parameters and acute 
nocturia, the following dose-volume parameters were investigated: the maximal 
bladder dose (Bmax [Gy]), the median dose to the clinical target volume (CTV) as 
surrogate for urethral dose (CTVmedian [Gy]), the maximal dose to the CTV 
(CTVmax [Gy]), and the CTV volume (CTVVol [cc]).  
Androgen deprivation therapy, consisting of administration of a luteinizing 
hormone releasing hormone analogue, was prescribed for 194 patients. 
A fixed questionnaire was used to register patients’ medical and surgical 
history and pretreatment GU symptoms for each patient (3).  
During treatment, patients were seen on a weekly basis and on the last 
treatment day. Afterward, follow-up was performed at 1 and at 3 months after 
treatment. Acute toxicity was recorded as the maximal score during radiation or 
within 3 months after the end of RT. In the present study, patients suffered from 
RT-induced GU haematuria, dysuria, urgency, nocturia, and increased 
frequency. However, because of the low incidence of the other symptoms, only 
RT-induced nocturia was included in the study. Grading was performed 
prospectively following the grading system proposed by De Meerleer et al (3). 
Pretreatment nocturia was taken into account to avoid overgrading. In brief, 
grade 1 nocturia was defined as 2-3 mictions overnight. Grade 2 nocturia was 
defined as 4-6 mictions overnight, a doubling of the pretreatment nocturia 
frequency, or the need for medication (tamsulosin or terazosin). Grade 3 
nocturia was defined as >6 mictions overnight. For this study, RT-induced 
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nocturia was defined as an increase in toxicity according to grade 2 or 3 in the 
toxicity scale. 
Genomic DNA was obtained from fresh blood using the Puregene genomic 
DNA purification kit (Gentra Systems, Minneapolis, MN). The study was 
approved by the local ethical committee and all study patients provided written 
informed consent. 
 
Genotyping analysis 
The single nucleotide polymorphisms (SNPs) -800 G>A, -509 C>T, codon 10 
T>C, codon 25 G>C, and g.10780 T>G in the TGFB1 gene were selected to 
capture all common variants in the 5’ region of the gene, according to (15). The 
polymorphic sites at position -800 (c.1638G>A; rs1800468), -509 (c.1347C>T; 
rs1800469), and codon 25 (Arg/Pro, c.74G>C; rs1800471) in the TGFB1 gene 
were examined by polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) analysis as described previously by (19). The 
codon 10 (Leu/Pro, c.29T>C; rs1800470) and the intronic g.10780 (T>G; 
rs2241717) SNPs were determined by high-resolution melting curve analysis 
(HRMA). Primer sequences and restriction-enzymes can be found in Tables e1 
and e2 in the Supplement. The HRMA assays were performed on an Applied 
Biosystems 7500 Fast Real-Time PCR system (Life Technologies, Gent, 
Belgium). Using the Applied Biosystems HRM v2.0 software, melt data and 
output profiles were generated.  
 
Statistical analysis 
Patients with or without RT-induced nocturia were compared by means of the 
Mann-Whitney test for continuous variables and the χ²-test for categorical 
variables. Tests for Hardy-Weinberg equilibrium (HWE) were conducted using 
the observed genotype frequencies and the χ² test with 1 degree of freedom 
(P>.0001). Estimation of haplotypes and calculation of the linkage 
disequilibrium (LD) coefficient r² was performed as described previously (19). 
To assess the independent effect of each polymorphism, unconditional logistic 
regression analyses were performed to calculate crude odds ratios (ORs). In 
addition, multiple unconditional logistic regression analyses with adjustment for 
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possible confounders were performed to calculate adjusted ORs. To correct for 
possible interaction between variables in the multivariate analysis, variance 
inflation factors (VIFs) are calculated to assess multicollinearity. VIF >10 
indicates multicollinearity. The Benjamini-Hochberg procedure was used for 
multiple testing (ie, 33 tests: 18 genetic and 15 clinical parameter tests). 
Statistical analysis was performed using SPSS 17.0 software (SPSS, Chicago, 
IL). 
RESULTS 
Pretreatment nocturia 
Overall, 137 of 322 patients (43%) presented with a form of nocturia existing 
pretreatment. Of them, 78% had grade 1 nocturia (ie, 2-3 times/night), 19% had 
grade 2 nocturia (ie, 4-6 times/night or needing medication), and 3% had grade 
3 nocturia (>6 times/night). 
 
Evolution of pretreatment nocturia 
Data concerning the presence of radiation-induced nocturia were available for 
all patients. Of these, 82 patients (25%) developed acute radiation-induced 
nocturia; 73 patients developed grade 2, and 9 patients developed grade 3 
radiation-induced nocturia. The occurrence of radiation-induced nocturia was 
not significantly different between the prescription doses for both treatment 
regimens (Table 1), but patients receiving postoperative RT seem to be less 
prone to the development of RT-induced acute nocturia (P<.001; Table 2). Only 
8% of the patients with grade 2 pretreatment nocturia and none of the patients 
with grade 3 pretreatment nocturia experienced worsening, whereas 49% of the 
patients with grade 1 pretreatment nocturia had an increase in grade. 
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Table 2: Associations between patient- and therapy-related characteristics and RT-induced acute nocturia. 
 
All patients  Primary IMRT group 
 All 
(n=322) 
No 
RT-induced 
nocturia 
(n=240) 
RT-induced 
nocturia 
(n=82) P-value 
 
All 
(n=222) 
No  
RT-induced 
nocturia 
(n=150) 
RT-induced 
nocturia 
(n=72) P-value 
Age (y) 
    
     
Median 66.0 65.0 66.0 
 
 67.0 67.0 68.0  
Range 49.0-82.0 49.0-81.0 51.0-82.0 .076  51.0-82.0 51.0-81.0 51.0-82.0 .398 
Missing 0 0 0 
 
 0 0 0  
Nicotine abuse (n) 
    
     
Former + never 267 (82.9) 198 (74.2) 69 (25.8) 
 
 183 (82.4) 123 (67.2) 60 (32.8)  
Current 54 (16.8) 42 (77.8) 12 (22.2) .576  39 (17.6) 27 (69.2) 12 (30.8) .807 
Missing 1 (0.3) 0 1 
 
 0 0 0  
Diabetes mellitus (n) 
    
     
No 282 (87.6) 210 (74.5) 72 (25.5) 
 
 191 (86.0) 129 (67.5) 62 (32.5)  
Yes 39 (12.1) 29 (74.4) 10 (25.6) .988  30 (13.5) 20 (66.7) 10 (33.3) .924 
Missing 1 (0.3) 1 0 
 
 1 (0.5) 1 0  
Hypertension (n) 
    
     
No 227 (70.5) 174 (76.7) 53 (23.3) 
 
 155 (69.8) 109 (70.3) 46 (29.7)  
Yes 95 (29.5) 66 (69.5) 29 (30.5) .178  67 (30.2) 41 (61.2) 26 (38.8) .182 
Missing 0 0 0 
 
 0 0 0  
Hypercholesteremia (n) 
    
     
No 188 (58.4) 138 (73.4) 50 (26.6) 
 
 126 (56.7) 83 (65.9) 43 (34.1)  
Yes 71 (22.0) 52 (73.2) 19 (26.8) .979  49 (22.1) 33 (67.3) 16 (32.7) .853 
Missing 63 (19.6) 50 13 
 
 47 (21.2) 34 13  
     
  continued on next page 
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Table 2 (continued) 
 
  
 
All patients  Primary IMRT group 
 All 
(n=322) 
No 
RT-induced 
nocturia 
(n=240) 
RT-induced 
nocturia 
(n=82) P-value 
 
All 
(n=222) 
No  
RT-induced 
nocturia 
(n=150) 
RT-induced 
nocturia 
(n=72) P-value 
Abdominal surgery (n) 
    
     
No 182 (56.5) 136 (74.7) 46 (25.3) 
 
 115 (51.8) 74 (64.3) 41 (35.7)  
Yes 139 (43.2) 103 (74.1) 36 (25.9) .899  106 (47.7) 75 (70.8) 31 (29.2) .288 
Missing 1 (0.3) 1 0 
 
 1 (0.5) 1 0  
TURP (n) 
    
     
No 271 (84.2) 198 (73.1) 73 (26.9) 
 
 176 (79.3) 112 (63.6) 64 (36.4)  
Yes 49 (15.2) 40 (81.6) 9 (18.4) .206  44 (19.8) 36 (81.8) 8 (18.2) .022 
Missing 2 (0.6) 2 0 
 
 2 (0.9) 2 0  
Nocturia pre-treatment (n) 
    
     
Grade 0 185 (57.5) 157 (85.4) 28 (14.6) 
 
 124 (55.9) 98 (79.0) 26 (21.0)  
Grade 1+ 137 (42.5) 83 (60.6) 54 (39.4) <.001   98 (44.1) 52 (53.1) 46 (46.9) <.001 
Missing 0 0 0 
 
 0 0 0  
Lymph node dissection (n) 
    
     
No 195 (60.6) 142 (72.8) 53 (27.2) 
 
 149 (67.1) 101 (67.8) 48 (32.2)  
Yes 122 (37.9) 95 (77.9) 27 (22.1) .314  69 (31.1) 46 (66.7) 23 (33.3) .870 
Missing 5 (1.5) 3 2 
 
 4 (1.8) 3 1  
Androgen deprivation (n) 
    
     
No 126 (39.1) 96 (76.2) 30 (23.8) 
 
 77 (34.7) 52 (67.5) 25 (32.5)  
Yes 194 (60.3) 142 (73.2) 52 (26.8) .549  143 (64.4) 96 (67.1) 47 (32.9) .952 
Missing 2 (0.6) 2 0 
 
 2 (0.9) 2 0  
     
  continued on next page 
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Table 2 (continued) 
 
  
 
All patients  Primary IMRT group 
 All 
(n=322) 
No 
RT-induced 
nocturia 
(n=240) 
RT-induced 
nocturia 
(n=82) P-value 
 
All 
(n=222) 
No  
RT-induced 
nocturia 
(n=150) 
RT-induced 
nocturia 
(n=72) P-value 
Radical prostatectomy (n) 
    
     
No (primary IMRT) 222 (68.9) 150 (67.6) 72 (32.4) 
 
 - - -  
Yes (post-operative IMRT) 100 (31.1) 90 (90.0) 10 (10.0) <.001  - - - - 
Missing 0 0 0 
 
     
Bladdermax (Gy) 
    
     
Median 79.0 78.0 79.0 
 
 79.0 79.0 79.0  
Range 10.0-87.0 10.0-87.0 73.0-83.0 .001  10.0-87.0 10.0-87.0 75.0-83.0 .561 
Missing 1 (0.3) 0 1 
 
 1 (0.5) 0 1  
CTVmedian (Gy) 
    
     
Median 78.0 77.0 78.0 
 
 79.0 79.0 79.0  
Range 72.0-86.0 72.0-86.0 72.0-83.0 <.001  74.0-86.0 74.0-86.0 74.0-83.0 .302 
Missing 1 (0.3) 0 1 
 
 1 (0.5) 0 1  
CTVmax (Gy) 
    
     
Median 81.0 80.0 82.0 
 
 82.0 82.0 82.0  
Range 70.0-89.0 74.0-89.0 70.0-88.0 <.001  77.0-89.0 77.0-89.0 77.0-88.0 .135 
Missing 2 (0.6) 1 1 
 
 2 (1.0) 1 1  
CTVVol (cc) 
    
     
Median 41.0 39.0 49.5 
 
 53.0 52.5 53.5  
Range 7.0-129.0 7.0-129.0 13.0-124 .003  17.0-129.0 19.0-129.0 17.0-124.0 .648 
Missing 4 (1.2) 2 2 
 
 3 (1.5) 1 2  
Abbreviations: RT = radiotherapy; TURP = transurethral resection of the prostate; IMRT = intensity-modulated radiation therapy; CTV 
= clinical target volume. Data in parentheses are percentages. 
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Association between clinical and dose parameters and RT-induced acute 
nocturia 
The associations between dose and clinical parameters and RT-induced acute 
nocturia are represented in Table 2. All studied dose parameters, radical 
prostatectomy, and the presence of pretreatment nocturia were significantly 
associated with the development of acute nocturia in univariate analysis. The 
difference in dose between patients with and without radiation-induced nocturia 
is statistically significant but clinically irrelevant. This difference is mainly driven 
by the patients in the postoperative setting who are treated with a lower dose 
prescription. Because the occurrence of acute nocturia was 3 times higher in 
patients treated with primary IMRT, the analyses were repeated in the primary 
IMRT group (Table 2). In this group, only TURP in patient’s medical history and 
presence of pretreatment symptoms were statistically significantly associated 
with the development of acute nocturia.  
 
Association between TGFb1 polymorphisms and RT-induced acute 
nocturia 
The minor allele frequencies of the TGFb1 polymorphisms in all patients with 
and without RT-induced acute nocturia are represented in Fig. e1 in the 
Supplement. All SNPs were in HWE. Univariate logistic regression analysis 
revealed that the TGFB1 -509, codon 10, and g.10780 polymorphisms were 
statistically significantly associated with an increased risk for RT-induced 
acute nocturia (Table 3). All associations hold after Benjamini-Hochberg 
procedure. 
 
Table 3: Associations between TGFB1 genotypes and RT-induced acute 
nocturia. 
 
All patients 
 
No 
RT-induced 
nocturia 
RT-induced 
nocturia OR 
BH 
adjusted 
p-value 
TGFB1 -800 G>A 
   
 
GG 198 (82.5) 64 (78.1) 1  
GA 39 (16.3) 15 (18.3) 1.19 0.846 
AA 3 (1.2) 1 (1.2) 1.03 1 
dominant (GA+AA vs GG) 
  
1.18 0.846 
recessive (AA vs GG+GA) 
  
1.00 1 
Missing 0 2 (2.4) 
 
 
continued on next page 
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Table 3 (continued) 
   
 
 
All patients 
 
No 
RT-induced 
nocturia 
RT-induced 
nocturia OR 
BH 
adjusted 
p-value 
TGFB1 -509 C>T 
   
 
CC 134 (55.9) 29 (35.4) 1  
CT 86 (35.8) 44 (53.7) 2.36 0.008 
TT 20 (8.3) 7 (8.5) 1.62 0.568 
dominant (CT+TT vs CC) 
  
2.22 0.010 
recessive (TT vs CC+CT) 
  
1.06 1 
Missing 0 2 (2.4) 
 
 
    
 
TGFB1 codon 10 T>C 
   
 
TT 106 (44.1) 18 (21.9) 1  
TC 100 (41.7) 54 (65.9) 3.18 0.001 
CC 34 (14.2) 9 (11.0) 1.56 0.568 
dominant (TC+CC vs TT) 
  
2.77 0.005 
recessive (CC vs TT+TC) 
  
0.78 0.802 
Missing 0 1 (1.2) 
 
 
    
 
TGFB1 codon 25 G>C 
   
 
GG 196 (81.7) 67 (81.7) 1  
GC 44 (18.3) 13 (15.9) 0.86 0.854 
CC 0 0 -  
dominant (GC+CC vs GG) 
  
0.86 0.854 
recessive (CC vs GG+GC) - - -  
Missing 0 2 (2.4) 
 
 
    
 
TGFB1 g.10780 T>G 
   
 
TT 92 (38.3) 18 (21.9) 1  
TG 107 (44.6) 50 (61.0) 2.39 0.015 
GG 41 (17.1) 13 (15.9) 1.62 0.491 
dominant (TG+GG vs TT) 
  
2.18 0.025 
recessive (GG vs TT+TG) 
  
0.93 1 
Missing 0 1 (1.2) 
 
 
Abbreviations: RT = radiotherapy; OR = odds ratio; BH = Benjamini-
Hochberg procedure; TGFB1 = transforming growth factor β1. 
Data in parentheses are percentages. 
 
Next, multivariate analysis was performed with following variables: 
pretreatment nocturia symptoms, radical prostatectomy, TURP, TGFB1 -509, 
codon 10, and g.10780 polymorphisms. Because the -509 and the codon 10 
SNP are not independent (VIF -509 = 34.1; VIF codon 10 = 38.7), only 1 of 
these SNPs was included in the analysis. Moreover, because the dose 
differences for RT-induced nocturia are clinically irrelevant, these were not 
included. Because of its clinical importance, TURP was also entered in the 
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analysis. This multivariate analysis revealed that the development of acute 
radiation-induced nocturia is significantly associated with radical prostatectomy, 
presence of pretreatment nocturia symptoms, previous TURP, and the TGFB1 
codon 10 and -509 polymorphisms (Table 4). The TGFB1 g.10780 SNP does 
not remain significantly associated with the development of radiation-induced 
nocturia in multivariate analysis. 
 
Table 4: Effect of clinical and genetic factors on the risk of radiation-induced nocturia from 
multivariate logistic regression. 
Analysis 1 
 
Analysis 2 
Clinical/Genetic 
Factor 
OR P-value 
 
Clinical/Genetic 
Factor 
OR P-value 
Nocturia pre-treatment (n) 4.64 <0.001 
 
Nocturia pre-treatment (n) 4.01 <0.001 
Radical prostatectomy (n) 0.14 <0.001 
 
Radical prostatectomy (n) 0.15 <0.001 
TURP (n) 0.31 0.010 
 
TURP (n) 0.37 0.016 
TGFB1 codon 10 T>C 
   
TGFB1 -509 C>T 
  
TT 1 
  
CC 1 
 
TC 3.45 0.001 
 
CT 2.50 0.030 
CC 0.95 0.927 
 
TT 1.93 0.377 
TGFB1 g.10780 T>G 
   
TGFB1 g.10780 T>G 
  
TT 1.00 
  
TT 
  
TG 1.84 0.107 
 
TG 1.42 0.441 
GG 1.45 0.473   GG 0.83 0.777 
Analysis 1: multivariate analysis with factors nocturia pre-treatment, radical prostatectomy, 
TURP, TGFB1 g.10780 T>G, TGFB1 codon 10 T>C. 
Analysis 2: multivariate analysis with factors nocturia pre-treatment, radical prostatectomy, 
TURP, TGFB1 g.10780 T>G, TGFB1 -509 C>T. 
 
 
Linkage analysis and haplotype determination 
All polymorphisms are located in the 5’ region of the TGFB1 gene. LD was 
measured among the SNPs using the allele frequency data of all patients. 
There was LD between the -509 and the codon 10 polymorphism (r²=.66) and 
between the -509 polymorphism and the intronic g.10780 (r²=.55). There was 
no LD between the other polymorphisms (r²≤.32). The polymorphisms have 
been used to reconstruct five TGFB1 haplotypes (H1-H5) (Table 5). The most 
frequent haplotype (H1) composes all wild-type alleles (GCTGT) and was 
considered as reference haplotype. To correlate haplotypes with clinical 
radiosensitivity, haplotype frequencies were calculated for the group with and 
without RT-induced acute nocturia. This analysis showed that the H2 haplotype 
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was more frequent in the acute nocturia group; however, this was not 
statistically significant (OR = 1.68; P=.124). 
 
Table 5: Associations between TGFB1 haplotypes and RT-induced acute nocturia. 
      
Estimated frequency (%)   
 
-800 
G>A 
-509 
C>T 
codon 
10 T>C 
codon 
25 G>C 
g.10780 
T>G 
All 
(n=322) 
No 
RT-
induced 
nocturia 
(n=240) 
RT-
induced 
nocturia 
(n=82) 
  
 
OR P-value 
H1 G C T G T 40.3 42.3 34.4 1 
 
H2 G T* C* G G* 28.4 26.0 35.6 1.68 0.124 
H3 G C T G G* 12.5 13.1 10.6 0.99 0.836 
H4 A* C T G T 9.5 9.4 10.0 1.31 0.730 
H5 G C C* C* T 8.6 8.8 8.1 1.13 0.999 
Abbreviations: RT = radiotherapy; OR = odds ratio. *alleles differing from the reference 
haplotype H1. 
DISCUSSION 
This study was performed to analyze the influence of nongenetic and genetic 
factors on the development of acute radiation-induced nocturia. Significant 
associations were found between the TGFB1 -509 C>T and codon 10 T>C 
variant alleles and the development of RT-induced acute nocturia in prostate 
cancer patients. Also, primary IMRT (as opposed to postoperative IMRT) and 
the presence of pretreatment nocturia contribute to the variability in radiation 
toxicity. 
This study is the first that examines genetic markers in TGFB1 and their 
association with acute nocturia following IMRT for prostate cancer patients. The 
polymorphisms in TGFB1 have been extensively examined in normal tissue 
radiobiology. Much research has been performed to find associations between 
SNPs in the TGFB1 gene and several RT-induced late adverse events (13). 
These results show no consistency, however. Currently, the radiogenomics 
consortium is working on a meta-analysis of published and unpublished data to 
confirm or refute the relationship between TGFB1 SNPs and late radiotoxicity 
(20). Only 2 studies have reported on the correlation of SNPs in the TGFB1 
gene and acute radiation toxicity. Whereas Suga et al (16) could not find an 
association between -509 C>T and early skin reactions in Japanese breast 
cancer patients, Zhang et al (17) were able to demonstrate an association of the 
variant allele of -509 C>T with an increased risk of acute radiation-induced 
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oesophageal toxicity in Chinese lung cancer patients. Our study demonstrates a 
significant association between the variant alleles of TGFB1 -509 C>T and 
codon 10 T>C and the occurrence of radiation-induced acute nocturia in 
prostate cancer patients.  
In this study, 1 specific radiation-induced side effect –nocturia- was 
considered. Former studies (13) used a single grade that resulted of combining 
multiple symptoms such as haematuria, dysuria, urgency, nocturia, and 
increased frequency. Using this approach in our study, 105 instead of 82 
patients would have been categorized as having RT-induced acute GU toxicity. 
Subdividing the patients in this manner leads to the loss of the significant 
associations between the TGFB1 polymorphisms (-509 C>T and codon 10 T>C) 
and the general radiation-induced GU injury (data not shown). This illustrates 
that combining multiple symptoms can mask significant effects and confound 
the analysis. 
In this study, pretreatment nocturia was strongly linked to the development 
of acute RT-induced nocturia. This was also found in the study of Peeters et al 
(6). Registering pretreatment symptoms data is mandatory, but omitting the 
registration implicates that the pretreatment symptom cannot be included as a 
confounding factor, leading to an inaccurate quantification of RT-induced 
toxicity. Jereczek-Fossa et al (7) showed that the development of acute 
genitourinary side effects is strongly correlated with the development of late 
events. This is also the case for nocturia in our study. Of the patients 
developing acute grade ≥2 nocturia, 51% developed at least late grade 1 
nocturia (ie, 2-3 times/night), and 38% developed late grade ≥2 nocturia (>4 
times/night or medication needing).  
Our study shows that the incidence of acute nocturia was 3 times lower in 
patients treated with postoperative IMRT compared with patients treated with 
definitive IMRT. This is in accordance with Zelefsky et al (11). Therefore, we 
hypothesize that edema of the prostatic urethra is the predominant factor 
contributing to acute urinary complications. This might also explain the excellent 
response to α-blocker therapy (1). The lack of a significant response of 
nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that the inflammatory 
component is clinically less important (11). Nevertheless, the current study 
indicates that TGFB1, a mediator of inflammation, is one of the many factors 
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involved in the pathogenesis of RT-induced nocturia. Because evidence exists 
that acute GU toxicity originates from damage to the urethra, we introduced a 
surrogate for the urethral dose, the CTVmedian. The difference between patients 
with and without acute nocturia was found to be clinically irrelevant. This raises 
the question of whether the parameter chosen is an adequate surrogate for the 
urethral dose. Nevertheless, in future work, it will be necessary to study the 
complete dose-volume histogram of the urethra. This will be difficult because it 
is not easy to delineate the urethra. 
A strength of our investigation is the relatively large number of patients 
enrolled. We were also able to build a nearly complete data set with few missing 
values (with the exception of hypercholesterolemia status). Furthermore, 
patients were from an ethnically homogeneous population, and patient 
recruitment as well as clinical outcome data collection were carried out 
prospectively. We investigated 1 endpoint of RT-induced GU injury and were 
able to include a large number of clinical and treatment variables, including the 
presence of pretreatment symptoms. Nevertheless, a major issue in genetic 
association studies is the increasing risk for false-positive findings. We 
anticipated this problem by controlling the false discovery rate by means of the 
Benjamini-Hochberg procedure. Although the associations hold after correcting 
for multiple testing, the results of this study should be validated in an 
independent study.  
In conclusion, radical prostatectomy and the presence of mild nocturia 
before therapy and the variant alleles of TGFB1 -509 C>T and codon 10 T>C 
are identified as factors involved in the development of acute radiation-induced 
nocturia. Because a specific symptom was investigated, this study is unique 
and is also a call for standardization of radiation toxicity assessment in RT 
treatment of prostate cancer. The results of this study may be useful in research 
focusing on prediction of late severe nocturia after IMRT for prostate cancer. 
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SUPPLEMENTARY MATERIAL 
 
Table e1: Polymerase chain reaction-restriction fragment length polymorphism (RFLP) 
methods. 
db SNP-ID Genotype Ta 
Restriction 
Enzyme 
Primers 
rs1800469 -800 G>A 60°C HpyCh4IV 
5'-GCA GTT GGC GAG AAC AGT TG-3' 
5’-TGG GTC ACC AGA GAA AGA GG-3' 
rs1800469 -509 C>T 60°C Bsu36I 
5'-GCA GTT GGC GAG AAC AGT TG-3' 
5’-TGG GTC ACC AGA GAA AGA GG-3' 
rs1800471 Arg25Pro 58°C BgI I 
5'-TGT TCG CGC TCT CGG CAG-3' 
5'-GAC CTC CTT GGC GTA GTA G-3' 
Abbreviations: Ta: annealing temperature of PCR reaction. 
 
 
Table e2: High Resolution Melting curve Analysis (HRMA) methods. 
db SNP-ID Genotype Ta Primers 
rs1800470 Leu10Pro 64°C 
5'-ACC ACA CCA GCC CTG TTC-3'  
5’-AGC ACC AGT AGC CAC AGC AG-3’ 
rs22241717 g.10780 T>G 60°C 
5’-GTC GGC TGG TTA CAA GGT C-3’  
5’-GCT TGG CAA CAG AGT GAG AC-3’ 
Abbreviations: Ta: annealing temperature of HRMA reaction. 
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ABSTRACT 
Background and purpose: To develop predictive models for late radiation-
induced haematuria and nocturia allowing a patient individualized estimation of 
pre-treatment risk. 
Materials and methods: We studied 262 prostate cancer patients treated with 
curative intensity modulated radiotherapy to the intact prostate or prostate bed. 
A total of 372 variables were used for prediction modeling, among which 343 
genetic variations. Toxicity was scored using an in-house developed toxicity 
scale. Predictor selection is achieved by the EMLasso procedure, a penalized 
logistic regression method with an EM algorithm handling missing data and 
crossvalidation avoiding overfit. Model performance was expressed by the area 
under the curve (AUC) and by sensitivity and specificity. 
Results: Variables of the model predicting late haematuria (36/262) are bladder 
volume receiving ≥75 Gy, prostatic transurethral resection and four 
polymorphisms. (AUC = 0.80, sensitivity = 83.3%, specificity = 61.5%). The 
AUC drops to 0.67 when the genetic markers are left out. The model that 
predicts for late nocturia (29/262) contains the minimal clinical target volume 
(CTV) dose, the CTV volume and three polymorphisms (AUC = 0.76, sensitivity 
= 75.9%, specificity = 67.4%). This model is a better predictor for nocturia 
compared to the nongenetic model (AUC of 0.60).  
Conclusions: We were able to develop models that predict for the occurrence 
of late radiation-induced haematuria and nocturia, including genetic factors 
which might improve the prediction of late urinary toxicity. 
INTRODUCTION 
Long-term toxicity after radiotherapy may cause substantial morbidity (1). 
Quality of life outcomes are of particular importance as most patients survive 
early-stage prostate cancer after treatment and should therefore be part of the 
treatment decisions (2). Prediction models of radiotherapy-induced side effects 
impairing patients’ quality of life, can help this medical decision making.  
Recent refinements of intensity-modulated radiotherapy (IMRT) and image-
guided techniques allow for a better sparing of the rectum, which results in an 
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acceptable level of severe late gastrointestinal (GI) complications, such as 
rectal bleeding (1-3). In contrast, due to the full inclusion of the bladder neck 
and, in case of postoperative RT, the vesicourethral anastomosis in the high-
dose region, the risk of developing severe genitourinary (GU) toxicity has 
remained rather unchanged (1, 4). GU symptoms occur with a 10-year 
cumulative incidence of approximately 20% in patients treated with high-dose 
IMRT.  
Moreover, the incidence does not seem to plateau, as it is the case for GI 
toxicity (1, 2). Factors already known to predict for chronic GU toxicity are pre-
treatment urinary complaints, prior transurethral resection of the prostate 
(TURP) and the presence of acute toxicity (5-7). Although bladder dose-volume 
effects are demonstrated (8-10), methodological differences have obscured the 
link between lower urinary tract dose and toxicity (11). Intrinsic factors as 
genetic polymorphisms, which are mainly responsible for the interpatient 
variability, can add predictive value to the pre-treatment risk-estimation of an 
individual patient. Therefore, the purpose of this study was to develop 
integrated predictive models containing clinical, dosimetric and genetic data for 
the prediction of late GU sequelae in prostate cancer patients. This would 
enable us to individualize patient treatment. 
MATERIALS AND METHODS. 
Study population 
This study enrolled 262 patients treated with IMRT as primary (n = 180) or post-
operative treatment (n = 82) for prostate cancer at the Ghent University Hospital 
between 1999 and 2011. All patients had at least 12 months of follow-up (range: 
1–13 yr). 
The dose was prescribed as the median dose to the planning target volume. 
Prescription doses were delivered with 18 MV photons of an Elekta linear 
accelerator (Crawley, UK) as described in detail in (7, 12, 13). Patients in the 
postoperative setting were treated with 74 Gy (adjuvant) or with 76Gy (salvage). 
Three dose levels (74, 76 and 80 Gy) were given to patients treated with 
primary IMRT. Patient setup, verification, target volume description and normal 
tissue constraints are reported previously (7, 12, 13). 
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Adjuvant androgen deprivation consisting of a luteinizing hormone-releasing 
hormone analog, was administered in 157 patients. Patient characteristics are 
listed in Table 1. 
 
Table 1: Patient and tumour characteristics. 
Characteristics All patients 
Age, yr 
 
Median 65 
Range 49-82 
Follow-up, yr 
 
Median 4 
Range 1-13 
Prescribed radiotherapy dose, Gy 
 
Median 80 
Range 74-80 
Prescription protocol  
74 Gy, 36 fractions 54 (20.6) 
76 Gy, 37 fractions 63 (24.0) 
80 Gy, 38 fractions 145 (55.3) 
Radical Prostatectomy 
 
Yes 82 (31.3) 
No 180 (68.7) 
Tumor stage 
 
T1 78 (29.8) 
T2 110 (42.0) 
T3 70 (26.7) 
T4 4 (1.5) 
Gleason score 
 
≤6 131 (50.0) 
7 83 (31.7) 
8-10 45 (17.2) 
Unknown 3 (1.1) 
PSA before RT, ng/ml 
 
Median 6.7 
Range 0.0-150.0 
≤10 ng/ml 187 (71.4) 
>10 ng/ml 75 (28.6) 
Lymph node dissection 
 
Yes 93 (35.5) 
No 168 (64.1) 
Unknown 1 (0.4) 
Adjuvant AD 
 
Yes 156 (59.5) 
No 106 (40.5) 
continued on next page 
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Table 1 (continued) 
Characteristics All patients 
Prior TURP 
 
Yes 39 (14.9) 
No 223 (85.1) 
Pre-treatment symptoms 
 
Yes 108 (41.2) 
No 154 (58.8) 
Abbreviations: PSA = prostate-specific antigen; 
AD = androgen deprivation; TURP = transurethral 
resection of the prostate. 
Data are given as no. (%) unless otherwise 
indicated. 
 
In order to have a comfortably filled bladder (>200 mL) patients were 
instructed to drink ±750 cc prior to their therapy. Bladder filling was checked to 
match the volume on planning computed tomography (CT) to avoid 
under/overfilling of the bladder. Before 2010, this was checked by a portable 
bladder ultrasound, thereafter, daily cone-beam CT was applied (7, 14). The 
maximum bladder dose was set at 80 Gy. Dose-volume histograms (DVH) were 
calculated using an in-house-developed planning system, with a final dose 
computation using a commercial radiotherapy planning system (Pinnacle; 
Philips Medical Systems, Best, The Netherlands). The bladder was delineated 
as a solid organ. The minimal, mean and maximal dose to the clinical target 
volume (CTV), the CTV volume (cc), the mean and maximal bladder dose (Gy), 
the bladder volume (Bvol (cc)) and the percentage of the bladder volume 
receiving more than 10, 20, 30, 40, 50, 60, 65, 70 and 75 Gy (termed B10 (%) 
to B75 (%)) were considered as predictors.  
All patients completed a pre-IMRT questionnaire, registering baseline GU 
symptoms and patients’ medical history (diabetes, hypertension, previous 
surgery, and smoking). These factors were also considered as predictors. 
Toxicity was registered following an in-house developed grading system (see 
Supplementary Table e1) based on the Radiation Therapy Oncology Group 
(RTOG), the Common Toxicity Criteria for Adverse Events (CTCAE v.3.0) and 
SOMA/LENT toxicity scoring systems (12, 13). It was defined as an increase in 
toxicity symptoms, taking the pre-RT score into consideration, and was 
recorded as the maximal score of radiation-induced toxicity. If symptom scores 
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improved (fewer symptoms after than before RT), these were recorded as a 
zero score. Acute toxicity was defined as toxicity occurring during or within 3 
months after the end of RT. Late toxicity was defined as toxicity occurring for 
the first time >3 months after the end of IMRT or as acute toxicity lasting longer 
than 3 months. Severe late GU symptoms were defined as grade 2 or 3 toxicity. 
Prediction models were only generated for symptoms with an incidence >10%. 
 
Genomic DNA was obtained from fresh blood using the Gentra Puregene 
Blood kit. The study was approved by the local ethics committee 
(UZG2007/560) and all study patients provided written informed consent.  
 
Single nucleotide polymorphism (SNP) selection 
Genes encoding proteins involved in the early response, DNA damage 
response, DNA repair, oxidative metabolism and steroid hormonal metabolism, 
were chosen after comprehensive literature search (more details in 
Supplementary File 1). SNPs in these genes were selected using ECR browser 
(15). This was based on functional tagging of multispecies evolutionary 
conserved regions, which is an indication for biological function. Details can be 
found in (16). The selection was expanded with a number of SNPs previously 
reported to be associated with radiation-induced injury or cancer. Finally, 384 
SNPs were retained.  
 
Genotyping 
Genotyping was performed using the Illumina GoldenGate assay (DNAVision, 
Charleroi, Belgium), genotyping data and clustering of SNP genotypes were 
managed in GenomeStudio (Illumina). Upon processing, quality control 
processes were run to guarantee the accuracy of the genotyped dataset. 
Genotypes were excluded based on call rate (<75%), GenCall score (<0.4) 
which is a measure of quality and reliability, minor allele frequency (<0.05) and 
deviation from Hardy-Weinberg equilibrium (p<0.001). This resulted in the 
elimination of approximately 9% of the SNPs.  
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Statistical analysis 
In a first step, model selection is achieved by the EMLasso procedure. The 
Lasso is a penalized regression method that shrinks down to zero the 
coefficient of the markers that have little apparent effect on the trait and retains 
those variables that have the strongest collective impact (17). Missing data are 
handled by a stochastic expectation-maximization (EM) algorithm that is 
imposed to the predictors. To control for overfit tenfold cross-validation is used. 
As such, a limited set of variables is selected (adding more variables does not 
increase the predictive stability). Details of the method are published by Sabbe 
et al. (18) and discussed by De Ruyck et al (19). Secondly, a simple logistic 
regression model is fit to the data with only the selected variables to obtain the 
model coefficients (β). The individual probabilities (p) were calculated through ln 
p/(1-p) = β0+β1*x1+β2*x2+β3*x3… with x = predictor. Subsequently, the 
prediction performance is measured by the area under the curve (AUC) of the 
receiver operating curve (ROC) and by sensitivity and specificity in the optimal 
operator point of the ROC curve. This point is determined with a higher penalty 
(1.5) for false negatives. To check for calibration the Hosmer-Lemeshow 
goodness-to-fit (GOF) test was applied. P-values >0.05 indicate that the fitted 
model adequately describes the observed outcomes in the data (20). Estimates 
of late GU probabilities were calculated using the Kaplan-Meier method. For all 
analyses, the statistical platform R was used (packages addendum, NumDfr, 
GLoMo, snowfall, EMLasso, Survival) (21).  
RESULTS 
Late GU toxicity 
The most frequently observed late grade 2+ GU symptoms were haematuria 
and nocturia present in 36 (14%) and 29 (11%) of the patients, respectively, 
with grade 3 toxicity present only in 1 and 4 patients. Together, they encompass 
more than 50% of the late urinary symptoms. Fig. 1 shows the cumulative 
incidence of grade 2–3 haematuria and nocturia. Other radiation-induced 
urinary toxicity included dysuria (n = 4), urgency (n = 9), increased daily 
frequency (n = 18) and incontinence (n = 20); the latter predominantly occurred 
in patients treated in the postoperative setting. The occurrence of late radiation-
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induced toxicity was not significantly different between the three prescription 
regimens. 
 
 
 
 
 
Fig 1: Cumulative incidence of late  Fig 2: ROC curves for the different 
radiation-induced haematuria and nocturia. endpoints. 
 
Prediction modeling 
Patient and clinical characteristics are depicted in Table 1. The 343 genetic 
polymorphisms and the 29 patient- and treatment-related parameters under 
consideration are available in Supplementary Tables e2 and e3. In total, 372 
variables were available for model selection. 
Late haematuria. The prediction model for late haematuria has an AUC of 0.80 
and consists of six parameters: B75, prior TURP and the genotypes 
rs3931914CG, rs2293054AG, rs708498GG and rs845552AG (GOF χ² = 10.5; p 
= 0.234). Sensitivity and specificity are 83.3% and 61.5%, respectively, at the 
threshold of 8%. The AUC drops to 0.67 when the 4 genetic markers are left out 
(Figure 2). Data for the variables in the model are shown in Table 2.  
 
Table 2: Data for factors included in the model for late haematuria. 
 
No  
RT-induced haematuria 
(n=226) 
RT-induced haematuria 
(n=36) 
B75 (%)   
Median 5.0 8.0 
Range 0-22 1-22 
Unknown 5 1 
continued on next page 
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Table 2 (continued) 
 
No  
RT-induced haematuria 
(n=226) 
RT-induced haematuria 
(n=36) 
Prior TURP 
  
No 200 (89.7) 23 (10.3) 
Yes 26 (66.7) 13 (33.3) 
HMGRC rs3931914   
CC 145 (92.4) 12 (7.6) 
CG 67 (75.3) 22 (24.7) 
GG 14 (87.5) 2 (12.5) 
NOS1 rs2293054   
GG 105 (82.0) 23 (18.0) 
GA 102 (94.4) 6 (5.6) 
AA 19 (73.1) 7 (26.9) 
PTGER2 rs708498   
GG 167 (90.8) 17 (9.2) 
GA 51 (75.0) 17 (25.0) 
AA 8 (80.0) 2 (20.0) 
EGFR rs845552   
AA 75 (92.6) 6 (7.4) 
AG 101 (80.2) 25 (19.8) 
GG 49 (90.7) 5 (9.8) 
Unknown 1 0 
Abbreviations: RT = radiotherapy; B75 = percentage of the bladder volume 
receiving 75 Gy or more; TURP = transurethral resection of the prostate; 
HMGRC = hydroxy-methyl-glutaryl CoA reductase gene; NOS1 = nitric 
oxide synthase 1 gene; EGFR = epidermal growth factor receptor gene; 
PTGER2 = prostaglandin E receptor 2 gene. 
Data are given as no. (%) unless otherwise indicated. 
 
 
Late nocturia. Variable selection procedure revealed a model comprising the 
following variables: the CTV min, the CTV volume and the rs1799983GT, 
rs1045485GG and rs4808611TC genotypes (GOF χ² = 3.8; p = 0.878). This 
model has an AUC of 0.76 with sensitivity of 75.9% and specificity of 67.4% at 
the threshold of 9%. Data for the variables in the model are shown in Table 3. 
The model including the SNPs was a better predictor for nocturia compared to 
the non-genetic model (AUC of 0.60) (Figure 2). The presence of acute grade 2 
toxicity also adds predictive value to the model (AUC = 0.78). This factor can, 
however, not be included in the model as the occurrence of acute toxicity is 
unknown before the start of RT (data not shown).  
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The coefficients for the calculation of the probability are available in 
Supplementary Tables e4 and e5. 
 
Table 3: Data for factors included in the model for late nocturia. 
 
No 
RT-induced nocturia 
(n=235) 
RT-induced nocturia 
(n=29) 
CTV min (Gy)   
Median 72 73 
Range 64-79 67-78 
Unknown 9 1 
CTV volume (cc)   
Median 41 54 
Range 7-129 17-127 
Unknown 7 0 
NOS3 rs1799983   
GG 83 (80.6) 20 (19.4) 
GT 122 (96.1) 5 (3.9) 
TT 27 (87.1) 4 (12.9) 
Unknown 1 0 
CASP8 rs1045485   
GG 178 (93.2) 13 (6.7) 
GC 49 (77.8) 14 (22.2) 
CC 6 (75.0) 2 (25.0) 
NR2F6 rs4808611   
CC 157 (94.0) 10 (6.0) 
CT 69 (80.2) 17 (19.8) 
TT 5 (71.4) 2 (28.6) 
Unknown 2 0 
Abbreviations: RT = radiotherapy; CTV = clinical target volume; 
NOS3 = nitric oxid synthase 3 gene; CASP8 = caspase 8 gene; 
NR2F6 = nuclear receptor subfamily 2, group F, member 6 gene. 
Data are given as no. (%) unless otherwise indicated. 
DISCUSSION 
The main purpose of the current study was to design predictive models suitable 
in clinical practice to identify patients at risk for developing severe urinary 
symptoms. Late radiation toxicity is related to both dosimetric and clinical risk 
factors, as well as, the patients’ genetic make-up. We were able to construct 
well-calibrated models for late radiation-induced haematuria and nocturia. 
This study shows that genetic factors have the potential to improve 
prediction of late toxicity. There are several advantages using genotypes as 
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biomarkers: easy to analyze, stable and affordable. Four genetic markers are 
included in the model predicting late radiation-induced haematuria. The 
potentially functional 5’UTR SNP, rs3931914, is situated in the HMGCR gene 
encoding hydroxy-methylglutaryl-coenzyme A reductase. This enzyme is rate-
limiting in the novo synthesis of cholesterol. The SNP can generate a binding 
motif and can induce the loss of several other motifs for transcription factors 
(22). In the current study, heterozygotes predict for the development of late 
haematuria. The other variants rs2293054, rs708498 and rs845552 in the 
NOS1 gene, the PTGER2 gene and the EGFR gene, respectively, were 
selected based on their evolutionary conservation. In case of nocturia, three 
genetic variants provide additional predictive value. The variant rs1799983 
(Asp298Glu) is located in the NOS3 gene, which protein is responsible for nitric 
oxide (NO) production. The functional variant has been shown to result in a 
reduction of the NO production which results in lower levels of oxidative stress 
(23). We show that carriers of the heterozygote genotype have a lower risk to 
develop late nocturia. Previous studies could demonstrate a similar effect for 
this SNP with a decreased risk for radiation-induced telangiectasia and 
pneumonitis (23, 24). Two SNPs included in our model were previously shown 
to be associated with breast cancer risk, rs4808611 and rs1045485 
(Asp302His) (25, 26). This is plausible as it is hypothesized that there is an 
overlap between polymorphisms associated with breast cancer and 
radiosensitivity (27). In the current study, rs4808611 heterozygotes and carriers 
of the variant allele of rs1045485 have a higher risk to develop late nocturia. 
Radiosensitivity is considered to be an inherited complex, polygenic trait 
dependent on many SNPs each with small effect sizes (28). Although, in this 
study, we notice that the contribution of SNPs is more than expected. This can 
be due to sample size. 
Only few studies were able to develop predictive models of late urinary 
toxicity including dose-volume information (8, 10). This is due to the highly 
variable bladder filling during radiotherapy which leads to difficulties in 
calculating the actual dose to the bladder (5). Specific instructions to ensure a 
stable bladder volume have been shown to minimize the discrepancy between 
the planning DVH and the actual dose (11). In the current study, daily medical 
imaging was applied to verify bladder filling and the discrepancy is expected to 
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be low. The percentage of the bladder volume receiving ≥75 Gy is shown to be 
predictive for late GU toxicity. Previous studies (8-10) also indicated that small 
high-dose regions contribute to the development of late GU injury, which 
confirms the serial behavior of the bladder for chronic urinary toxicity. The 
minimal dose to the CTV and the CTV volume indicate the involvement of the 
prostatic urethra for late nocturia as the prostatic urethra was not considered as 
an organ at risk in the planning system. 
We found prior TURP to be predictive for a higher occurrence of late 
haematuria. Previous studies have shown that TURP before RT was associated 
with less acute toxicity (7, 29). This procedure was probably performed to 
alleviate baseline urinary symptoms, as those increase the risk for acute 
toxicity. Nevertheless, this procedure might deteriorate the late urinary 
symptoms (30). We and many others found that the presence of acute 
radiation-induced grade 2 GU symptoms is predictive for the development of 
late toxicity (4-6). This factor is, however, unknown at the start of RT and is 
therefore no genuine predictor. The presence of baseline urinary symptoms was 
not found to be predictive for late toxicity. 
The prediction of radiation morbidity has been valued by others (6). 
Predictive models can guide the allocation of patients to treatment groups 
based on their probability of severe radiotherapy toxicity and simultaneously 
improve the therapeutic ratio. Patients at high risk may be offered an alternative 
treatment, such as, radical prostatectomy or active surveillance. Or, for patients 
who receive radiotherapy, advanced planning corrections can be introduced to 
better individualize radiotherapy treatment. It can enable us to define 
acceptance criteria for future use in RT treatment for prostate cancer. Current 
analyses are suitable for practice. Nevertheless, validation and assessment of 
clinical usefulness are needed before implementing these models in the clinic 
for routine use. Clinical usefulness can be quantified by decision-analytic 
methods, such as net benefit and decision curve analysis (20, 31). Therefore, 
an optimal clinical decision threshold should be determined taking into account 
the harms and benefits of the alternative treatment. In this context, adopting an 
alternative treatment without impairing local tumour control and survival, is a 
matter of further research and debate. In the current study, the threshold for late 
haematuria and late nocturia penalizes the number of false negatives. From a 
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clinical point of view, this is rather arbitrary as the alternative treatment is not 
yet known. 
This study is susceptible to the shortcomings of every retrospective analysis. 
We did not include the time-course of the events, which may restrict the 
applicability of the resulting models at different time points, especially when the 
events are reversible or transient. We welcome other centers to join in, testing 
the predictive power in independent cohorts and upgrading the number of 
events.  
 
In conclusion, late radiation-induced haematuria and nocturia can be 
predicted by combining clinical, dosimetric and genetic data. Inclusion of 
genetic data can refine prediction of late urinary toxicity. Validation and 
assessment of the clinical usefulness are necessary before implementing these 
models in the clinic. 
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SUPPLEMENTARY MATERIAL 
Supplementary Table e1: The in-house developed Genitourinary (GU) toxicity scale. 
GU Grade 1 Grade 2 Grade 3 Grade 4 
Nocturia Increase in 
frequency  
≤2 normal 
Increase >2 
normal  
but less than 
every hour 
Once or more 
per hour 
Not defined 
Frequency Increase in 
frequency 
≤2 normal 
Increase >2 
normal  
but less than 
every hour 
Once or more 
per hour 
Not defined 
Haematuria Microscopic Gross Gross with 
cloths 
Requiring 
transfusion 
Dysuria No therapy Oral treatment 
(no narcotic 
analgesics) 
Narcotic 
analgesics 
Not defined 
Urgency No therapy Urgency 
requiring 
therapy 
Narcotic 
analgesics 
Not defined 
Incontinence No therapy Therapy or 
using two or 
fewer pads per 
day 
Using more 
than two pads 
per day 
Surgery 
 
  
80 
Supplementary file 1 – References of the selection of SNPs 
 
SNPs selected for the current study were based on the reported association of 
several genes identified in the early response to ionizing radiation, DNA 
checkpoint control and repair of DNA damage upon exposure of cells to ionizing 
radiation [1-7]. We also included SNPs from genes encoding proteins involved 
in the metabolism of side products of the radiolysis of water [8]. In addition, 
genes in the hormonal metabolism were selected [9-12], complemented with 
SNPs in a variety of genes shown to be involved in radiation response [13-18]. 
Several of the selected SNPs are shown to be associated with cancer 
predisposition in case-control studies [19-28].  
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Table e1: The selection of 343 genetic polymorphisms suitable for analysis. 
Gene Description rs number MAF 
Allele 
substitution 
Genomic 
location 
Amino acid 
substitution 
       
DNA damage response     
       
ATM Ataxia 
Telangiectasia 
Mutated 
rs1801516 0.14 G>A Coding Asn1853Asp 
ATR Ataxia 
telangiectasia and 
Rad3 related 
rs1802904 0.17 A>G Coding Gln= 
 rs2229032 0.17 G>A Coding Arg2425Gln 
 rs2227929 0.37 T>C Coding Asp= 
 rs2227928 0.44 C>T Coding Met211Thr 
MRE11 Meiotic 
recombination 11 
homolog A 
rs2509943 0.45 G>C Coding Leu= 
      
RAD50 DNA repair protein 
RAD50 
rs17166050 0.22 C>T Intronic  
H2AFX H2A histone family, 
member X 
rs643788 0.42 T>C 5’-flanking  
MDC1 Mediator of DNA-
damage 
checkpoint1 
rs28986317 0.07 G>C Coding Ala= 
CHK1 Checkpoint kinase 
1 (Ser/Thr kinase) 
rs491528 0.30 G>T Intronic  
CHK2 Checkpoint kinase 
2 (Ser/Thr kinase) 
rs2236141 0.13 C>T 5’-flanking  
BRCA1 Breast cancer 1, 
early onset 
rs12516 0.32 C>T 3’-UTR  
 rs4986850 0.07 G>A Coding Asp693Asn 
BRCA2 Breast cancer 2, 
early onset 
rs9534262 0.49 C>T Intronic  
TP53 Tumor protein p53 rs2287498 0.07 G>A 5’-flanking  
TP53BP1 Tumor protein p53 
binding protein 1 
rs560191 0.33 G>C Coding Asp= 
TP53BP2 Tumor protein p53 
binding protein 2 
rs17739 0.16 C>T 3’-UTR  
 rs1153933 0.07 C>T Coding Ser= 
 rs34683843 0.09 C>A Coding Gln229Lys 
MDM2 MDM2 oncogene, 
E3 ubiquitin protein 
ligase 
rs769412 0.07 A>G Coding Glu= 
CDKN2B Cyclin-dependent 
kinase inhibitor 2B 
rs2069426 0.12 C>A   
CDKN2C Cyclin-dependent 
kinase inhibitor 2C 
rs12855 0.09 C>T 3’-UTR  
WRN Werner syndrome, 
RecQ helicase-like 
rs2230009 0.07 G>A Coding Val114Ile 
CDKN3 Cyclin-dependent 
kinase inhibitor 3 
rs2179896 0.28 G>A Intronic  
PLK2 Polo-like kinase 2 rs32613 0.07 G>T 3’-UTR  
 rs15009 0.35 C>G 3’-UTR  
 rs1042994 0.12 T>C Coding Phe= 
 rs702723 0.44 A>G Intronic  
 rs702722 0.13 T>C Coding Ile= 
 rs15915 0.21 G>A 5’-UTR  
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Gene Description rs number MAF 
Allele 
substitution 
Genomic 
location 
Amino acid 
substitution 
       
cdc6 Cell division cycle 6 rs13706 0.12 G>A Coding Val441Ile 
  rs4134994 0.14 A>G 5’-flanking  
CCND1 Cyclin D1 rs1944129 0.49 G>A 5’-flanking  
 rs9344 0.48 G>A Coding Pro= 
 rs7177 0.46 A>C 3’-UTR  
CCND2 Cyclin D2 rs1049612 0.41 A>G 3’-UTR  
       
DNA repair       
       
Non-homologous end-joining     
KU70 X-ray repair cross-
complementing 
protein 6 
rs2267437 0.38 C>G 5’-flanking  
KU80 X-ray repair cross-
complementing 
protein 5 
rs207906 0.14 G>A Coding Thr= 
 rs7581055 0.11 A>G Intronic  
 rs1438162 0.39 A>G Intronic  
XRCC4 X-ray repair cross-
complementing 
protein 4 
rs17284218 0.43 A>T Intronic  
 rs11951257 0.48 T>C Intronic  
 rs6872787 0.07 G>C Intronic  
 rs1056503 0.13 T>G Coding Ser= 
PRKDC Protein kinase, 
DNA activated, 
catalytic 
polypeptide 
rs10109984 0.38 T>C Intronic  
 rs8178071 0.17 G>A Intronic  
LIG4 DNA ligase IV rs1805388 0.13 C>T Coding Thr9Ile 
 rs9520823 0.31 T>G Intronic  
XLF Non-homologous 
end-joining factor 1 
rs1378641 0.32 T>C Intronic  
 rs17608747 0.21 C>T Intronic  
POLM DNA polymerase 
mu 
rs3218655 0.16 G>T Coding Leu= 
POLL DNA polymerase 
lambda 
rs3730477 0.23 C>T Coding Arg438Trp 
 rs3730475 0.31 T>C Intronic  
RPA1 Replication protein 
A1 
rs3786136 0.23 C>T Intronic  
 rs12150513 0.47 T>G Intronic  
 rs2230930 0.17 C>T Coding Ser= 
 rs3744766 0.15 G>C 3’-UTR  
 rs12727 0.20 G>C 3’-UTR  
 rs17734 0.34 A>G 3’-UTR  
Homologous recombination     
Rad51 DNA repair protein 
RAD51 homolog 1 
rs1801320 0.06 G>C 5’-UTR  
XRCC2 X-ray repair cross-
complementing 
protein 2 
rs3218536 0.09 G>A Coding Arg188His 
XRCC3 X-ray repair cross-
complementing 
protein 3 
rs1799796 0.35 A>G Intronic  
 rs861539 0.36 C>T Coding Thr241Met 
 rs1799794
 
0.20 A>G 5’-UTR  
RAD52 DNA repair protein 
RAD52 homolog 
rs7303748 0.44 C>T Intronic  
84 
Gene Description rs number MAF 
Allele 
substitution 
Genomic 
location 
Amino acid 
substitution 
       
Base-excision repair     
PARP-1 Poly-(ADP-ribose)-
polymerase 
rs732284 0.18 G>C Intronic  
 rs1805405 0.19 C>A Intronic  
OGG1 8-oxoguanine DNA 
glycosylase 
rs2269112 0.17 C>T Intronic  
 rs2072668 0.23 C>G Intronic  
NUDT1 Nucleoside 
diphosphate linked 
moiety X-type motif 
1 
rs1799832 0.21 C>T Coding Asp= 
APEX1 Apurinic-
apyrimidinic 
endonuclease 1 
rs2275007 0.41 G>A Coding Gln= 
 rs1130409 0.49 T>G Coding Asp148Glu 
XRCC1 X-ray repair cross-
complementing 
protein 1 
rs25487 0.37 G>A Coding Gln399Arg 
 rs1799782 0.08 C>T Coding Arg194Trp 
 rs3213245 0.41 T>C Coding Gly59Ser 
 rs2682587 0.17 C>A Intronic  
LIG3 DNA ligase 3 rs2066505 0.11 G>A Intronic  
PCNA Proliferating cell 
nuclear antigen 
rs17349 0.11 C>T Intronic  
FEN1 Flap structure-
specific 
endonuclease1 
rs174538 0.30 G>A 5’-flanking  
       
Nucleotide-excision repair     
       
XPC Xeroderma 
pigmentosum, 
complementation 
group C 
rs2279017 0.40 G>T Intronic  
 rs2227998 0.28 G>A Coding Arg= 
 rs2228000 0.25 C>T Coding Ala499Val 
 rs2228001 0.42 A>C Coding Lys939Gln 
ERCC1 Excision repair 
cross-
complementing 
rodent repair 
deficiency, 
complementation 
group 1 
rs3212961 0.16 C>A Intronic  
 rs11615 0.39 T>C Coding Asn= 
 rs3212986 0.24 G>T 3’-UTR  
ERCC2 Excision repair 
cross-
complementing 
rodent repair 
deficiency, 
complementation 
group 2 
rs13181 0.37 T>G Coding Lys751Gln 
 rs1052555 0.33 C>T Coding Asp= 
ERCC4 Excision repair 
cross-
complementing 
rodent repair 
deficiency, 
complementation 
group 4 
rs762521 0.23 G>A Intronic  
 rs1799801 0.31 T>C Coding Ser= 
RAD23B RAD23 homolog B rs1805330 0.11 C>T Intronic  
 rs1805329 0.17 C>T Coding Ala249Val 
 rs10868 0.13 C>T 3’-UTR  
POLK DNA polymerase 
kappa 
rs3213801 0.23 G>A Coding Ala= 
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Gene Description rs number MAF 
Allele 
substitution 
Genomic 
location 
Amino acid 
substitution 
       
Oxidative metabolism     
       
SOD2 Superoxide 
dismutase 2, 
mitochondrial 
rs2842960 0.47 T>C Intronic  
CAT Catalase rs1049982 0.31 C>T 5’-UTR  
GPx2 Glutathione 
peroxidase 2 
rs3759681 0.27 C>T 5’-flanking  
GPx3 Glutathione 
peroxidase 3 
rs4958872 0.23 T>C Intronic  
 rs8177447 0.16 C>T Intronic  
GPx4 Glutathione 
peroxidase 4 
rs4807542 0.19 G>A Coding Pro= 
PRDX1 Peroxiredoxin 1 rs2356559 0.33 G>A Intronic  
TXNRD2 Thioredoxin 
reductase 2 
rs1139795 0.17 G>A Coding Pro= 
 rs5993853 0.33 C>T Intronic  
GSTA4 Glutathione S-
transferase alpha 4 
rs16883343 0.25 C>T 5’-flanking  
GSTA5 Glutathione S-
transferase alpha 5 
rs2397118 0.05 T>C Coding Val55Ile 
GSTP1 Glutathione S-
transferase pi 1 
rs1138272 0.09 C>T Coding Ala114Val 
 rs1871042 0.35 C>T Intronic  
GSTM2 Glutathione S-
transferase mu 2 
rs592792 0.14 G>A Coding Asn= 
GSTM5 Glutathione S-
transferase mu 5 
rs2229059 0.09 T>C Coding Leu= 
p22phox Cytochrome b-245, 
alpha polypeptide 
rs4673 0.34 C>T Coding Tyr72His 
NOS1 Nitric oxide 
synthase 1 
rs2291908 0.29 A>G Intronic  
 rs1093329 0.43 G>A Intronic  
 rs2293054 0.30 G>A Coding Ile= 
 rs11612772 0.27 G>C Intronic  
 rs561712 0.41 G>A Intronic  
 rs3782218 0.15 C>T Intronic  
NOS2 Nitric oxide 
synthase 2 
rs1137933 0.27 C>T Coding Asp= 
  rs3794763 0.21 G>A Intronic  
  rs3794766 0.26 C>T Intronic  
NOS3 Nitric oxide 
synthase 3 
rs3918226 0.09 C>T 5’-flanking  
 rs1799983 0.36 G>T Coding Asp298Glu 
 rs3918227 0.11 C>A 3’-UTR  
 rs3730305 0.09 C>A Intronic  
 rs753482 0.23 T>G Intronic  
 rs7830 0.32 C>A Intronic  
MT1X Metallothionein 1 rs4783950 0.38 T>C ncRNA  
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Gene Description rs number MAF 
Allele 
substitution 
Genomic 
location 
Amino acid 
substitution 
       
Hormonal metabolism     
       
HMGCR 3-hydroxy-3-
methylglutaryl-CoA 
reductase 
rs11742194 0.09 C>T Intronic  
 rs3931914 0.24 C>G 5’-flanking  
  rs3846662 0.44 T>C Intronic  
CYP17A1 Cytochrome P450, 
family 17, subfamily 
A, polypeptide 1 
rs6163 0.38 C>A Coding Ser= 
Cyp19A1 Cytochrome P450, 
family 19, subfamily 
A, polypeptide 1 
rs17601241 0.09 G>A Intronic  
 rs4324076 0.43 C>A Intronic  
 rs4646 0.24 C>A 3’-UTR  
 rs6493497 0.12 G>A 5’-flanking  
HSD17B3 Hydroxysteroid (17-
beta) 
dehydrogenase 3 
rs7022250 0.39 G>C Intronic  
SRD5A2 Steroid-5-alpha-
reductase, alpha 
polypeptide 2 
rs523349 0.31 C>G Coding Leu89Val 
GnRH1 Gonadotropin 
releasing hormone 
1 
rs6185 0.24 G>C Coding Trp16Ser 
CGA Glycoprotein 
hormones, alpha 
polypeptide 
rs932742 0.30 A>G Intronic  
FSHB Follicle stimulating 
hormone, beta 
polypeptide 
rs609896 0.46 A>G Intronic  
FSHR Follicle stimulating 
hormone receptor 
rs2072488 0.26 T>C Intronic  
 rs12473181 0.13 C>T Intronic  
 rs3788981 0.44 G>T Intronic  
 rs3913668 0.38 T>C Intronic  
 rs3788982 0.13 G>A Intronic  
 rs3913665 0.43 C>T Intronic  
 rs1504190 0.48 C>T Intronic  
 rs11894971 0.06 C>T Intronic  
 rs13033004 0.25 T>C Intronic  
 rs1394205 0.28 G>A 5’-UTR  
 rs2268363 0.17 T>C Intronic  
ESR1 Estrogen receptor 1 rs3020331 0.44 C>T   
 rs6899458 0.26 G>A Intronic  
 rs7761133 0.18 T>C Intronic  
 rs12204714 0.38 T>C Intronic  
 rs3020328 0.27 T>C Intronic  
 rs3020432 0.32 A>G Intronic  
 rs9322351 0.12 T>C Intronic  
 rs1062577 0.08 T>A 3’-UTR  
 rs2228480 0.22 G>A Coding Thr= 
 rs2234693 0.43 T>C Intronic  
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Gene Description rs number MAF 
Allele 
substitution 
Genomic 
location 
Amino acid 
substitution 
       
ESR2 Estrogen receptor 2 rs2987983 0.32 T>C Intronic  
PGR Progesterone 
receptor 
rs1042838 0.19 G>T Coding Val660Ala 
SHBG Sex hormone-
binding globulin 
rs13894 0.09 C>T Coding Arg126Cys 
 rs858521 0.42 C>G Intronic  
 rs6259 0.13 G>A Coding Asp356Asn 
COMT Catechol-O-
methyltransferase 
rs4633 0.47 T>C Coding His= 
CYP1B1 Cytochrome P450, 
family 1, subfamily 
B, polypeptide 1 
rs1056836 0.45 C>G Coding Leu432Val 
NR5A2 Nuclear receptor 
subfamily 5, group 
A,                 
member 2 
rs2821361 0.49 G>A Intronic  
 rs17722672 0.05 A>C Intronic  
 rs2821367 0.33 T>C Intronic  
 rs2821368 0.17 C>G Coding Pro= 
 rs3828112 0.29 A>G Intronic  
 rs2247328 0.35 A>G Intronic  
 rs2737673 0.46 T>C Intronic  
 rs12041297 0.14 A>C Intronic  
 rs2737679 0.13 A>T Intronic  
 rs2816969 0.13 T>C Intronic  
 rs3790800 0.30 C>T Intronic  
 rs16846145 0.06 A>G Intronic  
 rs7556049 0.11 T>C Intronic  
 rs2247019 0.19 C>T Intronic  
 rs1060060 0.33 G>A Coding Asn= 
 rs1060061 0.48 C>T 3’-UTR  
 rs2816912 0.34 C>A 3’-UTR  
NCOA1 Nuclear receptor 
coactivator 1 
rs11125744 0.10 C>G Coding Thr= 
 rs2289394 0.44 G>A Intronic  
 rs3731628 0.09 A>T Coding Pro= 
 rs17737058 0.24 C>G 3’-UTR  
NCOA3 Nuclear receptor 
coactivator 3 
rs1537306 0.11 G>C Intronic  
 rs2230782 0.09 G>C Coding Gln586His 
 rs4810648 0.12 T>C Intronic  
 rs11699879 0.27 A>G 3’-UTR  
 rs11547289 0.25 G>A 3’-UTR  
       
Early response 
       
EGR1 Early growth 
response 1 
rs11743810 0.41 T>C Intronic  
FOS FBJ murine 
osteosarcoma viral 
oncogene homolog 
rs2239615 0.26 A>T 5’-UTR  
 rs7101 0.26 T>C 5’-UTR  
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Allele 
substitution 
Genomic 
location 
Amino acid 
substitution 
       
FOSB FBJ murine 
osteosarcoma viral 
oncogene homolog 
B 
rs2282695 0.31 C>G Coding Ala= 
 rs1049739 0.41 A>G 3’-UTR  
NFKB1 Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
1 
rs3774932 0.45 G>A Intronic  
 rs230492 0.34 G>A Intronic  
 rs3774964 0.34 A>G Intronic  
ATF2 Activating 
transcription factor 
2 
rs212348 0.20 T>A Intronic  
 rs212347 0.15 T>C Intronic  
 rs12693057 0.08 G>A Intronic  
MAPK1 Mitogen-activated 
protein kinase 1 
rs7286558 0.06 C>T Intronic  
 rs2986657 0.45 A>G Intronic  
 rs4233292 0.10 A>G Intronic  
 rs1982227 0.18 C>G Intronic  
MAPK11 Mitogen-activated 
protein kinase 11 
rs2076139 0.22 C>T Coding Ser= 
 rs742185 0.23 G>A Intronic  
MAPK12 Mitogen-activated 
protein kinase 12 
rs1129880 0.32 C>T Coding Ser= 
MAPK13 Mitogen-activated 
protein kinase 13 
rs1059227 0.31 C>A Coding Thr= 
NFKBIA Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor, alpha 
rs8904 0.41 C>T 3’-UTR  
 rs2233419 0.19 C>T Intronic  
 rs1050851 0.21 C>T Coding Ala= 
 rs1957106 0.35 G>A Coding Asp= 
 rs2233409 0.23 C>T 5’-flanking  
CHUK Conserved helix-
loop-helix 
ubiquitous kinase 
rs11597086 0.44 A>C Intronic  
 rs2230804 0.48 A>G Coding Ile268Val 
IKBKB Inhibitor of kappa 
light polypeptide 
gene enhancer in 
B-cells, kinase beta 
rs2294100 0.06 T>A Intronic  
Varia       
       
DDX17 DEAD (Asp-Glu-
Ala-Asp) box 
helicase 17 
rs1043402 0.29 G>A 3’-UTR  
 rs5750609 0.12 C>T Intronic  
POLA2 Polymerase (DNA 
directed), alpha 2, 
accessory subunit 
rs487989 0.11 G>A Coding Gly583Arg 
PPP2CA Protein 
phosphatase 2, 
catalytic subunit, 
alpha isozyme 
rs2302599 0.15 G>T Intronic  
PPP6C Protein 
phosphatase 6, 
catalytic subunit 
rs6744 0.49 G>A 3’-UTR  
 rs4838249 0.35 A>G 3’-UTR  
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Gene Description rs number MAF 
Allele 
substitution 
Genomic 
location 
Amino acid 
substitution 
       
PPARγ Peroxisome 
proliferator-
activated receptor 
gamma 
rs13433696 0.25 G>A Intronic  
 rs1801282 0.12 C>G Coding Pro12Ala 
 rs2972162 0.47 T>C Intronic  
 rs709158 0.35 A>G Intronic  
 rs1175543 0.35 A>G Intronic  
 rs3856806 0.12 C>T Coding His= 
HSPA1A Heat shock 70kDa 
protein 1A 
rs1043618 0.47 G>C 5’-UTR  
HSPA1L Heat shock 70kDa 
protein 1-like 
rs2227956 0.18 T>C Coding Thr493Met 
COX1 Prostaglandin-
endoperoxide 
synthase 1 
rs1213266 0.07 G>A Intronic  
 rs5788 0.15 C>A Coding Gly= 
COX2 Prostaglandin-
endoperoxide 
synthase 2 
rs689466 0.20 A>G 5’-flanking  
 rs20417 0.17 G>C 5’-flanking  
 rs5275 0.36 T>C 3’-UTR  
 rs5277 0.15 G>C Coding Val= 
PTGES Prostaglandin E 
synthase 
rs2302821 0.08 A>C 3’-UTR  
PTGER2 Prostaglandin E 
receptor 2 (subtype 
EP2) 
rs708498 0.17 G>A Intronic  
 rs708494 0.37 T>C 5’-flanking  
PTGER3 Prostaglandin E 
receptor 3 (subtype 
EP3) 
rs493489 0.12 C>A Intronic  
PTGER4 Prostaglandin E 
receptor 3 (subtype 
EP4) 
rs11957406 0.45 A>G Intronic  
mTOR Mechanistic target 
of rapamycin 
rs1135172 0.26 C>T Coding Asp= 
 rs2295080 0.30 T>G 5’-flanking  
AKT v-akt murine 
thymoma viral 
oncogene                          
homolog 1 
rs1130233 0.28 G>A Coding Glu= 
 rs2494748 0.35 T>C Intronic  
IL1A Interleukin 1, alpha rs2856836 0.30 T>C 3’-UTR  
 rs3783550 0.29 A>C Intronic  
 rs3783546 0.29 G>C Intronic  
 rs17561 0.29 G>T Coding Ala114Ser 
 rs3783539 0.28 G>A Intronic  
EGFR Epidermal growth 
factor receptor 
rs4947963 0.37 T>C Intronic  
 rs11766798 0.29 G>A Intronic  
 rs2302535 0.33 A>C Intronic  
 rs11238350 0.16 T>C Intronic  
 rs845552 0.45 A>G Intronic  
 rs1050171 0.43 A>G Coding Gln= 
 rs1140475 0.11 C>T Coding Thr= 
 rs2293348 0.30 G>A Intronic  
 rs2293347 0.11 G>A Coding Asp= 
 rs2227983 0.27 G>A Coding Lys521Arg 
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ENG Endoglin rs16930129 0.09 C>T Coding Leu= 
 rs10987759 0.07 T>C 5’-flanking  
ITGB2 Integrin, beta 2 rs235326 0.35 C>T Coding Val= 
 rs2230528 0.23 G>A Coding Gly= 
TGFB1 Transforming 
growth factor,     
beta 1 
rs1800468 0.10 G>A 5’-flanking  
 rs1800469 0.28 C>T 5’-flanking  
 rs1800470 0.37 T>C Coding Pro10Leu 
 rs1800471 0.09 G>C Coding Arg25Pro 
 rs2241717 0.42 T>G Intronic  
       
SNPs previously found associated with cancer susceptibility through GWAS analysis 
       
  rs3888929 0.30 G>A Unknown  
  rs4867592 0.39 C>A Unknown  
HAL Histidine ammonia-
lyase 
rs7970524 0.25 T>C 5’-flanking  
  rs12003093 0.27 A>G Unknown  
VDR 1,25- 
dihydroxyvitamin 
D3 receptor 
rs4760658 0.34 A>G Intronic  
EPDR1 Ependymin related 
protein 1 
rs1376264 0.35 C>T 5’-flanking  
MRE11A Meiotic 
recombination 11 
homolog A 
rs2155209 0.33 T>C 3’-UTR  
MRE11A rs569143 0.44 C>G Intronic  
     
GWAS Breast cancer     
CASP8 Caspase 8 rs1045485 0.14 G>C Coding Asp302His 
IL1B Interleukin 1, beta rs1143634 0.24 C>T Coding Phe= 
IL4 Interleukin 4 rs2070874 0.15 C>T 5’-UTR  
FGFR2 Fibroblast growth 
factor receptor 2 
rs2981582 0.38 C>T Intronic  
FGFR2 rs2981579 0.39 C>T Intronic  
CASC16  Long intergenic 
non-protein coding 
RNA 918 
rs3803662 0.23 C>T ncRNA  
  rs889312 0.27 A>C Unknown  
  rs13281615 0.39 A>G Unknown  
LSP1 Lymphocyte-
specific protein 1 
rs3817198 0.32 T>C Intronic  
EMBP1 Embigin 
pseudogene 1 
rs11249433 0.40 T>C Intronic  
RAD51B RAD51 homolog B rs999737 0.25 C>T Intronic  
  rs2067980 0.14 A>G Unknown  
STXBP4 Syntaxin binding 
protein 4 
rs6504950 0.29 G>A Intronic  
CCDC170 Coiled-coil domain 
containing 170 
rs3757318 0.06 G>A Intronic  
  rs1562430 0.43 A>G Unknown  
TNNT3 Troponin T type 3 rs909116 0.49 T>C Intronic  
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Allele 
substitution 
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location 
Amino acid 
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  rs13387042 0.46 A>G Unknown  
CDKN2B-
AS1 
CDKN2B antisense 
RNA 1 
rs1011970 0.17 G>T Intronic  
ZMIZ1 Zinc finger, MIZ-
type containing 1 
rs704010 0.42 G>A Intronic  
  rs614367 0.14 C>T Unknown  
BABAM1 BRISC and BRCA1 
A complex member 
1 
rs8170 0.20 C>T Coding Lys= 
BABAM1 rs3745185 0.41 G>A Intronic  
NR2F6 Nuclear receptor 
subfamily 2, group 
F, member 6 
rs4808611 0.18 C>T Intronic  
ANKLE1 Ankyrin repeat and 
LEM domain 
containing 1 
rs2363956 0.48 T>G Coding Leu184Trp 
     
GWAS Prostate cancer     
  rs2660753 0.10 C>T Unknown  
SLC22A3 Solute carrier family 
22, member 3 
rs9364554 0.28 C>T Intronic  
LMTK2 lemur tyrosine 
kinase 2 
rs6465657 0.44 T>C Intronic  
  rs6983267 0.42 G>T Unknown  
LOC727677 uncharacterized 
LOC727677 
rs1447295 0.14 C>A Intronic  
MSMB microseminoprotein
, beta- 
rs10993994 0.47 C>T 5’-flanking  
CTBP2 C-terminal binding 
protein 2 
rs4962416 0.28 T>C Intronic  
HNF1B HNF1 homeobox B rs4430796 0.46 A>G Intronic  
HNF1B rs11649743 0.20 G>A Intronic  
  rs1859962 0.46 G>T Unknown  
  rs2735839 0.15 G>A Unknown  
CLPTM1L CLPTM1-like rs401681 0.47 C>T Intronic  
JAZF1 JAZF zinc finger 1 rs10486567 0.23 G>A Intronic  
DAB2IP DAB2 interacting 
protein 
rs1571801 0.25 C>A Intronic  
EEFSEC Eukaryotic 
elongation factor, 
selenocysteine-
tRNA-specific 
rs10934853 0.34 C>A Intronic  
  rs16902094 0.17 A>G Unknown  
  rs445114 0.31 T>C Unknown  
  rs8102476 0.40 C>T Unknown  
  rs11228565 0.24 G>A Unknown  
EHBP1 EH domain binding 
protein 1 
rs2710647 0.42 C>T Intronic  
EHBP1 rs721048 0.20 G>A Intronic  
  rs6545977 0.48 G>A Unknown  
THADA thyroid adenoma 
associated 
rs1465618 0.25 G>A Intronic  
PDLIM5 PDZ and LIM 
domain 5 
rs17021918 0.35 C>T Intronic  
PDLIM5 rs12500426 0.47 C>A Intronic  
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  rs7679673 0.35 C>A Unknown  
  rs1512268 0.48 G>A Unknown  
  rs5759167 0.48 G>T Unknown  
  rs10086908 0.32 T>C Unknown  
  rs620861 0.30 C>T Unknown  
  rs4242382 0.14 G>A Unknown  
  rs7841060 0.24 T>G Unknown  
  rs12543663 0.30 A>C Unknown  
  rs1016343 0.25 C>T Unknown  
  rs13252298 0.27 A>G Unknown  
  rs4871008 0.40 C>T Unknown  
  rs6470494 0.31 C>T Unknown  
  rs10090154 0.14 C>T Unknown  
 
 
 
Table e3: Overview of the 29 patient and treatment related parameters. 
Patient data 
(n=9) 
Treatment parameters 
(n=20) 
Pre-therapy symptoms Lymph node dissection 
(RT-induced acute symptoms) Radical prostatectomy 
Age Gleason score 
Diabetes Adjuvant androgen deprivation 
Hypertension B10 (%) 
Smoking B20 (%) 
Haemorrhoids B30 (%) 
Previous surgery B40 (%) 
Crohn disease or irritable bowel disease B50 (%) 
Transurethral resection of the prostate B60 (%) 
 B65 (%) 
 B70 (%) 
 B75 (%) 
 Bladder Mean (Gy) 
 Bladder Max (Gy) 
 Bladder Volume (cc) 
 CTV Min (Gy) 
 CTV Mean (Gy) 
 CTV Max (Gy) 
 CTV Volume (cc) 
Abbreviations: RT = radiotherapy; PSA = prostate-specific antigen; BX = 
percentage of the bladder volume receiving X Gy or more; CTV = clinical 
target volume. 
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Table e4: Outcome of modeling analysis for late haematuria. 
 Complete model Non-SNP model 
Model Predictors Coefficients  
(Intercept) -3.32 -3.67 
Bladder Vol 75 (cc) 0.44 0.40 
HMGRC_rs3931914_CG 1.67 - 
NOS1_rs2293054_GA -1.46 - 
PTGER2_rs708498_GG -1.42 - 
EGFR_rs845552_AG 0.95 - 
TUR 1.20 1.43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For both models: Model expression: ln p/(1-p) = β0 + β1*x1 + β2*x2 + β3*x3 + β4*x4 + β5*x5 + β6*x6 
+ … with p=probability to develop severe late haematuria/nocturia, β=coefficient, 
x=variable/parameter/predictor and e
β1
=increase in odds for predictor 1 (in the case of 
continuous variables: for an increase of the predictor by 1) when the other predictors remain 
unchanged. 
 
Table e5: Outcome of modeling analysis for late nocturia. 
 Complete model Non-SNP model 
Model Predictors Coefficients  
(Intercept) -1.34 -2.21 
CTV Volume (cc) 0.36 0.31 
CTV Min (Gy) 0.27 0.36 
NOS3_rs1799983_GT -1.67 - 
CASP8_rs1045485_GG -1.30 - 
NR2F6_rs4808611_CT 1.14 - 
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ABSTRACT 
Background: After breast-conserving radiation therapy most patients 
experience acute skin toxicity to some degree. This may impair patients’ quality 
of life, cause pain and discomfort. In this study, we investigated treatment and 
patient-related factors, including genetic polymorphisms, that can modify the 
risk for severe radiation-induced skin toxicity in breast cancer patients. 
Methods: We studied 377 patients treated at Ghent University Hospital and at 
Clinic and Maternity Sainte-Elisabeth in Namur, with adjuvant intensity 
modulated radiotherapy (IMRT) after breast-conserving surgery for breast 
cancer. Women were treated in a prone or supine position with 
normofractionated (25x2 Gy) or hypofractionated (15x2.67 Gy) IMRT alone or in 
combination with other adjuvant therapies. Patient- and treatment-related 
factors and genetic markers in regulatory regions of radioresponsive genes and 
in LIG3, MLH1 and XRCC3 genes were considered as variables. Acute 
dermatitis was scored using the CTCAEv3.0 scoring system. Desquamation 
was scored separately on a 3-point scale (0-none, 1-dry, 2-moist).  
Results: Two-hundred and twenty patients (58%) developed G2+ dermatitis 
whereas moist desquamation occurred in 56 patients (15%). Normofractionation 
(both p<0.001), high body mass index (BMI) (p=0.003 and p<0.001), bra cup 
size ≥D (p=0.001 and p=0.043) and concurrent hormone therapy (p=0.001 and 
p=0.037) were significantly associated with occurrence of acute dermatitis and 
moist desquamation, respectively. Additional factors associated with an 
increased risk of acute dermatitis were the genetic variation in MLH1 
rs1800734, smoking during RT (p=0.008) and supine IMRT (p=0.004). Patients 
receiving trastuzumab showed decreased risk of acute dermatitis (p<0.001).  
Conclusions: The normofractionation schedule, supine IMRT, concomitant 
hormone treatment and patient related factors (high BMI, large breast, smoking 
during treatment and the genetic variation in MLH1 rs1800734) were associated 
with increased acute skin toxicity in patients receiving radiation therapy after 
breast-conserving surgery. Trastuzumab seemed to be protective.  
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BACKGROUND 
Breast-conserving therapy with the adjuvant use of radiotherapy (RT) has 
gained an established role in the treatment for early-stage breast cancer with 
excellent long-term local control and survival (1). During or shortly after the 
course of breast cancer RT, a large portion of the patients will experience acute 
radiation dermatitis to some degree, varying from mild to brisk erythema with or 
without moist desquamation and occasionally ulceration of the skin (2). There is 
accumulating clinical evidence that acute reactions are associated with the 
development of late toxicity: Lilla et al. showed that telangiectasia are in fact 
late sequelae of moist desquamation and acute erythema is shown to be a risk 
factor for poor cosmetic outcome (3-5). Though the skin is not a dose-limiting 
tissue, skin toxicity is associated with impairment of patients’ quality of life, 
causes pain and discomfort and limits activities (2, 6). The challenge is to 
minimize these side effects without losing efficacy of the treatment. 
Over the years, many attempts have been made to reduce the number of 
patients experiencing acute skin toxicity and inferior cosmetic outcome by 
introducing improved radiation techniques, such as intensity-modulated 
radiotherapy (IMRT). This technique has been shown to be superior over 
conventional wedge-based whole breast irradiation by delivering a more 
homogenous dose through the breast and removing the radiation hot spots; it 
results in an approximately 20% reduction of the frequency of moist 
desquamation (6, 7). Large breast size significantly contributes to dose 
inhomogeneity, hot spots and toxicity (7, 8). The variation in clinical response is, 
however, only partly explained by treatment factors such as radiation dose, 
fractionation scheme, and concomitant therapies. Patient-related features (e.g. 
bra cup size and body mass index (BMI)) also play a role together with an 
unknown contribution from genetic factors. Up to now there are no data 
available to estimate directly the heritability of clinical radiosensitivity based 
upon family history of radiotherapy toxicity, but it is likely to be somewhat lower 
than for chromosomal and cellular radiosensitivity, which have been calculated 
to be 58-78% (9). 
Acute toxicity is initiated by depletion of acutely responding epithelial tissues 
and damage to microvessels (10). Numerous studies have reported on genetic 
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variations modifying the clinical radiosensitivity risk, predominantly in pathways 
based on mechanistic understanding of the radiation pathogenesis (reviewed in 
(11)). In the present study, single nucleotide polymorphisms (SNPs) in genes 
involved in major DNA repair pathways (LIG3, XRCC3, MLH1) and in regulatory 
regions that influence the expression levels of radioresponsive genes are 
considered (12-16).  
To gain a better insight into the development of radiation-induced dermatitis 
and moist desquamation, we evaluated the association between patient and 
treatment features with these endpoints. The association between SNPs and 
the different clinical endpoints was also studied.  
METHODS 
The study population consists of 377 breast cancer patients treated with 
adjuvant IMRT with curative intent after breast-conserving surgery (stage T1-3, 
N0-1, M0). Of them, 282 breast cancer patients were treated at the Ghent 
University Hospital (GUH) and 95 patients were treated at Clinique and 
Maternité Sainte-Elisabeth (CMSE) in Namur. All patients had a follow-up of at 
least 3 months after RT. 
At GUH, patients were treated in prone or supine position using a multi-
beam IMRT technique in supine position and a tangential 2-beam field-in-field 
IMRT technique in prone position as described previously (17). The whole 
breast was treated with hypofractionated radiotherapy (40.05 Gy in 15 fractions 
(18)) with 6-MV photons of an Elekta Synergy linear accelerator (Crawley, 
United Kingdom). An additional photon boost of 10 Gy in 4 fractions to the 
tumour bed was given to 75% of the patients. For the prone patient setup, a 
unilateral breast holder (Van De Velde, Schellebelle, Belgium) and a prone 
breast board (Orfit Industries) were used (19). Twenty-two patients were treated 
in prone position with voluntary moderate deep inspiration breath hold. At 
CMSE Namur, a sliding window tangential field-IMRT technique was used 
associated with moderate deep inspiration breath hold whenever the primary 
beam intersected the heart as previously described by Remouchamps et al 
(20). Patients with bra cup size ≥D received normofractionated radiotherapy 
(50.00 Gy in 25 fractions), women with bra cup size <D received 
hypofractionation or normofractionation according to the preference of the 
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radiation oncologist (n=28). More than 90% received an additional boost of 10 
Gy in 4 fractions with electron beams.  
 
Adjuvant systemic therapy 
Adjuvant hormone therapy, consisting of tamoxifen or aromatase inhibitors, was 
administered in most patients concomitantly with IMRT. The others received 
hormone therapy sequentially after IMRT. Patients who received adjuvant 
chemotherapy, combination of antracyclines and taxanes, completed 
chemotherapy before IMRT, while trastuzumab was allowed concomitantly with 
IMRT.  
 
Data collection 
Data on patients’ medical history, tumor and treatment characteristics were 
collected prospectively. Table 1 gives an overview of the patient characteristics 
for patients treated at GUH and CMSE Namur.  
Acute toxicity was assessed weekly during treatment and at 1-2 weeks after 
treatment. The reported toxicity represents the maximal reported acute toxicity, 
either during or after completion of IMRT. Acute dermatitis was documented 
according to a standard protocol using the Common Terminology Criteria for 
Adverse Events (CTCAE) v3.0 scoring system. This grades patients with mild 
erythema or dry desquamation as 1, moderate to brisk erythema or patchy 
moist desquamation mostly confined to the skin folds as 2 and confluent moist 
desquamation as 3. Desquamation was scored separately on a 3-point scale (0-
none, 1-dry, 2-moist). Grade 2-3 toxicity was considered clinically relevant and 
was included in the analysis. Genomic DNA was isolated from a fresh blood 
sample taken before start of radiotherapy, using the Puregene genomic DNA 
purification kit (Gentra Systems, Minneapolis, MN). The study was approved by 
the local ethics committees and all study patients provided written informed 
consent. 
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Table 1: Patient characteristics for patients treated at 
GUH and CMSE Namur. 
Patient/clinical factor 
GUH 
(n=282) 
CMSE Namur 
(n=95) 
Age (years)   
Median 57.5  59,0  
Range 30-82 35-82 
Bra cup size   
Small 
A 13 (4.6) 3 (3.2) 
B 85 (30.2) 33 (34.7) 
C 101 (35.8) 34 (35.8) 
   
Large 
D 53 (18.8) 16 (16.8) 
E 16 (5.7) 5 (5.3) 
F 7 (2.5) 3 (3.2) 
G + H 2 (0.6) 1 (1.0) 
Missing 5 0 
BMI   
Median 25.5 26  
Range 16-50 16-38 
Missing 2 0 
Menstruation   
No 235 (83.3) 76 (80.0) 
Yes 45 (16.0) 18 (18.9) 
Missing 2 1 
Smoking during RT   
No 244 (86.5) 79 (83.2) 
Yes 35 (12.4) 16 (16.8) 
Missing 3 0 
Diabetes   
No 254 (90.1) 84 (88.4) 
Yes 22 (7.8) 11 (11.6) 
Missing 6 0 
Hypertension   
No 196 (69.5) 66 (69.5) 
Yes 81 (28.7) 29 (30.5) 
Missing 5 0 
Fractionation   
Normo 0 45 (47.4) 
Hypo 282 50 (52.6) 
Missing 0 0 
Treatment position   
Supine 195 (69.1) 95 (100.0) 
Prone 87 (30.9) 0 
Missing 0 0 
continued on next page 
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Table 1 (continued) 
Patient/clinical factor 
GUH 
(n=282) 
CMSE Namur 
(n=95) 
Boost   
No 64 (22.7) 7 (7.4) 
Yes 218 (77.3) 88 (92.6) 
Missing 0 0 
Nodal irradiation   
No 241 (85.5) 87 (80.6) 
Yes 41 (14.5) 21 (19.4) 
Missing 0 0 
Hormonal therapy   
No 46 (16.3) 25 (26.3) 
Concomitant 236 (83.7) 7 (7.4) 
Sequential (after IMRT) 0 63 (66.3) 
Missing 0 0 
Chemotherapy   
No 188 (66.7) 55 (57.9) 
Yes 94 (33.3) 40 (42.1) 
Missing 0 0 
Trastuzumab   
No 257 (91.1) 83 (87.4) 
 Yes 25 (8.9) 12 (12.6) 
Missing 0 0 
Abbreviations: GUH = Ghent University Hospital; CMSE = 
Clinic Maternity Sainte-Elisabeth; BMI = Body Mass 
Index.  
Data are given as no. (%) unless otherwise indicated. 
 
Selection of candidate genes/polymorphisms and genotyping 
Eight candidate polymorphisms were selected for genotyping (Table 2). Of 
these, five SNPs (rs3888929, rs4867592, rs7970524, rs12003093, rs4760658) 
were chosen as they putatively affect the expression levels of radiation-
responsive genes directly, or by trans effects, based on genetic linkage and 
association analysis as described previously by Smirnov et al.. The authors 
suggested that those regulatory variants might be able to contribute to the 
development of genetic tools for radiosensitivity (16). The other SNPs were 
chosen based on their previous association with toxicity induced by 
radiotherapy or methylating agents (XRCC3 rs861539, LIG3 rs3744355, MLH1 
rs1800734) (12-15). Genotyping was performed using restriction fragment 
length polymorphism analyses, high resolution melting curve analyses, single 
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base extension techniques or direct sequencing. For reproducibility control, 
15% of all samples were duplicated. The concordance rate between duplicate 
samples was 100%. Primers details are available on request. Tests for 
deviation from Hardy-Weinberg equilibrium, for the entire sample showed that 
the rs4867592 SNP had a p-value <0.0001 and was excluded from further 
analyses. 
 
Table 2: Characteristics of the SNPs. 
Gene or 
gene 
regulator rs number MAF* 
Nucleotide 
substitution 
Genomic 
location 
Amino 
acid 
substitution Ref. 
LIG3 rs3744355 9.1 G>C 5’-flanking - [12, 13] 
MLH1 rs1800734 22.6 G>A 5’-UTR - [14] 
XRCC3 rs861539 39.0 C>T Coding Thr241Met [15] 
PHLDA3 rs3888929 30.3 G>A Unknown - 
[16] 
LCP2 rs4867592 19.1 C>A Unknown - 
LTHA4 rs7970524 25.1 T>C 5’-flanking - 
NDUFB6 rs12003093 23.4 A>G Unknown - 
VDR rs4760658 36.6 A>G Intronic - 
Abbreviations: Minor allele frequency in Caucasian population. 
 
 
Statistical analysis  
The studied endpoints were development of acute radiation-induced dermatitis 
(CTCAE G2+) and moist desquamation. For the clinical association analysis, 
univariate analysis was initially carried out to assess the relationship between 
patient- (age, bra cup size (A+B+C vs. ≥D), BMI, menstruation, smoking during 
RT, diabetes, hypertension) and treatment-related factors (fractionation 
scheme, treatment position, boost dose to tumour bed, nodal irradiation, 
hormone therapy, chemotherapy and trastuzumab) and the endpoints. Patients 
with and without G2+ acute skin toxicity were compared by means of the Mann-
Whitney test for continuous variables and the χ²-test for categorical variables. 
Power calculations were performed with Power for Genetic Association 
analyses (21). For these we took into account: the incidence of dermatitis (58%) 
or moist desquamation (15%) observed in our cohort, the lowest minor allele 
frequency (9%) of the considered SNPs, a probability adjusted by the number of 
SNPs (α=6.25 x 10-3) under a dominant genotypic test, and a genotype relative 
risk of ≥1.5. This resulted in a power of 94.3% for acute dermatitis and 60.9% 
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for moist desquamation. To assess the independent effect of each 
polymorphism, unconditional logistic regression analyses were performed to 
calculate crude ORs. The Benjamini-Hochberg (BH) procedure was used to 
control for multiple testing (i.e. 43 tests per endpoint: 28 genetic and 15 clinical 
parameter tests) to reduce the risk of finding false-positive associations. 
Variables with p<0.05 were tested in a multivariate logistic regression analysis. 
Statistical analyses were performed using SPSS 17.0 software (SPSS Inc., 
Chicago, IL). R library multtest (http://www.r-project.org/) was used to perform 
the multiple testing analyses. 
RESULTS 
Acute radiation-induced skin toxicity data were available for all 377 patients. 
Two-hundred twenty patients (58%) developed G2+ dermatitis. The occurrence 
of dermatitis did not differ between both centres (GUH: 57% (162/282), CSME: 
61% (58/95)). Moist desquamation (patchy or confluent) occurred in 56 patients 
(15%) and differed between both centres: 10% of the patients treated at GUH 
and 30% of the patients treated at CMSE (p<0.001).  
 
Table 3: Associations between patient- and therapy-related characteristics and acute G2+ 
dermatitis. 
Patient/clinical factor  
All 
(n=377) 
G0-1 
(n=157) 
G2+ 
(n=220) P-value PBH-value 
Bra cup size      
A+B+C 269 (71.4) 130 (48.3) 139 (51.7)   
≥D 103 (27.3) 26 (25.2) 77 (74.8) <0.001 0.001 
BMI      
Median 26 24 26   
Range 16-50 16-37 16-50 <0.001 0.001 
Smoking during RT      
No 323 (85.7) 141 (43.7) 182 (56.3)   
Yes 51 (13.5) 14 (27.5) 37 (72.5) 0.029 0.156 
Fractionation      
Normo 45 (11.9) 6 (13.3) 39 (86.7)   
Hypo 332 (88.1) 151 (45.5) 181 (54.5) <0.001 <0.001 
Treatment position      
Supine 290 (76.9) 108 (37.2) 182 (62.8)   
Prone 87 (23.1) 49 (56.3) 38 (43.7) 0.002 0.019 
continued on next page 
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Table 3 (continued) 
Patient/clinical factor  
All 
(n=377) 
G0-1 
(n=157) 
G2+ 
(n=220) P-value PBH-value 
Nodal irradiation      
No 315 (83.6) 141 (44.8) 174 (55.2) 
 
 
Yes 62 (16.4) 16 (25.8) 46 (74.2) 0.006 0.037 
Hormonal therapy      
No 71 (18.8) 39 (54.9) 32 (45.1) 
 
 
Concomitant 243 (64.5) 94 (38.7) 149 (61.3)   
Sequential (after IMRT) 63 (16.7) 24 (38.1) 39 (61.9) 0.041 0.207 
Hormones (concomitant)      
Tamoxifen 155 62 (40.0) 93 (60.0)   
Aromatase inhibitor 85 32 (37.6) 53 (62.4)   
Chemotherapy      
No 243 (64.5) 92 (37.9) 151 (62.1) 
 
 
Yes 134 (35.5) 65 (48.5) 69 (51.5) 0.045 0.215 
Trastuzumab      
No 340 (90.2) 133 (39.1) 207 (60.9) 
 
 
Yes 37 (9.8) 24 (64.9) 13 (35.1) 0.003 0.026 
Abbreviations: G = CTCAEv.3 grade; BMI = Body Mass Index; pBH = corrected p-value by 
Benjamini-Hochberg procedure.  
Data are given as no. (%) unless otherwise indicated. 
 
Acute radiation-induced skin toxicity 
Table 3 depicts the parameters associated with acute G2+ dermatitis, in 
univariate analysis. Bra cup size ≥D (p<0.001), BMI (p<0.001) and smoking 
during RT (p=0.029) were associated with the development of G2+ dermatitis. 
Irradiation of the nodal region (p=0.006) and the use of concomitant hormone 
therapy (p=0.041) were also associated with an increased risk of acute 
dermatitis, with no difference in incidence between aromatase-inhibitors and 
tamoxifen. In contrast, patients receiving trastuzumab or having received 
chemotherapy seem to be less prone to the development of RT-induced acute 
dermatitis (p=0.003 and p=0.045, respectively). Furthermore, patients treated 
with hypofractionated radiotherapy develop less dermatitis when compared to 
patients treated in the normofractionated regimen (p<0.001). And, patients 
treated in prone position developed less dermatitis than patients treated supine 
(p=0.002). In multivariate analysis, chemotherapy and nodal irradiation were no 
longer significant (Table 4).  
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Table 4: Multivariate analysis for G2+ dermatitis and moist desquamation. 
Clinical/genetic factor 
Acute G2+ dermatitis  Moist desquamation 
OR P-value  OR P-value 
Center (CMSE vs. GUH) - -  3.206 0.158 
BMI 1.088 0.003  1.170 <0.001 
Bra cup size (cup ≥D vs. cup A+B+C) 2.833 0.001  2.146 0.043 
Smoking (yes vs. no) 2.711 0.010  - - 
Fractionation (hypo vs. normo) 0.083 <0.001  0.096 <0.001 
Treatment position (prone vs. supine) 0.399 0.004  0.373 0.074 
Hormone therapy      
No 1   1  
Concomitant 3.207 0.001  4.770 0.037 
Sequential (after IMRT) 1.003 0.994  1.078 0.901 
Nodal irradiation (yes vs. no) 1.975 0.100  - - 
Chemotherapy (yes vs. no) 0.954 0.877  - - 
Trastuzumab (yes vs. no) 0.177 <0.001  - - 
MLH1 rs1800734 G>A      
GG 1   -  
GA 0.492 0.008  - - 
AA 0.537 0.232  - - 
Abbreviations: GUH = Ghent University Hospital; CMSE = Clinic Maternity Sainte-
Elisabeth; BMI = Body Mass Index; MLH1 = MutL protein homolog 1 
 
For moist desquamation, univariate significant associations were found with 
bra cup size ≥D (p<0.001), BMI (p<0.001), normofractionation (p<0.001), supine 
positioning (p=0.002), concurrent hormone therapy (p=0.004) and CSME center 
(p<0.001) (Table 5). In multivariate analysis (Table 6), bra cup size ≥D, BMI, 
fractionation and hormone therapy remained statistically significant. Treatment 
center was no longer significantly associated with moist desquamation due to 
the fact that the normofractionated schedule was only prescribed at CMSE. 
 
Table 5: Associations between patient- and therapy-related characteristics and moist 
desquamation. 
 Patient/clinical factor  
All 
(n=377) 
No 
(n=321) 
Yes 
(n=56) P-value PBH-value 
Bra cup size      
A+B+C 269 (71.4) 242 (90.0) 27 (10.0) 
 
 
≥D 103 (27.3) 76 (73.8) 27 (26.2) <0.001 0.001 
BMI      
Median 26 25 29 
 
 
Range 16-50 16-40 21-50 <0.001 <0.001 
Fractionation      
Normo 45 (11.9) 22 (48.9) 23 (51.1) 
 
 
Hypo 332 (88.1) 299 (90.1) 33 (9.9) <0.001 <0.001 
continued on next page 
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Table 5 (continued) 
 Patient/clinical factor  
All 
(n=377) 
No 
(n=321) 
Yes 
(n=56) P-value PBH-value 
Treatment position      
Supine 290 (76.9) 239 (82.4) 51 (17.6) 
 
 
Prone 87 (23.1) 82 (94.3) 5 (5.7) 0.002 0.019 
Hormonal therapy      
No 71 (18.8) 62 (87.3) 9 (12.7)   
Concomitant 243 (64.5) 214 (88.1) 29 (11.9)   
Sequential (after IMRT) 63 (16.7) 45 (71.4) 18 (28.6) 0.004 0.029 
Hormones (concomitant)      
Tamoxifen 155 139 (89.7) 16 (10.3)   
Aromatase inhibitor 85 74 (87.1) 11 (12.9)   
Abbreviations: GUH = Ghent University Hospital; CMSE = Clinic Maternity Sainte-
Elisabeth; BMI = Body Mass Index; pBH = corrected p-value by Benjamini-Hochberg 
procedure.  
Data are given as no. (%) unless otherwise indicated. 
 
 
Genetic analysis 
The only significant p-value, in univariate analysis, was for acute radiation-
induced dermatitis with the GA genotype of rs1800734 in the MLH1 gene with a 
BH-adjusted p-value of 0.029 (Table 6). Adjusting for above mentioned factors 
by multivariate regression analysis had no effect on the statistically significant 
association. None of the other SNPs had any effect on the risk of acute skin 
toxicity. 
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Table 6: Effect of MLH1 rs1800734 on radiotherapy acute skin reactions. 
 
Acute G2+ dermatitis  Moist desquamation 
 
G0-1 
(n=157) 
G2+ 
(n=220) OR P-value PBH-value  
No 
(n=321) 
Yes 
(n=95) OR P-value PBH-value 
MLH1 rs1800734 G>A 
    
  
    
 
GG 81 (51.6) 146 (66.4) 
  
  189 (58.9) 38 (67.9) 
  
 
GA 64 (40.8) 60 (27.3) 0.52 0.004 0.029  110 (34.3) 14 (25.0) 0.63 0.172 0.477 
AA 9 (5.7) 12 (5.5) 0.74 0.514 0.804  17 (5.3) 4 (7.1) 1.17 0.788 0.915 
Missing 3 (1.9) 2 (0.9) 
  
  5 (1.6) 0 
  
 
     
  
    
 
GG vs. GA+AA 
(dominant)   
0.55 0.005 0.033  
  
0.71 0.257 0.575 
GG+GA vs. AA 
(recessive)   
0.94 0.889 0.936  
  
1.35 0.600 0.860 
Abbreviations: MLH1 = MutL protein homolog 1, pBH = corrected p-value by Benjamini-Hochberg procedure. 
Data are given as no. (%) unless otherwise indicated. 
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DISCUSSION 
This study was performed to analyze the influence of treatment and patient-
related factors on the development of acute radiation-induced skin toxicity. Bra 
cup size, BMI, smoking, treatment position, choice of RT schedule and the 
administration of adjuvant therapies seem to contribute to the variability in 
radiation skin toxicity. Also, the MLH1 rs1800734 SNP was found to be 
significantly associated with the development of acute dermatitis.  
 
Our data support the hypothesis that acute toxicity does not increase with 
moderate hypofractionation (22). In fact, the occurrence of acute skin toxicity 
was significantly higher among patients treated with normofractionation 
compared to the hypofractionated schedule. There are only few reports studying 
hypofractionation in overweighed or large-breasted patients (23, 24). We 
observe a 20% decrease in dermatitis and an even larger decrease (70%) in 
moist desquamation in large-breasted patients treated in supine position with 
hypofractionation compared to normofractionation (see supplementary table 
e1). Bra cup size and BMI were also confirmed as significant risk factors for the 
development of acute skin toxicity, in accordance with the majority of published 
reports (7, 8, 25-27). Both are measures of breast volume as BMI was 
previously found to be strongly correlated with breast volume (27). The 
association between larger breast volume and toxicity is thought to be due to 
dose inhomogeneity, high dose regions, and the bolus effect in the 
inframammary and axillary regions (8). Due to the unavailability of dose 
homogeneity and hot spot data for the complete dataset, we were unable to test 
this for the total patient population, but the hypothesis is confirmed in a subset 
of the population (19). Goldsmith et al. show that dose inhomogeneity is 
insufficient to explain the association and other factors like the presence of 
more adipose tissue might also play a role (25). In prone position, the skin 
creases disappear, dose homogeneity is improved and hot spots are reduced 
leading to a reduction in acute skin toxicity (17). In this study, we found a 
decrease in radiodermatitis and moist desquamation in patients treated with 
prone-IMRT. Especially patients with large breast sizes are expected to have a 
great benefit from prone-IMRT as shown by Mulliez et al. (19). 
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In this study, two types of adjuvant hormone therapy, tamoxifen or 
aromatase-inhibitors, were concurrently administered with radiotherapy to 
hormone receptor positive breast cancer patients. Present data show that use 
of hormone therapy is, regardless the type, associated with an increase in 
radiation-induced dermatitis. This is in accordance with a previous study 
investigating the effect of tamoxifen on acute skin reactions (26). But in contrary 
with the COHORT randomized trial, that shows no difference between 
concurrent and sequential administration of letrozole; the latter was 
administered 3 weeks after RT when it is supposed that the radiosensitising 
effect of endocrine therapy is minimal (28). Concurrent administration of 
trastuzumab and IMRT was found to be associated with lower rates of acute 
dermatitis in the present study. This finding needs to be put in perspective as it 
is in contradiction with the observation of a large randomized study that could 
not find a difference in acute toxicity (29). Longer follow-up will be necessary to 
observe the effect of concurrent administration on cardiac toxicity. 
 
Our study shows an association between the MLH1 rs1800734 SNP and 
lower rates of acute radiation-induced dermatitis: heterozygotes are less 
present in the G2+ dermatitis group. The SNP maps 93 base pairs upstream of 
the MLH1 transcription site in the core promoter, a region essential for 
maximum transcriptional activity (30). The SNP was previously shown to be 
associated with acute myeloid leukemia after methylating chemotherapy for 
Hodgkin disease (15). MLH1 gene encodes MutL protein homolog 1 which is 
involved in DNA mismatch repair. Suga et al. found statistically significant 
associations with rs3744355 in the 5’ flanking region of the LIG3 gene and 
acute radiation-induced skin reactions in the Japanese population and Murray 
et al. provided replicated evidence for this association in a European Caucasian 
population (12, 13). We, however, could not confirm this association. Smirnov et 
al. hypothesized that regulatory variants might be able to contribute to the 
development of genetic tools to predict for radiosensitivity (16). This could not 
be demonstrated in our study population. 
Radiation-induced dermatitis includes erythema, edema, dry and moist 
desquamation as symptoms of inflammation probably triggered by cell death 
(31). One of the shortcomings in this study is the fact that erythema was not 
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measured objectively with a colorimeter. As the CTCAE criteria are based on 
subjective scoring, the difference between mild, moderate and brisk erythema is 
observer-dependent. This probably explains the large number of patients 
developing G2+ acute dermatitis when compared to other reports. A strength of 
our investigation is the nearly complete data set for a relatively large number of 
patients enrolled. Furthermore, patient recruitment as well as clinical outcome 
data collection were carried out prospectively. Although the associations hold 
after correcting for multiple testing, the results of this study should be validated 
in an independent study. 
CONCLUSION 
A number of treatment and patient related factors are identified that modify the 
risk for the development of acute skin toxicity after whole-breast IMRT. Large 
bra cup, BMI, normofractionation and concomitant hormone therapy contribute 
to the development of moist desquamation. Patient related factors (high BMI, 
large breast, smoking during treatment and the genetic variation MLH1 
rs1800734), choice of RT schedule and the administration of adjuvant therapies 
affect the development of radiodermatitis.  
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SUPPLEMENTARY MATERIAL 
Table e1: Toxicity in large-breasted patients (cup ≥D) treated in supine position for the 
different fractionation schedules. 
 
Acute G2+ dermatitis  Moist desquamation 
 
G0-1 
(n=10) 
G2+ 
(n=59) P-value  
No 
(n=46) 
Yes 
(n=23) P-value 
Fractionation        
Normo 0 17 (100.0)   5 12 (70.6)  
Hypo 10 42 (79.2) 0.058  41 11 (20.8) <0.001 
  
 
  
 
 
 
 
 
 
 
Part III 
General discussion 
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9 Challenges in radiation toxicity research 
In this section, different issues will be discussed based on the hurdles that we 
got over during current PhD project and these will need to be taken into 
consideration in future research in the field. 
Predicting the risk to develop normal tissue toxicity has been referred to as 
‘the Holy Grail of radiobiology’ (1). Two approaches can be applied for risk 
stratification: the individual and the population approach (2). The individual 
approach identifies individuals at high risk for whom an alternative to the 
conventional treatment can prevent the development of toxicity or, conversely, 
identifies the patients at low risk for whom intensification of treatment is a 
possibility. The population approach focuses on identifying the underlying cause 
of treatment-related toxicity and provides a generalized intervention that shifts 
the whole risk distribution at the population level (3). The different 
characteristics of prediction (individual approach) and association (population 
approach) are described in the first section.  
Because of the lack of standardising the assessment of radiation-induced 
toxicity, multiple symptoms are recorded by multiple scoring systems. In the 
second section, possible approaches are described that handle this kind of 
information. Adverse events are usually scored as a graded response but 
analysed as a binary endpoint, with potential loss of information. In this section, 
special interest goes to the prediction of an ordinal response which is illustrated 
by the prediction of acute dermatitis. 
The first generation of GWASs provided valuable insights into the genetic 
basis of human traits and diseases with common variants conferring small 
increments in risk (4). In the third section, the predictive value of these variants 
under the form of polygenic risk profiles is illustrated in other traits and diseases 
with a longer history of genetic research, like height and cancer susceptibility. 
Then, an overview is given of the progress made in the radiogenomics field.  
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9.1 Association versus prediction 
This PhD dissertation includes association models for severe acute radiation-
induced nocturia in prostate cancer patients (chapter 6) and for severe acute 
radiodermatitis and moist desquamation in breast cancer patients (chapter 8). It 
also includes prediction models for late radiation-induced nocturia and 
haematuria in prostate cancer patients (chapter 7). Such association and 
prediction models are different in their objectives, their measurements, and their 
applicability in clinical context. Association studies aim to identify aetiological 
associations of factors with a disease and may be an indication for potential 
interventions for preventing or treating the disease (5). Prediction studies, on 
the other hand, are applied to evaluate factors in making individual clinical 
decisions. The performance measures of association studies, odds ratio (OR), 
relative risk or correlation coefficient, are related to statements made at 
population level, but do not apply in decision making; a strong association 
between a factor and disease is usually not sufficient to adequately discriminate 
individuals between different outcomes (5, 6). The performance of prediction 
models should be assessed on three fundamental levels: (i) discrimination, 
reflecting the ability to discriminate between different outcomes, can be 
quantified by measures as sensitivity, specificity and area under the receiver 
operating characteristic curve (AUC) (or concordance statistic), (ii) calibration, 
reflects how close the predictions are similar to the actual risk and (iii) clinical 
usefulness, by quantifying the harms and benefits of the alternative leading to 
an optimal decision threshold (as discussed in chapter 7) (7, 8). A good 
prediction model is a model that includes the smallest number of factors while 
preserving predictive value. 
 
Many studies (9-12) use the standard back- or forward stepwise procedure 
for predictor selection. This method sequentially introduces predictors into the 
model and makes a judgement solely based on p-values. This is in contrast to 
the method applied in this PhD dissertation. Here, we performed the Lasso 
method that is based on effect sizes by imposing penalties to the regression 
coefficients. The Lasso procedure is particularly useful when a large amount of 
predictors is considered. It is a logistic regression method that includes only a 
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subset of predictors into the model, setting the coefficients of the variables with 
negligible effects to zero (13). In this PhD research, models are developed to 
predict urinary toxicity in prostate cancer patients. The models contained 
dosimetric and clinical variables and genetic markers and resulted in acceptable 
predictive performance (results see chapter 7). A comparable approach was 
previously performed to predict esophagitis in lung cancer patients (including 
chemotherapy treatment, lymph node stage, mean esophageal dose, gender, 
overall treatment time, RT technique and four polymorphisms), dysphagia 
(including concurrent chemotherapy, dose delivered to 2% of the superior 
pharyngeal constrictor muscle and one polymorphism) and xerostomia 
(including age, mean dose to contralateral parotid glands, to ipsilateral parotid 
gland and to contralateral submandibular gland, volume of contralateral 
submandibular gland and baseline xerostomia score) in head-neck cancer 
patients (14-16). The Lasso method is the recommended approach for normal 
tissue complication modelling over stepwise selection and Bayesian model 
averaging due to its better predictive power (16). 
Other modelling methods to obtain an individualised estimation of the risk of 
toxicity including dosimetric and clinical factors, involve machine learning 
techniques like artificial neural networks, support vector machines or random 
forest model (17, 18).  
 
A totally different approach to predict normal tissue toxicity includes the 
radiobiological NTCP models; they calculate the probability that a certain 
percentage of patients will experience adverse reactions. These models convert 
dose inhomogeneity within an organ at risk to the equivalent uniform dose 
(EUD), incorporating information from the entire dose-volume histogram (DVH) 
(19). In the previous approach single dose-volume points derived from the 
DVHs are included. Recently, NTCP models with inclusion of known clinical risk 
factors and genetic data have been developed. Two studies investigated late 
rectal toxicity in prostate cancer patients: DeFraene et al. published results on 
NTCP models on rectal bleeding (including abdominal surgery and 
cardiovascular disease), late faecal incontinence (including abdominal surgery 
and diabetes) and on high stool frequency (including baseline stool frequency) 
(20) and Rancati et al. developed models for late rectal bleeding (including 
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abdominal surgery and acute toxicity), severe chronic faecal incontinence and 
mean faecal incontinence (both including disease of the colon or abdominal 
surgery) (21). One study developed an NTCP model for radiation pneumonitis in 
lung cancer patients including mean lung dose, smoking status and four 
polymorphisms (22). For GU toxicity, clinically useful prediction tools have not 
yet been developed. Several studies have, however, defined dose constraints to 
limit late GU toxicity (23-26). As these models can be used as a guidance tool in 
clinical practice, they are more indicative for average trends rather than 
outcomes on individual patients (19). 
 
9.2 Normal tissue toxicity phenotype 
In radiation oncology, the search for (bio)markers associated with or predictive 
for radiation-induced toxicity is impeded by the use of multiple and diverse 
endpoints from a variety of scoring systems (27). First, multiple individual 
symptoms of a specific organ, are merged into a single grade (28, 29). For this 
PhD research, we chose to study the individual urinary symptoms, with nocturia 
being the most prevalent, as the aetiology of these different symptoms is 
unknown and probably different from each other (30). We showed that 
aggregation of multiple symptoms is associated with a loss of specificity and 
statistical resolution (chapter 6). This approach is supported by Bentzen et al. 
who demonstrate that there is no association between the late reactions fibrosis 
and telangiectasia in breast cancer patients and, because of their difference in 
aetiology, they recommend to analyse them as two separate endpoints (31). 
Second, miscellaneous scoring systems impair between-study comparisons and 
pooling of data. These problems can be anticipated by the development of a 
novel metric like the Standardized Total Average Toxicity (STAT) score, 
measuring the overall clinical radiosensitivity (27). Another possible direction is 
the investigation of one type of normal tissue reaction, like fibrosis, assessed in 
different patient cohorts, instead of examining different normal tissue reactions 
in patients treated for the same disease (32).  
Normal tissue reactions can be ordered into a spectrum ranging from simple 
biological endpoints to complex functional endpoints as shown in Figure 9.1 
(32). Depending on the nature of the research, a pragmatic patient-centred or a 
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mechanistic biology-centred approach can be applied. If the aim of the study is 
to establish predictive signatures suitable for clinical decision making, patient-
oriented endpoints are of importance. Conversely, biological endpoints will be 
more appropriate for the analysis of the pathogenic mechanisms (28, 32). This 
is of particular importance in studies using genome-wide approaches, where 
robust phenotyping is essential (33).  
 
Figure 9.1: Spectrum of normal tissue 
reactions. From Andreassen et al. (32). 
 
 
 
 
 
The available toxicity scoring systems allocate dynamic continuous 
symptoms into different grades, ranging from 0 to 5 according to the severity of 
the symptoms. These graded endpoints are in many studies dichotomised into 
no or mild (G0-1) and moderate or severe toxicity (G2+). Although this 
approach is associated with a loss of information, it is often applied for statistical 
reasons. Moreover, logistic regression modelling of binary endpoints has 
advantages in terms of interpretation of the findings (28, 34). Considering 
outcome as an ordinal variable is another possibility and is illustrated in 9.2.1 for 
the prediction of acute dermatitis in breast cancer patients. 
 
Nonetheless, grading of continuous symptoms is prone to subjectivity which 
can be related to differences in toxicity scales between research groups and, 
when medical intervention is included in the scoring system, to the physician’s 
clinical practice and perception of the severity of the event (34, 35). Therefore, it 
would be of great interest to define radiation-induced injury by objective, 
quantitative measurements on a continuous scale (35). Kelsey et al. uses the 
dose-dependent changes in single photon emission computed tomography 
(SPECT) lung perfusion as an objective measure of radiosensitivity (36). De 
Ruysscher et al. studied the potential of CT density changes to quantify 
radiation-induced lung damage (35). Moist desquamation could be predicted in 
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hairless mice by measuring the thermal effusivity of the skin by three-
dimensional thermal tomography (37). Tissue compliance meter is recently 
shown to be a reproducible method to quantify radiation-induced fibrosis (38). 
Furthermore, bladder and rectal function could be objectively measured by anal 
sphincter pressures and rectal capacity or by an urodynamic examination 
including flowmetry and cystometry (39, 40). 
Such objective measurements together with laboratory tests can, in their 
turn, serve as surrogate endpoints which might be useful as early indicators of a 
subclinical effect since some symptoms appear after a long latency period. 
Evidently, surrogacy requires an association between changes in the clinical 
endpoint and changes in surrogate endpoints (28). This is a matter of further 
investigation. 
 
9.2.1 Prediction of acute dermatitis as ordinal endpoint 
In paper III of this PhD dissertation, the association of patient and treatment 
factors with acute dermatitis after irradiation for breast cancer was investigated. 
It was recorded by the CTCAEv3.0 scoring system that grades symptoms like 
mild erythema or dry desquamation as grade 1 (G1), moderate to brisk 
erythema or patchy moist desquamation mostly confined to the skin folds is 
classified as grade 2 (G2) and confluent moist desquamation as grade 3 (G3). 
Further details of treatment and patient characteristics can be found in paper III. 
As the dataset has very few missing values, a complete case analysis was 
performed omitting the patients with incomplete data. 
 
To predict acute dermatitis, two approaches were studied. For the binary 
approach, patients with moderate-severe (G2+) versus no-mild (G0-G1) toxicity 
were considered; the ordinal approach handles all separate grades. Binary and 
ordinal logistic regression, respectively, were applied for prediction modeling. 
Variable selection was performed by the LASSO procedure for both 
approaches. The final binary model was based on the AUC, the final ordinal 
model was based on the VUS (Volume under the ROC surface). For both 
models maximisation of the Youden Index (J) was used to define the optimal 
cut-off values. A J=0 is complete overlap and J=1 is complete separation of the 
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different classes, prediction models with J≥0.20 have acceptable prediction 
performance (41). All steps are carried out with cross validation to control for 
overfit, 10-fold cross validation for binary outcome, 3-fold for ordinal approach 
which is preferred over 5 and 10-fold cross validation as the analysis deals with 
all classes. 
Individual risk scores are calculated according to the formula, with β the 
coefficient of its corresponding predictor Χ: 
Risk score = β1Χ1 + β2Χ2 + … + βpΧp 
The higher the risk score, the higher the risk for developing toxicity. Based on 
these risk scores, the probability to develop a certain grade of toxicity is 
calculated for each patient. In case of ordinal analysis, this risk score will give 
each patient its probability to develop G0, G1, G2 or G3 toxicity. 
 
In total, 345 breast cancer patients can be included in the analysis. Of them, 
3.2% develop no toxicity (G0), 38.3% develop G1 dermatitis, G2 toxicity is 
present in 48.1% and 10.4% develop G3 toxicity; one hundred forty-three 
patients develop no toxicity and two hundred and two patients develop G2+ 
dermatitis. 
 
The final prediction model for the binary outcome is shown in Table 9.1. This 
model has an AUC of 0.77 with sensitivity of 83% and specificity of 61% at 
cutoff of 20% with J=0.20 (Figure 9.2). The model contains, apart from smoking, 
all the variables that remained statistically significant in multivariate modeling. 
Nodal irradiation, on the other hand, was picked up in the prediction model, 
while it did not reach statistical significance in the association study. 
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Table 9.1: Predictors and their coefficients 
for acute dermatitis as a binary endpoint. 
Predictors (Χ) Coefficients (β) 
Intercept 1.342 
BMI 0.022 
Hypofractionation 
schedule 
-0.748 
Prone treatment 
position  
-0.406 
Nodal irradiation 0.119 
Trastuzumab -0.559 
Bra cup size cup ≥D 0.539 
Concomitant hormone 
therapy 
0.106 
MLH1 rs1800734 GG 0.104 
 
Figure 9.2: ROC curves for acute 
dermatitis as binary endpoint. 
 
 
The model to predict acute dermatitis as an ordinal endpoint is shown in 
Table 9.2. Nodal irradiation, hormone therapy and the MLH1 SNP are no longer 
selected compared to the binary prediction model. This is a consequence of 
selecting variables for optimal prediction of four classes instead of two classes. 
The model has a VUS of 0.72 with J=0.28. 
 
 
Table 9.2: Predictors and their coefficients 
for acute dermatitis as an ordinal endpoint. 
Predictors (Χ) Coefficients (β) 
BMI 0.098 
Hypofractionation 
schedule 
-1.792 
Prone treatment 
position 
-1.112 
Trastuzumab -1.431 
Bra cup size cup ≥D 0.662 
 
Based on the coefficients, risk scores and probabilities are calculated; they 
are plotted against each other in Figure 9.3. The risk score cut-offs separate the 
different classes, optimizing the number of true positives in each class.  
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Figure 9.3: Risk scores vs. the probability to develop a certain grade of toxicity for 
the study population. The latter is represented by the coloured lines. The vertical lines 
represent the risk score cut-off values to classify patients into different classes. In a model 
with perfect classification, the highest probabilities to develop a certain grade of toxicity 
would correspond to the category the patient is classified to. For the current model, there is 
moderate overlap as represented by the VUS of 0.72. 
 
For this preliminary analysis, it was chosen to calculate cut-off values based 
on the maximisation of J; this is comparable with the calculation of sensitivity 
and specificity by taking the minimal distance to the perfect point of the ROC 
curve when considering a binary endpoint. Dependent on the harms and 
benefits of the alternative treatment (clinical usefulness), this trade-off between 
false negatives and false positives can be penalized differently, for example as 
applied in paper II (chapter 7). In the prediction analysis of an ordinal endpoint, 
this trade-off is more difficult; the grades in-between are bounded by two cut-off 
values which makes it difficult to optimize sensitivity and specificity for each 
grade. This means that more choices need to be made in relation to the costs 
and benefits of the alternative treatments. Uniformity of scoring by different 
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clinicians becomes a more critical issue in ordinal approach. And, another 
criticism to the ordinal approach is that there is more chance to have classes 
that are not well-balanced from statistical point of view, especially for the 
extremes. This can add more uncertainty into the model and can lead to an 
underestimation of the coefficients. Nonetheless, the ordinal prediction 
approach goes together with gain in information compared to the binary 
approach, it also enters a new level of complexity. For these reasons it is 
recommended to implement an ordinal approach model only when different 
alternative treatments are available and adjust the number of classes to the 
number of available alternatives. 
Hypofractionated IMRT in prone position would be a valid alternative to offer 
patients at high risk for developing G2 or G3 toxicity. With the right guidance 
and expertise, it would be feasible to implement this technique and it does not 
affect tumour control. Therefore, the binary approach would be the best solution 
to reduce severe acute skin toxicity after breast irradiation. 
These results warrant some caution as all the measurements are performed 
on the same patient population and should be validated in an independent 
cohort before clinical implementation. 
 
9.3 Added value of genomics 
Entering the era of GWASs, the search for genetic variants associated with 
common traits and diseases was accelerated with impressive results in finding 
genetic factors involved in many conditions (a comprehensive list of studies can 
be found at www.genome.gov/gwastudies/ (42, 43). In order to make this 
possible, large consortia were established to facilitate and promote multi-centre 
collaboration of researchers. The GIANT consortium, for example, identified in 
183.727 individuals more than 180 loci influencing height, the most heritable 
human trait (44). These loci, which explain ~10% of the phenotypic variation, 
are non-randomly clustered within biologically relevant pathways and probably 
underlie relevant functional and biological information to the study of human 
growth (44).  
Furthermore, GWASs have identified common genetic variants that confer 
susceptibility to different types of cancer. Although, the low effect size of each 
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sequence variant implies a poor predictive utility of a genetic test based on one 
risk allele. The combination of multiple susceptibility alleles, assuming a 
multiplicative model, may result in a polygenic risk profile that can be used for 
risk prediction (45). To date, a total of 76 susceptibility loci for breast cancer and 
77 for prostate cancer have been identified in approximately 87.000 and 50.000 
individuals, respectively, performed by the COGS consortium (46-48). The 
estimated proportion of familial risk explained by those loci is ~15% for breast 
cancer and ~30% for prostate cancer (47, 48). The polygenic risk profile for 
breast and prostate cancer based on these susceptibility loci shows an AUC of 
0.63 and 0.68, respectively (49) and can identify a small portion of the 
population at a clinically meaningful level of risk; the top 1% of the individuals in 
the highest risk stratum has a 3.2-fold greater risk for breast cancer and a 4.7-
fold greater risk for prostate cancer, relative to the population average (3, 48, 
49). For comparison, the latter risk estimate is similar to that conferred by 
deleterious mutations in BRCA2 (48, 50). These findings suggest that polygenic 
profiling is promising for risk stratification which can be further improved as 
more susceptibility loci are identified and by adding more information (like 
lifestyle factors) into the risk model. 
 
In radiogenomics research, the radiogenomics consortium (RGC) was 
established in 2009 and has about 150 members from >80 institutions in 19 
countries, among them are major collaborative groups from the United Kingdom 
(RAPPER) (51), the United States (GenePARE) (52) and Japan 
(RadGenomics) (53). The RGC acts as a framework to pursue grant 
applications, share data and samples and conduct meta-analyses (54, 55). It 
also develops guidelines to encourage best practices for data collection and for 
reporting radiogenomics studies (56). 
Many, mostly small, studies have reported associations between SNPs in 
candidate genes involved in DNA repair, inflammation and radiation response 
pathways, and radiation toxicity in multiple types of cancer (reviewed in (57)). 
The most intensively studied genetic variant in radiogenomics is the -509 
(rs1800469) SNP in the TGFB1 gene. Large studies or meta-analyses testing 
this association with radiation-induced toxicity could, however, not confirm the 
previous associations. Two literature based meta-analyses (58, 59), a large 
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RAPPER study comprising 778 participants (60) and a meta-analysis conducted 
through a joint RGC effort, including published and unpublished data from 2782 
patients (61), did not detect any significant association between the TGFB1 
SNP and late toxicity. The latter two studies were well-powered to detect small 
differences (60, 61). All other previously reported associations were tested in a 
large (n=1613) independent validation study and could also not confirm the 
associations (62). Recently, the first well-replicated report identified a SNP near 
the TNFα gene to be associated with late RT adverse reactions in breast 
cancer. This candidate gene study was carried out on a test set containing 340 
women, followed by replication of these results in three additional cohorts, two 
German cohorts containing 748 patients and a RAPPER cohort including 948 
women (63).  
Several GWASs in radiogenomics have been performed (64-68). The first 
GWAS was published by Kerns et al.. Radiation-induced ED was studied in 
African-American men (n=79) after prostate cancer treatment. The rs2268363 
SNP in the FSHR gene was found to be associated with the endpoint at the 
genome-wide significance level (p=5.5 × 10-8) (64). The RadGenomics project 
performed a genome-wide screen of microsatellites in 360 patients with diverse 
cancer types. They identified a marker in the SEMA3A promoter region 
associated with acute adverse reactions (65). Furthermore, three 2-stage 
GWASs, consisting of a discovery and replication cohort, were performed in 
prostate cancer patients treated with RT to identify SNPs with the development 
of late urinary symptoms, defined as the change in AUA Symptom Score 
relative to baseline, late rectal bleeding and late ED (66-68). Late urinary 
symptoms are associated with the 9p21.2 region containing 8 SNPs, with 
combined p-values ranging from 8.8x10-6 to 6.5x10-7. These variants reside in a 
haplotype block encompassing the IFNK gene which is involved in inflammation 
(66). Two SNPs that tag the 11q14.3 locus have combined p-values reaching 
genome-wide significance (5.4x10-8 and 6.9x10-7) for association with late rectal 
bleeding. A polygenic risk score including the top 17 SNPs resulted in an OR of 
1.7 and an AUC of 0.74 in the replication cohort (67). For ED, 12 SNPs were 
identified in both cohorts. Combining these SNPs in a cumulative score, a one-
allele increase in the cumulative SNP score increased the OR of developing ED 
with 2.2, taking into account the nongenetic factors age, androgen deprivation, 
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treatment and ancestry. This model including SNPs and the nongenetic factors, 
resulted in an AUC of 0.89 which drops to 0.75 when the genetic markers are 
left out. The model was validated in two small external cohorts (68). In our 
study, we did not first perform association tests to select the SNPs for the 
prediction model. We relied on the Lasso method to select those SNPs (and 
other variables) with the largest effect size. We noticed the same trend that 
including genetic information into a model already containing patient or 
treatment-related data, increases the predictive performance. The AUC of the 
models for haematuria or nocturia decreases more than 0.10 points of AUC 
when the genetic data was left out (see paper II). However, the rather large 
effect of the SNPs on the predictive performance can be an overestimation due 
to sample size. The findings need to be confirmed in additional validation 
studies with larger sample sizes. 
 
We noticed in this doctoral research, that for some cases the heterozygous 
genotypes but not the homozygotes for the minor allele are associated with 
toxicity. A possible explanation is that these results are consistent with the over-
dominant model in which the heterozygotes confer an advantageous effect over 
both homozygotes. However, in large GWASs most SNPs are consistent with 
the additive (allele-dose) model (69), with only a minority of SNPs deviating 
from this and follow the common dominant or recessive models (47, 48). This 
means that our results might be biased by insufficient numbers of patients 
carrying the homozygous variant genotype. 
 
In this PhD research, the SNP selection was predominantly based on the 
candidate gene approach. We notice that genome-wide significance (p≤5x10-8) 
(70) is difficult to achieve and that the GWAS approach is the way to go. 
Progress is already made by studies performed by Kerns et al. (66-68) but 
larger cohorts and independent validation sets are needed to identify true 
susceptibility loci. Currently, the OncoArray project is ongoing. OncoArray is a 
custom-genotyping chip containing, besides 300,000 GWAS backbone SNPs, 
1,000 prostate SNPs and 1,000 breast SNPs specifically chosen by the RGC 
(71). In total, 5,450 RGC prostate samples will be genotyped from five RGC 
groups, including the Ghent group.   
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10 Alternative strategies to predict radiosensivity 
Other than genetic variations, cellular assays can be developed to predict 
clinical radiosensitivity. Among them are DNA damage assays, radiation-
induced apoptosis and gene expression profiles. They involve the analysis of 
changes before and after the ex vivo irradiation of a blood or cell sample.  
A number of in vitro methods have been examined to determine the intrinsic 
radiation sensitivity of patients. These include clonogenic cell survival assays, 
chromosomal damage (dicentrics, micronuclei) and chromatid breaks (G2 
assay) but have shown to be of limited use (72-75). 
 
One of the earliest steps in the cellular repair of DNA DSB is 
phosphorylation of thousands of H2AX molecules, presented as γH2AX, in the 
chromatin flanking the DSB site (76). γH2AX foci, each representing one DSB, 
can be measured by flow cytometry or counted in cell nuclei by 
immunofluorescence microscopy (77). The kinetics of foci loss is a measure of 
DNA repair capacity and can be exploited as a measure of cellular 
radiosensitivity (78-80). Several studies evaluated whether patients with severe 
toxicity have impaired DNA repair mechanisms, with the intention to develop a 
diagnostic test predicting these responses. In the study of Rübe et al., the highly 
sensitive γH2AX foci assay was applied to identify patients with impaired DSB 
repair capacity. They could distinguish ATM homozygote, heterozygote and 
normal individuals. They were also able to detect DSB repair deficiencies in 
three of 23 children with solid tumours. Of them, two children manifested 
unexpected serious adverse events, like life-threatening radiation pneumonitis 
and lethal spinal cord necrosis (81). Chua et al. assessed the number of 
γH2AX/53BP1 foci in lymphocytes of breast cancer patients exhibiting severe 
late clinical radiation-induced photographic changes compared to women (n=7) 
with mild or no changes (n=7). Higher levels of residual DSB were expressed in 
women with clinical changes (82). γH2AX/53BP1 foci were stained as 53BP1 
co-localizes with γH2AX in order to ensure the enumeration of genuine 
radiation-induced foci (82). Residual γH2AX expression in head-neck cancer 
patients increased with the severity of acute mucositis and skin reactions (83). 
The findings of Burton et al. and Li et al. are in line with these results; persistent 
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γ-H2AX expression, measured by flow cytometry, is higher in lymphocytes from 
overreactors compared to lymphocytes of non-overreactors (84, 85). Li et al. 
confirmed the predictive value of γ-H2AX expression for severe mucositis. A 
relative fluorescence intensity of γ-H2AX cut-off value was determined at 24 h 
post-irradiation, with an AUC value of approximately 0.80 and sensitivity and 
specificity being 100% and 53.8%, respectively (85). Other studies could, 
however, not verify this correlation between γ-H2AX foci and acute or late tissue 
damage (86-89). These studies are performed in rather small study populations 
and large prospective cohorts are necessary to validate these findings. 
 
A French research group proposed radiation-induced lymphocyte apoptosis 
(RILA) as a useful tool for the prediction of radiation-induced toxicity. RILA is 
assessed by flow cytometry on fresh blood samples exposed to 8 Gy x-rays. A 
decreased apoptotic response of CD4+ or CD8+ T-lymphocytes to irradiation 
has been observed in AT patients and in patients suffering from late radiation-
induced adverse events when compared to healthy controls (90-95). This assay 
was prospectively investigated in 399 patients with miscellaneous cancers 
treated with RT. The AUC for the development of grade ≥2 at 2 years was for 
CD8 0.83 and 0.71 for CD4, reflecting a greater effect for the CD8 than the CD4 
apoptosis assay. Sensitivity and specificity for the cut-off values of the 
percentage apoptotic CD4 >15% and ≤10%, were ~80% and for the cut-off 
values of CD8 >24% and ≤16% were ~90% (94). The discriminative power of 
the test was confirmed in a recent study of the research group (96). CD4+ and 
CD8+ T-lymphocytes were chosen because of their better flow cytometrical 
separation compared with other types of lymphocytes (90, 93). There is still no 
biological explanation for this relationship. Nowadays, other research groups 
have replicated this finding (97-99) but not always with success (89, 100-102). 
Although, the ones that refute the predictive potential of RILA, deviated from the 
protocol proposed by Oszahin et al. (94).  
 
Gene expression profiling is another approach for the prediction of normal 
tissue toxicity. Its potential is already proven in other disciplines, for example 
the development of Mammaprint® for the identification of women at risk of 
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breast cancer metastasis (103, 104). A number of studies investigated gene 
expression profiles to predict normal tissue toxicity after RT (105-114). 
However, only one study has been validated (113, 115). A classifier was 
developed containing 13 genes that show differential expression in fibroblast 
cell lines irradiated in vitro with the fractionated scheme of 3x3.5 Gy in intervals 
of 24h. The cell lines were derived from 14 breast cancer patients (113, 114). 
This classifier was reduced to 9 genes for technical reasons in the validation 
study. It was tested in fibroblast cultures derived from 160 head-neck cancer 
patients. The classifier showed a sensitivity of 100% and a very low specificity 
of 19.5% for the prediction of grade 3 subcutaneous fibrosis (115). 
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11 Final conclusions 
Knowledge of the factors that modify the risk or models calculating the risk for 
toxicity are useful in clinical practice to prevent the development of radiation-
induced toxicity. In this PhD research, factors related to RT dosimetry, adjuvant 
cancer treatments, acquired co-morbid conditions or factors inherent to the 
patient are investigated for their association or their predictive value for the 
endpoint under investigation.  
Acute and late radiation-induced nocturia in prostate cancer patients was a 
frequently recorded urinary symptom in our patient cohort. The presence of mild 
pre-treatment complaints and treatment with primary RT were confirmed as risk 
factors. Additionally, an association between acute nocturia and the -509 and 
codon 10 TGFB1 SNPs were found and remain statistically significant after 
multiple testing correction. Acute radiation-induced nocturia improves the 
predictive performance of the prediction model developed for late nocturia. 
Although, as it is no genuine predictor (unknown at start RT) it cannot be 
included in the model to calculate the individualized pre-treatment risk. Other 
factors in the model are the minimal clinical target volume (CTV) dose, the CTV 
volume and the NOS3 rs1799983GT, CASP8 rs1045485GG and NR2F6 
rs4808611TC genotypes. They had an acceptable level of discriminating ability 
(AUC=0.76) with sensitivity of 75.9% and specificity of 67.4%. Another urinary 
symptom, predominantly expressed in late phase, is haematuria. A prediction 
model was constructed and included the bladder volume receiving ≥75 Gy, 
prostatic transurethral resection and the HMGRC rs3931914CG, NOS1 
rs2293054AG, PTGER2 rs708498GG and EGFR rs845552AG polymorphisms. 
The model also shows a good discrimination with AUC=0.80 and with sensitivity 
of 83.3% and specificity of 61.5%. The AUC drops to 0.60 and 0.67 for nocturia 
and haematuria, respectively, when leaving the genetic markers out of the 
model. This research implies a valuable role for genetic polymorphisms in 
prediction, albeit with a smaller contribution. Radiation-induced moist 
desquamation and radiation-induced dermatitis, an aggregation of inflammatory 
symptoms like erythema, edema and desquamation, were studied in breast 
cancer patients. The factors influencing the development of both these 
symptoms are BMI, large bra cup size, fractionation schedule and concurrent 
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hormone therapy. Additional factors modifying the risk of acute dermatitis were 
supine IMRT, the administration of trastuzumab and the genetic variation MLH1 
rs1800734. The latter association holds after correction for multiple testing.  
This PhD research shows that the success of predicting normal tissue 
toxicity after RT will depend on our efforts to collaborate. On the one hand, this 
research field connects experts from different disciplines like radiobiologists, 
radiation oncologists and geneticists but also radiation physics and statisticians. 
On the other hand, large patient groups with a standardized collection of 
radiation dosimetric, clinical and biological data will be necessary to perform the 
genotyping studies. Recently, through the RGC, a EU-funded project called 
REQUITE is started. This project aims at validating the existing prediction 
models, with or without genetics, in 5,300 prostate, breast and lung cancer 
patients undergoing RT using identical treatment and toxicity data collection 
forms.   
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12 Future perspectives 
The aim of developing a prediction model is to find a combination of factors that 
accurately predicts an individual patient’s outcome. Validating such a model 
should demonstrate that the combination of these factors is reliable and suitable 
in independent external datasets. Then, the clinical usefulness should be 
determined by comparing the tailored treatment with standard treatments in the 
clinic (116). It should, however, be noticed that alleviating normal tissue toxicity 
may not be at the expense of local tumour control or survival. Therefore large 
integrated predictive systems will have to be developed incorporating factors 
simultaneously predicting for local control, survival, treatment toxicity, quality of 
life and costs (116). 
Furthermore, in highly technological, innovative and rapidly evolving fields 
such as radiotherapy, predictive models will need continuous re-evaluation 
(116, 117). As evidence-based medicine and consecutive guidelines always lag 
somewhat behind practice, data mining of historical data from routine clinical 
practice could be used for decisions concerning new patients, also known as 
Rapid Learning, to speed-up this process (118-121). An additional advantage is 
the large number of readily available patients with unbiased selection compared 
to clinical trials (only 3% of cancer patients are included in clinical trials). A 
drawback of this approach is the low quality of the data (117). 
 
Even after large GWASs of tens of thousands of people, much of the 
heritability remains unexplained. This is also referred to as the ‘missing 
heritability’ (4, 122). Some of this can be attributed to imperfect tagging of a 
strongly associated SNP leading to underestimation of the true effect size (123) 
or to the presence of rare variants with relatively large effects that are not 
tagged by the typical markers used in GWAS (4, 33). These variations can be 
identified by extending the reach of GWAS through fine mapping, imputation 
and denser single-nucleotide polymorphism (SNP) arrays (122). An additional 
drawback of GWAS is the ineffective capturing of structural variations such as 
insertions, deletions, inversions and copy number variants, which commonly 
occur in the human genome (124). Such variants have already been shown to 
have strong associations with several conditions (125, 126). Another possibility 
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is the application of next-generation sequencing technologies, which enable 
identification of rare and private (unique to an individual or family) variants 
through whole-exome or whole-genome sequencing (33, 127). Subsequently, 
acquiring such an enormous amount of data will require the development and 
optimisation of available software to handle data storage and data analysis 
(128). Other sources of phenotypic variation to explore are through 
transcriptome and proteome profiling, miRNAs, epigenomics and protein 
modification studies. 
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